kidney

INTERNATIONAL

Volume 28, 1985

Editor Emeritus
Roscoe R. Robinson, Nashville

Editor
Thomas E. Andreoli, Houston

Associate Editors
Claude Amiel, Paris
James P. Knochel, Dallas

Consulting Editors
J. S. Cameron, London
Ramzi Cotran, Boston
William G. Couser, Seattle
Gerhard Giebisch, New Haven
Nishio Honda, Hamamatsu
Priscilla Kincaid-Smith, Melbourne
Wilhelm Kriz, Heidelberg
François Morel, Paris

Editorial Board
Vittorio E. Andreucci, Naples
A. W. Asscher, Cardiff
Robert C. Atkins, Melbourne
Knut Aukland, Bergen
Peter Bàlint, Budapest
Lindsay J. Barratt, Bedford Park
Jonas Bergstrom, Stockholm
Ori S. Better, Haifa
Roland C. Blantz, San Diego
Adalbert Bohle, Tubingen
Jean-Philippe Bonjour, Berne
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Neal S. Bricker, Los Angeles
Hans R. Brunner, Lausanne
Ruth E. Bulger, Houston
Anthony R. Clarkson, Adelaide
Jack W. Coburn, Los Angeles
Guiseppe D'Amico, Milan
Hugh E. de Wardener, London
Vincent W. Dennis, Durham
Evert J. Dorhout Mees, Utrecht
Jean Dormont, Clamart
Ratislav Dzúrik, Bratislava
Laurence E. Earley, Philadelphia
Bryan T. Emmerson, Brisbane
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Eli A. Friedman, Brooklyn
Carmelo Giordano, Naples
Richard J. Glassock, Los Angeles
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Robert A. Gutman, Durham
Renée Habib, Paris
Jean Hamburger, Paris
Lee W. Henderson, San Diego
Robert H. Heptinstall, Baltimore
Klaus Hierholzer, Berlin
Norman K. Hollenberg, Boston
Malcolm A. Holliday, San Francisco
Rex L. Jamison, Stanford
Colin I. Johnston, Melbourne
D. N. S. Kerr, Newcastle-upon-Tyne
Fredrik Kiil, Oslo
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester
Juha P. Kokko, Dallas
Franciszek Kokot, Katowice
Kiyoshi Kurokawa, Tokyo
Neil A. Kurtzman, Lubbock
Paul H. Lambert, Geneva
Jacob Lemann, Jr., Milwaukee
David Z. Levine, Ottawa
Guy Lemieux, Montreal
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Joël Menard, Paris
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
John F. Moorhead, London
L. Gabriel Navar, Birmingham
T. J. Neale, Wellington
Alphonse Nizet, Liege
Karl D. Nolph, Columbia
Jack Orloff, Bethesda
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Gabriel Richet, Paris
Jose L. Rodicio, Madrid
George E. Schreiner, Washington, D.C.
Robert W. Schrier, Denver
Donald W. Seldin, Dallas
Fred L. Shapiro, Minneapolis
David P. Simpson, Madison
Jay H. Stein, San Antonio
Liliane Striker, Seattle
Wadi N. Suki, Houston
Roger A. L. Sutton, Vancouver
Richard L. Tannen, Ann Arbor
Klaus Thurau, Munich
C. Craig Tisher, Gainesville
Bruno Truniger, Lucerne
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Pierre Verroust, Paris
Herman Villarreal, Mexico, D.F.
Mackenzie Walser, Baltimore
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla
Douglas R. Wilson, Toronto

Manuscript Editor
Joy Royer, Houston

Editorial Assistants
Patricia Broussard, Houston
André Ulmann, Paris

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1985 by International Society of Nephrology

Author Index for Volume 28

Abdel-Rahman Y (abst) 253
Abdelhamid S (abst) 705
Abdulmassih Z (abst) 277, 316
Abe T (abst) 363
Abouna GM (abst) 397
Abouzeid M (abst) 253
Abramowicz D (abst) 268
Abrashkin S (abst) 226
Acchiardo S (abst) 303
Acerbi MA (abst) 342
Achenbach V (abst) 254
Achenbach V (abst) 705
Acheson EJ (abst) 259
Acitelli S (abst) 355
Ackrill P (abst) 239
Adafer E (abst) 373
Adam K (abst) 337
Adami S (abst) 242
Adamson JW (abst) 285
Adamson JW: *see* Eschbach et al 1
Adel Hassan A (abst) 263, 263
Adler AJ, Ferran N, Berlyne GM: Effect of inorganic phosphate on serum ionized calcium concentration in vitro: A reassessment of the "trade-off hypothesis" 932
Adler AJ: *see* Berlyne GM et al S-175
Adler S: *see* Couser et al 879
Adu D (abst) 259, 392, 393, 398
Aebischer N (abst) 316
Aebischer P (abst) 316, 592
Agami Y (abst) 310
Agar J (abst) 859, 864
Agazia B (abst) 237
Agishi T (abst) 364
Agoury D (abst) 253
Aguilera S (abst) 332
Ahmad R (abst) 316, 316
Ahmed K (abst) 400
Ahmed R (abst) 239
Ahrenholz P (abst) 331
Aitchison TC (abst) 389
Akizawa T (abst) 317
Al Mosawi M (abst) 272, 307
Al-Awqati Q: The cellular renal response to respiratory acid-base disorders (Nephrology Forum) 845
Alamillo CG (abst) 385
Albers F (abst) 317, 317
Albert FW (abst) 708
Albertazzi A (abst) 247, 253, 280, 317, 318, 329
Albonico G (abst) 349
Albrecht KH (abst) 700
Alcaix D (abst) 692
Alcazar JM (abst) 294, 584
Alcazar JM: *see* Praga et al 69
Aldridge C (abst) 327
Aletras O (abst) 334, 335
Alexander Ch (abst) 706
Alexandre GPJ (abst) 382
Alexopoulos E (abst) 279, 279, 391
Alfonso L: *see* Mastrangelo F et al S-188
Alfonso L (abst) 344, 345
Alinei P (abst) 594
Aljama P (abst) 585
Allain B (abst) 342, 342
Allan PL (abst) 358
Allen GG (abst) 862
Allen R (abst) 231
Allende MT (abst) 239, 373
Alsina J (abst) 224, 224, 225, 230, 284, 395, 589, 590
Altieri P (abst) 223, 303
Altmann P (abst) 318
Altomonte M (abst) 234
Alvarez A (abst) 227
Alvarez Chiva V (abst) 586
Alvarez L (abst) 385
Alvarez MA (abst) 367, 590
Alvarez-Grande J (abst) 385, 385
Alvestrand A (abst) 283, 328
Amado JA (abst) 385
Amata M (abst) 288
Amato G: *see* De Santo N et al S-166
Amato M (abst) 231, 358
Amatruda O (abst) 305, 375
Amemiya T (abst) 364
Amend W (abst) 372
Amendola G (abst) 259
Amenos AM (abst) 590
Amerio A: *see* Coratelli P et al S-143
Amodio P (abst) 223
Amore A (abst) 260, 275, 280
Anasis P (abst) 391
Anastassiades E (abst) 318
Anaya F (abst) 389
Anders D (abst) 259
Andersen HK (abst) 391
Anderson GH (abst) 312
Anderton JL (abst) 282, 282
Andonian C: *see* Berland Y et al S-183
Andrassy K (abst) 695, 702, 711, 712
Andrejak M (abst) 277, 293
Andres E (abst) 224, 224, 225, 230, 585, 589, 590
Andreu L (abst) 589
Andreucci V: *see* Dal Canton A et al S-154
Andreucci VE (abst) 229,233,234,251, 259, 284, 284, 332, 345
Andujar J (abst) 589
Ang ES (abst) 387
Ang KS (abst) 354, 873
Angeli P (abst) 280
Angoletta F (abst) 237
Ansquer JC (abst) 691
Antiqnac C (abst) 371
Antoniewicz K (abst) 270
Antonov S (abst) 318, 339
Appay MD (abst) 272
Appiani A (abst) 253
Aprile C (abst) 281
Aprile M: *see* Mastrangelo F et al S-188
Aprile M (abst) 344, 345
Aranzabal J (abst) 585, 586
Araujo V (abst) 341
Arbeit LA, Serra SR: Decreased total and active urinary kallikrein in normotensive Dahl salt susceptible rats. 440
Ardaillou R (abst) 692

Ardillo G: *see* Dal Canton A et al S-154
Arduini R (abst) 298
Arenas J (abst) 350
Arends B (abst) 281, 707
Argentiero P (abst) 346
Arguelles M (abst) 323
Ariano MG (abst) 332
Arias M (abst) 385, 385
Arisz L (abst) 291, 304, 308
Armstrong V (abst) 354
Armstrong VW: *see* Schrader et al 823
Arnfred J (abst) 391
Arnold IR (abst) 322
Aroldi A (abst) 268, 281
Arribas F (abst) 584
Arrieta A (abst) 585
Arrieta J (abst) 311, 311, 352
Arrigo G (abst) 223
Arrizabalaga P (abst) 333, 588
Arruda JAL: *see* Rastogi et al 801
Asano Y (abst) 317
Ash FR: *see* Winchester JF et al S-127
Ashcroft R (abst) 310
Aslam M (abst) 274
Asokan A (abst) 259
Assadi FK, John EG, Justice P, Fornell L: Beta 2-microglobulin clearance in neonates: Index of tubular maturation. 153
Assael BM (abst) 253
Asscher AW, Harber MJ: Virulence of urinary pathogens (Editorial Review) 717
Assman KJM (abst) 696
Assmann KJM (abst) 702
Astrug A (abst) 236
Aten J (abst) 696
Athersmith K (abst) 395
Atik A (abst) 277, 316, 351
Atik H (abst) 281, 365
Atkins RC (abst) 314, 859, 864, 865, 866
Attardi A (abst) 358
Atuk N (abst) 371
Aubia J (abst) 351, 376, 381, 381, 381, 382
Auciello A (abst) 284
Auer J (abst) 334
Augustin J: *see* Ritz E et al S-84
Augustin J (abst) 288
Aurisch R (abst) 300
Austen KF: *see* Spragg et al 75
Avner ED, Sweeney WE Jr, Finegold DN, Piesco NP, Ellis D: Sodium-potassium ATPase activity mediates cyst formation in metanephric organ culture. 447
Avram MM: Predialysis BUN and creatinine do not predict adequate dialysis clinical rehabilitation or longevity S-100
Avram MM (abst) 319
Azar P: *see* Weinberg et al 975
Aziz Z (abst) 253

Baak Mv (abst) 279
Bacchini M (abst) 367
Bach JF (abst) 379, 691
Bach PH, Hardy TL: Relevance of animal models to analgesic-associated renal papillary necrosis in humans (Editorial Review) 605
Bacon P (abst) 259
Baczyk K (abst) 270, 273, 291, 328, 362
Baczynski R (abst) 247
Baczynski R, Massry SG, Magott M, El-Belbessi S, Kohan R, Brautbar N: Effect of parathyroid hormone on energy metabolism of skeletal muscle 722
Badia N (abst) 380
Baerlocher K (abst) 596
Baert A (abst) 701
Bahlman J (abst) 369
Bahmann J (abst) 263
Bahr V (abst) 705
Bailey RR (abst) 858, 862, 863, 863, 864, 864
Baillod R (abst) 334
Baker FE (abst) 258
Baker JD: *see* Klotman et al 118
Baker LRI (abst) 327
Baker PJ: *see* Couser et al 879
Balaguer G (abst) 244
Balas EA (abst) 248
Balboni GC (abst) 374
Balcke P (abst) .. 239,319,329,355,378,378,379, 401, 402, 701, 709
Baldari G (abst) 346
Baldamus C, Quellhorst E: Outcome of long-term hemofiltration S-41
Baldrati L (abst) 241
Balducchi JP (abst) 322, 349
Baldwin D (abst) 348
Baldwin DS: *see* Neugarten et al 135
Baldwin III WM (abst) 711
Baldwin WM (abst) 371
Balicchia C (abst) 346
Ballanti P: *see* Coen et al 783
Ballardie FW (abst) 362, 391
Ballarin J (abst) 373
Ballarin JA (abst) 231
Balletta M (abst) 229, 259
Balzar E (abst) 226, 267
Bander SJ, Buerkert JE, Martin D, Klahr S: Long-term effects of 24-hr unilateral ureteral obstruction on renal function in the rat. 614
Bandini S (abst) 231, 358
Bandino D (abst) 356
Banfi G (abst) 392
Bankir L (abst) 689
Bankir L: *see* Bouby et al 456
Banks R (abst) 294
Banks RA (abst) 383
Barat A (abst) 586, 587
Baratelli L (abst) 305, 375
Barbolini G (abst) 240
Barcelo P (abst) 231, 232
Bardare M (abst) 366
Bardin T (abst) 246
Bariety J (abst) 272, 272, 871
Barnes AD (abst) 392, 393
Barnes J (abst) 318
Barnes RMR (abst) 372
Baron R (abst) 595
Barone P (abst) 697
Barracca A (abst) 223, 303
Barragan F (abst) 284, 590
Barral X (abst) 249, 372
Barratt LJ (abst) 860, 862
Barrio V (abst) 367, 590
Barsotti G (abst) 281
Barsoum M (abst) 253

Barsoum R (abst) 253
Barth H (abst) 319
Barthelemy C (abst) 692
Bartoli E (abst) 256, 258, 278
Bartolozzi D (abst) 292
Bartos V (abst) 371
Bartova V (abst) 319
Baruffaldi M (abst) 245
Basile A (abst) 248
Basile C (abst) 364, 364, 364
Basolo B (abst) 360, 275, 280
Bataille P (abst) 281, 282, 282
Batavier P (abst) 359
Battaglia C (abst) 274
Battaglia C: *see* Remuzzi et al 21
Baucells FM (abst) 284
Baucells JM (abst) 590
Bauknecht HJ (abst) 360
Baumann PC (abst) 290
Baumelou A (abst) 691, 871
Baumgartner D (abst) 377, 597
Baylis C, Rennke HG: Renal hemodynamics and glomerular morphology in repetitively pregnant aging rats. 140
Bayliss JM: *see* Rastogi et al 801
Baz M (abst) 347
Bazzato G, Colli U, Landini S, Lucatello S, Fracasso A, Morachello P, Righetto F, Scalera F: Temperature monitoring in dialysis-induced hypotension S-161
Bazzato G (abst) 320, 367
Bazzerla G (abst) 223
Bazzi C (abst) 349
Beasley CRW (abst) 867
Beason-Griffin C: *see* Savin et al 926
Beauchamp D, Poirier A, Bergeron MG: Increased nephrotoxicity of gentamicin in pyelonephritic rats. 106
Beaufils H (abst) 399, 691
Becaus I (abst) 227
Bechstein PB (abst) 386
Beck W (abst) 223
Bedogna V (abst) 357
Bedrossian J (abst) 689
Behm E (abst) 331
Bell GM (abst) 282, 282
Bell J (abst) 857
Bell PD: Cyclic AMP-calcium interaction in the transmission of tubulo- glomerular feedback signals 728
Bell PRF (abst) 400
Bellamy J (abst) 375
Belli L (abst) 393
Bellighieri G (abst) 228
Bellinghieri G (abst) 320, 353
Bello I (abst) 294, 584
Bello I: *see* Praga et al 69
Bellotti Z (abst) 350
Beltrandi E (abst) 268
Beltrandi E: *see* Cagnoli et al 646
Benazzi E (abst) 233, 237
Bendia N (abst) 691
Benedetti RG, Linas SL: Effect of potassium depletion on two-kidney, one-clip renovascular hypertension in the rat 621
Benelmoufok S (abst) 351
Benigni A (abst) 269
Bennett A (abst) 268
Bennett RR: *see* Maher et al 16
Bennett WL: Lead nephropathy (Nephrology Forum) 212
Bennett WM (abst) 366
Bennett-Jones DN (abst) 303, 303
Bennhold I (abst) 278
Benoit G (abst) 375
Bens M (abst) 692
Bensman A (abst) 691
Benvenisty A (abst) 394
Beranek P (abst) 283
Berardinelli L (abst) 374, 390
Berden JHM (abst) 320, 700, 703
Beretta-Piccoli C (abst) 594, 597
Beretta-Piccoli C: *see* Marone et al 658
Beretta-Piccoli C: *see* Schohn et al 814
Berger J (abst) 692
Berger J: *see* Monteiro et al 666
Bergeron MG: *see* Beauchamp et al 106
Bergren C (abst) 388
Bergström J: Uremia is an intoxication S-2
Bergström J (abst) 283, 289, 328
Berkofsky J: *see* Lemieux et al 760
Berland Y, Grandvuillemin M, Charhon S, Olmer M, Adonian C, Aluminum and renal osteodystrophy in chronic uremia S-183
Berlin A (abst) 321
Berlyne GM, Dudek E, Adler AJ, Ruvin JE, Seidman M: Silicon metabolism: The basic facts in renal failure S-175
Berlyne GM: *see* Adler et al 932
Bernardi D (abst) 320
Bernasconi P (abst) 223
Bernhardt JP (abst) 372
Bernheim J (abst) 254, 255, 255, 256, 307, 310
Berniot G (abst) 871
Bertani T (abst) 260, 269, 274
Bertani T: *see* Remuzzi et al 21
Berthoux F (abst) 263, 263
Berthoux FC (abst) 249, 269, 372
Bertin A (abst) 313
Bertolatus JA, Hunsicker LG: Glomerular sieving of anionic and neutral bovine albumins in proteinuric rats. 467
Bertoli S: *see* Ferrario et al 513
Bertotti A (abst) 224
Bertram HP (abst) 301
Bertrou L (abst) 324, 331
Berweck W (abst) 305
Bessoud Y (abst) 365
Bettelheim H (abst) 379, 709
Betteridge DJ (abst) 265
Bettinelli A (abst) 367
Betuel H, Gebuhrer L, Traeger J: Pitfalls in tissue typing for kidney transplantation S-170
Betuel H: *see* Esposito R et al S-98
Bewick M (abst) 396, 398
Beyer J-M (abst) 368
Bhakdi S (abst) 272, 272, 871
Biagi R: *see* Cagnoli et al 646
Bianchetti MG: *see* Marone et al 658
Bianchi AR: *see* Coen et al 783
Bianchi F (abst) 281
Biasioli S (abst) 305, 306
Bibiano L (abst) 228
Bichet DG: *see* Shapiro et al 206
Bichsel G (abst) 295
Bielmann D (abst) 597
Biemesderfer D (abst) 695
Biemesderfer D: *see* Kashgarian et al 899
Bigazzi R (abst) 346

Bijland H (abst) 261
Bilgin N (abst) 334
Binswanger U (abst) . 290, 304, 315, 338, 363, 377, 377, 592, 597
Biolchini A (abst) 366
Birkeland SA (abst) 377, 395
Bisceglia I (abst) 321, 321
Bisesti V (abst) 254
Bishop A (abst) 858
Bishop GA (abst) 858
Bishop V (abst) 863
Bizollon Ch (abst) 236
Bizzarri D (abst) 297, 330
Black AMS (abst) 383
Blaha J (abst) 384
Blair-West JR (abst) 861
Blamey RW (abst) 374
Blanc N (abst) 391
Blanchart A (abst) 587
Blantz RC, Pelayo JC, Gushwa LC, Myers RR, Evan AP: Functional basis for the glomerular alterations in uranyl nitrate acute renal failure 733
Blantz RC: *see* Tucker et al 28
Blasco R (abst) 292, 586
Bleiber R (abst) 286
Block T (abst) 395
Bloem JL (abst) 401
Bloodworth L (abst) 244
Blumberg A (abst) 596
Blumenfield M (abst) 341
Boatman JE: *see* Klotman et al 118
Bock HA (abst) 594, 700
Bockhorn H (abst) 378, 708, 709
Boechat MI (abst) 246
Boelaert J (abst) 321
Boer P (abst) 707
Boer WH (abst) 291
Boero R (abst) 255
Boeschoten EW (abst) 304, 308
Boesken WH (abst) 703
Boffo V: *see* Milito G et al S-157
Boggi R (abst) 228
Bogicevio M (abst) 355
Bogman MJJT (abst) 710
Bognetti E (abst) 258
Bohm R (abst) 279, 698, 707
Bohnert U (abst) 315
Bolasco PG (abst) 223, 303
Bomio F: *see* Marone et al 658
Bommer J: *see* Ritz E et al S-84
Bommer J (abst) 250, 287, 319, 711, 712
Bonal J (abst) 588
Bonanno D (abst) 284
Bondatti F (abst) 240
Bone JM (abst) 372, 396
Bonechi I (abst) 320
Boner G (abst) 256, 257, 373
Bonet F (abst) 321
Bongiorno G (abst) 260, 280
Bonneville M: *see* Vie et al 553
Bonomini V, Feletti C, Scolari MP, Stefoni S: Benefits of early initiation of dialysis S-57
Bonomini V (abst) 392
Bonsdorff Mv (abst) 283, 336
Bonser R (abst) 393
Bonser RS (abst) 392
Bonucchi D (abst) 323
Bonucci E: *see* Coen et al 783
Bonzel K (abst) 290
Bonzel KE (abst) 390
Boobes Y (abst) 347
Boomsma F (abst) 698
Booth LJ (abst) 337
Borca M (abst) 242
Bordoni E (abst) 228, 346
Borgeat A (abst) 594
Borgnino LC (abst) 392
Borin D (abst) 368
Borowiecka A (abst) 325
Bosch A (abst) 290
Bosch R (abst) 321
Bosman C (abst) 696
Bossaller C (abst) 301
Botey A (abst) 350
Boubenider S (abst) 375
Bouby N, Bankir L, Trinh-Trang-Tan M-M, Minuth WM, Kriz W: Selective ADH-induced hypertrophy of the medullary thick ascending limb in Brattleboro rats. . 456
Bouillon R (abst) 693
Boulton Jones JM (abst) 269
Bourdais A (abst) 365
Bourquelot P (abst) 689
Bovio G (abst) 353
Boyce NW (abst) 856, 865
Boyd AS (abst) 298
Boyd S (abst) 360
Bracq C (abst) 691
Bracs P (abst) 858
Bradbury R (abst) 857
Bradley BA (abst) 374, 380
Bradley JA (abst) 376
Bragantini L (abst) 232, 305, 306, 368, 368
Brana D (abst) 332
Branca GF (abst) 356, 378
Brancaccio D, Minetti A, Sabbioni E, Pietra R, Bugiani O, Como G, Gallien M: Minimal laboratory monitoring of uremic patients S-108
Brancaccio D (abst) 321, 321
Brancaleone C: *see* Milito G et al S-157
Brandeis WE (abst) 380
Brando B (abst) 393
Branellec A (abst) 691
Branger B (abst) 322, 349
Bratelj Z (abst) 351
Brauereiss K (abst) 277
Braun J (abst) 277
Braun R (abst) 287
Brautbar N: *see* Baczynski et al 722
Brech W (abst) 322
Bredolan A (abst) 306
Breimer DD (abst) 396
Brenchley PEC (abst) 360, 362, 369, 376
Brendolan A (abst) 232, 305, 370, 370
Brewer DB (abst) 359
Brichard S (abst) 265
Briggs JD (abst) 312, 376, 377, 389
Briner J (abst) 596
Brivet F (abst) 872, 872
Broccoli AV: *see* Chevalier et al 891
Brodde O-E (abst) 326, 698
Brodehl J: *see* Doehring et al 520
Broggi ML (abst) 393

Broggini M: *see* Remuzzi et al 21
Brook AH (abst) 861
Brown CB (abst) 228, 243, 260, 308, 313, 376
Brown EA (abst) 322, 341
Brown MA (abst) 861, 868
Brown RC (abst) 244, 244
Brown Z (abst) 392
Broyer M: *see* Niaudet T et al S-148
Broyer M (abst) 341, 371
Bru A (abst) 331
Bruggemann M (abst) 386
Bruguera M (abst) 381
Bruning I (abst) 277
Brunisholz M (abst) 694
Brunkhorst R (abst) 301, 369
Brunner FP (abst) 594, 700
Brunori G (abst) 393, 399, 399, 399
Bruton D (abst) 869
Bruyns C (abst) 268
Bucht H (abst) 283
Buemi M (abst) 283
Buerkert JE: *see* Bander et al 614
Buerkle HR (abst) 322
Bugiani O: *see* Brancaccio D et al S-108
Bugiani O (abst) 321
Buoncristiani U: Combining hemodialysis and peritoneal dialysis S-50
Buoncristiani U (abst) 322, 323
Buongiorno B (abst) 226
Buongiorno E (abst) 325
Burch HB, Cambon N, Lowry OH: Branched-chain amino acid aminotransferase along the rabbit and rat nephron 114
Burckhardt P (abst) 243, 243
Burden RP (abst) 374
Burdiel LG (abst) 585
Burger HR (abst) 377, 594
Burger MC (abst) 286
Burgers J (abst) 270
Burnatowska-Hledin M (abst) 356
Burnier M (abst) 401, 593
Busnach G (abst) 393
Buss J: *see* Porter GA et al S-34
Bussel A (abst) 692
Bussieres L (abst) 253
Bussmann WD (abst) 249
Bustamante Bustamante J (abst) 344
Butkowski RJ, Carone FA, Grantham JJ, Hudson BG: Tubular basement membrane changes in 2-amino-4,5-diphenylthiazole-induced polycystic disease 744
Buttfield I (abst) 867

Cabili S (abst) 232
Cabrol A (abst) 399
Cabrol C (abst) 399
Cachofeiro V (abst) 586
Caglar S (abst) 232
Cagnoli L (abst) 268, 268
Cagnoli L, Beltrandi E, Pasquali S, Biagi R, Casadei-Maldini M, Rossi L, Zucchelli P: B and T cell abnormalities in patients with primary IgA nephropathy 646
Caimi D (abst) 281
Cakmakci M (abst) 334, 376
Calabrese G (abst) 326
Calabro R (abst) 353
Calico I (abst) 376
Callea F (abst) 266, 399
Callice P (abst) 325
Caloprisco G (abst) 324
Calvete Garcia H (abst) 587
Calzavara P (abst) 299
Cam G (abst) 354, 873
Cambi V, Garini G: Optimized patient care demands flexibility in choosing therapy S-54
Cambon N: *see* Burch et al 114
Cambon-Thomsen A (abst) 691
Cameron JS (abst) 233, 268, 273, 275, 275, 303, 303, 392
Camici M (abst) 224
Campa P (abst) 355
Campanini M (abst) 266
Campese, VM *see* Iseki et al 11
Campos H (abst) 373, 379
Canavese C (abst) 238
Candiano G: *see* Ghiggeri et al 168
Canizares F (abst) 584
Cannata JB (abst) 239, 239, 373
Cantaluppi A (abst) 242, 304, 313
Cantarovich M (abst) 377
Cao Huu T (abst) 690
Capani F (abst) 347
Capasso G: *see* Capodicasa G et al S-112
Capasso G: *see* De Santo NG et al S-166
Capelli S (abst) 324
Capiod JC (abst) 234
Capitanio L (abst) 323
Caplan M: *see* Kashgarian et al 899
Capodicasa G, De Santo NG, Vaccaro F, Capasso G, Giordano C: Standardization of CAPD in adults and children S-112
Capodicasa G: *see* De Santo NG et al S-166
Cappelli G (abst) 240, 342, 343, 365
Cappelli P (abst) 253, 280
Caprioli R (abst) 281
Capuano A (abst) 284
Caramelo C (abst) 321, 587
Caramia M (abst) 345, 347
Carbonaro L (abst) 254, 295
Caregaro L (abst) 280
Carel AS (abst) 347
Carena M (abst) 281
Cariou R: *see* Vie et al 553
Carlier B (abst) 330
Carlson R (abst) 862
Carmichael D (abst) 336
Carminati C (abst) 269
Carmines PK: *see* Casellas et al 752
Carmody M (abst) 333
Carmona AR (abst) 307
Carepa A: *see* Tizianello A et al S-79
Caro P (abst) 299, 586
Carone FA: *see* Butkowski et al 744
Carozzi S (abst) 236, 273, 304, 393, 397
Carquin J (abst) 296
Carreno V (abst) 586
Carrera M (abst) 333, 588, 589
Carreras L (abst) 590
Carrillo J (abst) 239
Carrol N (abst) 373
Casadei-Maldini M: *see* Cagnoli et al 646
Casado Perez S (abst) 587
Casado S (abst) 321, 587
Casati M (abst) 367

Casati S (abst) ... 242, 323
Casciani CU: *see* Milito G et al ... S-157
Casciani CU (abst) ... 345, 347, 356
Cascone C (abst) ... 298
Casellas D, Carmines PK, Navar LG: Microvascular reactivity of in vitro blood perfused juxtamedullary nephrons from rats ... 752
Cashman S (abst) ... 275
Casol D (abst) ... 324
Cassandro E (abst) ... 345
Cassani D (abst) ... 305, 375
Cassidy MJD (abst) ... 241
Castelao AM (abst) ... 224, 224, 225, 230, 284, 395, 589, 590
Castellani A (abst) ... 323
Castellet R (abst) ... 232
Castelli P (abst) ... 228, 346
Castelnovo C (abst) ... 242, 281, 304, 313
Castelnuovo C (abst) ... 390
Castier B (abst) ... 234, 234, 235
Castiglione A: *see* Ferrario et al ... 513
Castillo D (abst) ... 585
Castro N (abst) ... 332
Catalano C (abst) ... 343
Catalfamo R (abst) ... 276, 313, 313
Cattarelli D (abst) ... 323
Cattell V (abst) ... 225, 269
Cattell WR (abst) ... 327
Catto GRD (abst) ... 383
Cavagna R (abst) ... 324
Cavaliere G (abst) ... 223
Cavanna G (abst) ... 253
Caverzasio J (abst) ... 593
Cawley S (abst) ... 869
Cecchin E (abst) ... 348, 328
Cecuk L (abst) ... 351
Cengic M (abst) ... 292
Cenzato M (abst) ... 323
Cerrina ML (abst) ... 872
Cerutti M (abst) ... 324
Cesca D: *see* Milito G et al ... S-157
Chaabouni MN (abst) ... 689
Chakrabarti E: *see* Maher et al ... 16
Chamoiseau S (abst) ... 324, 331
Chan KW (abst) ... 859, 864
Chan M (abst) ... 861
Chanard J (abst) ... 296, 694
Chandrachud L (abst) ... 269
Channon SM (abst) ... 240
Charhon S: *see* Berland Y et al ... S-183
Charmes JP (abst) ... 872
Charpentier B (abst) ... 375, 377, 390, 692
Chatenoud L (abst) ... 379
Chauveau P (abst) ... 290
Chedel D (abst) ... 595
Cheigh J (abst) ... 384, 384
Chen X-M: *see* Kobayashi et al ... 193
Chena C (abst) ... 332
Cheng IKP (abst) ... 866, 866
Chesney RW, Dabbagh S, Uehling DT, DeLuca HS: The importance of early treatment of renal bone disease in children ... S-75
Cheung HS: *see* Lemann et al ... 951
Chevalier Ph (abst) ... 293
Chevalier RL, Peach MJ, Broccoli AV: Hemodynamic effects of enalapril on neonatal chronic partial ureteral obstruction ... 891
Chevet D (abst) ... 250
Chew EC (abst) ... 860
Chiang GSC (abst) ... 267
Chiaramonte S (abst) ... 232, 305, 306, 368, 368
Chiarini C (abst) ... 247
Chine M (abst) ... 381
Chkoff N (abst) ... 373, 379
Choquenet C (abst) ... 379
Chretien M (abst) ... 286
Christollet M (abst) ... 333, 339
Chung H-M: *see* Shapiro et al ... 206
Cianciaruso B (abst) ... 258, 284, 284
Ciancioni C (abst) ... 324
Ciardella F (abst) ... 281
Ciliberto R (abst) ... 225
Cinotti GA (abst) ... 240, 252, 265
Cinotti GA: *see* Coen et al ... 783
Cinti S (abst) ... 340
Cirillo D: *see* Esposito R et al ... S-98
Citterio A (abst) ... 323, 368
Civati G: *see* Minetti L et al ... S-116
Civati G (abst) ... 393
Claas FHJ (abst) ... 371, 711
Clair F (abst) ... 240
Clark AS: *see* May et al ... 490
Claver R (abst) ... 398
Cledes J (abst) ... 302
Clemens C (abst) ... 353
Clement J (abst) ... 284
Clutterbuck EJ (abst) ... 391
Cocciolo G (abst) ... 340
Codet MP (abst) ... 242
Coen G (abst) ... 240
Coen G, Mazzaferro S, Bonucci E, Taggi F, Ballanti P, Bianchi AR, Donato G, Massimetti C, Smacchi A, Cinotti GA: Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH) $_2$D $_3$ administration in a long-term follow-up ... 783
Coevoet B (abst) ... 234, 234, 242
Cofelice E (abst) ... 251
Cohar F (abst) ... 292
Cohen D (abst) ... 235
Cohen J (abst) ... 298
Cohen S (abst) ... 380
Cohen SL (abst) ... 285, 373
Colasanti G: *see* Ferrario et al ... 513
Coleman M (abst) ... 860
Coles GA (abst) ... 244, 244
Coli U: *see* Bazzato G et al ... S-161
Coli U (abst) ... 320, 367
Colin B (abst) ... 871
Colla L (abst) ... 238
Collard M (abst) ... 690
Collart F (abst) ... 324, 325, 330
Colleoni N (abst) ... 252
Collins AJ, Keshaviah P, Ilstrup KM, Shapiro F: Clinical comparison in hemodialysis and hemofiltration ... S-18
Colombe BW (abst) ... 372
Colon S (abst) ... 262
Colussi G (abst) ... 233, 233, 237, 252
Commare MC (abst) ... 295
Como G: *see* Brancaccio D et al ... S-108
Comoy E (abst) ... 225
Company X (abst) ... 588, 589
Compton F (abst) ... 398
Condamin-Meyrier M-C (abst) ... 871

Conesa J (abst) 312
Consoli A (abst)..... 247
Consolo F (abst) 228
Constantini C (abst) 321
Constantino D (abst)..... 374
Conte G (abst) 233, 234, 251, 332
Contu B (abst) 258, 258, 278
Cook HT (abst) 269
Cooker JE (abst) 375
Cooksey G (abst)..... 374
Coppo R (abst) 260, 275, 280
Coratelli P, Passavanti G, Munno I, Fumalaro D, Amerio A: New trends in hepatorenal syndrome S-143
Coratelli P (abst)..... 226, 325
Cordonnier D (abst)..... 333, 339
Corliano C: *see* Mastrangelo F et al S-188
Corliano C (abst) 338, 339
Cornud F (abst)..... 349
Corradi B (abst) 233, 237
Corridoni C (abst)..... 349
Corsi M (abst) 353
Cosci P (abst) 233, 237
Costantino G (abst)..... 276
Cosyns JP (abst) 265
Coto A (abst)..... 294
Cotton RE (abst)..... 368
Coupes BM (abst) 260, 262, 269, 276
Courouce AM (abst)..... 290
Couser WG, Baker PJ, Adler S: Complement and the direct mediation of immune glomerular injury: A new perspective (Editorial Review) 879
Couser WG: Mechanisms of glomerular injury in immune-complex disease (Nephrology Forum). 569
Coutaud C (abst)..... 689
Coward RA (abst)..... 260
Cozzari M (abst) 323
Craig K (abst) 278
Creazzo G (abst)..... 337
Crevat A (abst) 325, 341
Crino M (abst) 228
Cristinelli L (abst)..... 266, 393, 399, 399, 399
Crockett R (abst)..... 400
Crosnier J (abst) 379
Crowson M (abst)..... 392, 398
Crowson MC (abst)..... 393
Cubela R (abst) 867
Cuesta MV (abst) 239
Cuesta V (abst) 373
Cuevas X (abst)..... 376, 381, 381, 382
Cuinas J (abst)..... 586
Cummings NB: Uremia therapy: The resource allocation dilemma from a global perspective S-133
Cundy T (abst)..... 241
Cupisti A (abst) 281
Curtis JR (abst) 318
Cuss F (abst) 330
Cutillo F (abst)..... 269
Cutler SJ: *see* Nolph et al 198
Cyzewska K (abst) 270
Czarnecki R (abst) 362
Czekalski S (abst) 261, 285, 325

d Heyden AJV (abst) 597
da Porto A (abst)..... 299
D'Agati V (abst) 394
D'Agostino C (abst) 344
D'Amico C, Petrella E: Standardization of hemodialysis material S-105
Dabbagh S: *see* Chesney RW et al S-75
Daha MR (abst)..... 270, 371, 381, 696, 711
Dahlhoff K (abst)..... 709
Dal Canton A, Russo D, Gallo R, Ardillo G, Trevico S, Cianciaruso B, Andreucci V: Diuretic therapy in uremic patients S-154
Dal Canton A (abst)..... 233, 234, 251, 332, 345
Dalhoff K (abst)..... 709
Dalhoff R (abst)..... 708
Dalla Rosa C (abst)..... 299
D'Amico G (abst)..... 223, 252, 349
D'Amico G: *see* Ferrario et al 513
Damjantschitsch V (abst)..... 230
Dandavino R: *see* Parfrey et al..... 959
D'Angelo A (abst)..... 252
Daniel P (abst)..... 316
Daniels L (abst)..... 863
Daniilidis M (abst)..... 391
Danti L (abst)..... 235
Darai G (abst) 712
Dardenne M (abst) 691
Darnell A (abst) 250, 264
Dartois AM (abst)..... 286
Datzman M (abst)..... 303
Daudon M (abst)..... 872
Daugirdas JT (abst)..... 341
Daul A (abst)..... 326
Daul AE (abst)..... 698
Davanzo R (abst)..... 224
Davidson JK (abst)..... 389
Davies DJ (abst) 860
Davies M (abst)..... 261
Davies SJ (abst)..... 328
Davila D (abst)..... 255
Davin JC (abst)..... 261, 690
Davison AM (abst) 248
Day JP (abst)..... 239
De Biase L (abst) 355
De Blasi V: *see* Mastrangelo F et al S-188
De Blasi V (abst) 344, 345
De Broe ME (abst)..... 226, 230
De Ferrari ME (abst) 233
De Francisco AM (abst)..... 241
De Fremont JF (abst)..... 246, 365
De Fronzo RA, Smith JD: Is glucose intolerance harmful for the uremic patient?..... S-88
de Goede WJ (abst) 707
de Groc F (abst) 691
de Heer E (abst) 270, 270, 696, 702
de Jong PA (abst) 235
de Jong PE (abst) 261, 343, 359, 699
De Keijzer MH (abst)..... 710
De Luca HF: *see* Chesney RW et al..... S-75
De Luca M (abst) 298
De Maio A (abst)..... 375
De Maio A (abst)..... 305
De Marchi S (abst)..... 224, 248, 328
de Massougnes M (abst) 693
De Mia M (abst) 234
De Miguel A (abst) 239
De Mitrio V (abst)..... 369
De Nurra T (abst) 258
De Paoli Vitali E (abst) 374
de Pedro C (abst) 244

de Pedros C (abst) ... 312
De Plaen JF (abst) ... 394
de Prost D, Kanfer A, Le Floch V: Quantitative assessment of procoagulant activity in isolated rat glomeruli (Technical Note) ... 566
de Rave S (abst) ... 701
De Santo NG, Carella C, Leumann E, Amato G, Fine S, Nuzzi F, Capasso G, Capodicasa G, Lama G, Dileo VA, Giordano C: Thyroid function in uremic children ... S-166
De Santo NG: *see* Capodicasa et al ... S-112
De Sole P (abst) ... 88, 346
De Stefano V (abst) ... 309
de Urioste M (abst) ... 584
De Vecchi A (abst) ... 394, 394
De Vetter L (abst) ... 330
de Villa LF (abst) ... 584
de Waal RMW (abst) ... 710
de Zeeuw D (abst) ... 699
Deabate MC (abst) ... 255
Debrevi L (abst) ... 867
Debure A (abst) ... 373, 379
Debusche X (abst) ... 329
Dechaux M (abst) ... 335
Dechelette E (abst) ... 333, 339, 359
Dechenne CA (abst) ... 261
Decker G (abst) ... 361
Decobelli O (abst) ... 281
Degiannis D (abst) ... 374
Deinhardt F (abst) ... 712
del Canizo FJ (abst) ... 586
Del Favero E (abst) ... 393
Del Rio G (abst) ... 231, 232
Del Rosso G (abst) ... 247, 253
Delfino G: *see* Ghiggeri et al ... 168
Delgi Esposti E (abst) ... 247
Dellafiore L (abst) ... 223
Dell'Aquila R (abst) ... 232, 305, 306
Delling G (abst) ... 378
Dell'Oro C (abst) ... 225
Delmas V (abst) ... 349
Delobel J (abst) ... 234
Delons S (abst) ... 324
Deltz E (abst) ... 380
DelVecchio C (abst) ... 241
Delwiche F (abst) ... 285
Denney DL: *see* Spragg et al ... 75
Dennin RH (abst) ... 708, 709
Denton J (abst) ... 239
Derfler K (abst) ... 239, 329, 378, 379, 401, 402
Derkx FHM (abst) ... 698, 707
Descamps-Latscha B: *see* Nguyen et al ... 158
Descoeudres C (abst) ... 361, 595, 598
Desmottes RM (abst) ... 690
Deulofeu R (abst) ... 588, 589
Devalon M (abst) ... 307
DeVecchi A (abst) ... 379
Devogelaer JP (abst) ... 265
D'Haenens P (abst) ... 227
Dhondt JL (abst) ... 376
Diaz-Buxo J: CCPD is even better than CAPD ... S-24
di Belgioioso GB: *see* Ferrario et al ... 513
Deferrari G: *see* Tizianello A ... S-79
Dileo VA: *see* De Santo NG ... S-166
Di Maggio A (abst) ... 364, 364, 364
Di Marco T (abst) ... 280, 318
Di Minno G (abst) ... 258
Di Natale M (abst) ... 252
Di Paolo B (abst) ... 253, 280, 317, 318, 329
Di Paolo N (abst) ... 234
Diaz Rubio P (abst) ... 584
Dibble JB (abst) ... 248
D'Iddio S (abst) ... 359
Dietrich RB (abst) ... 246
Dieval J (abst) ... 234
Diez J (abst) ... 590
Diezi J (abst) ... 594, 595
Digard N (abst) ... 395, 400
Digito A (abst) ... 368
Dimitriadis A (abst) ... 279, 389
Dimopoulos P (abst) ... 860
Dinya Z (abst) ... 342
Dirks JH: *see* Mavichak et al ... 914
Dische F (abst) ... 396
Distler A (abst) ... 254, 360, 361, 697, 705, 706
Dittadi R (abst) ... 237
Djordjevic V (abst) ... 329, 338, 355
Dkhissi H (abst) ... 277, 293, 329, 365
do Pico JL (abst) ... 332
Dobbie J (abst) ... 336
Docci D (abst) ... 241
Docobu J (abst) ... 330
Doehring E, Ehrich HH, Vester U, Feldmeier H, Poggensee U, Brodehl J: Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis ... 520
Dogliani M (abst) ... 238
Doi S (abst) ... 348
Doichinov D (abst) ... 236
Doig A (abst) ... 282, 282
Domann M (abst) ... 708
Dombrouski J (abst) ... 356
Donati D (abst) ... 305, 369
Donato G (abst) ... 240
Donato G: *see* Coen et al ... 783
Donato L (abst) ... 248
Donker AJM (abst) ... 257, 697, 699, 711
Donnai P (abst) ... 231
Donohoe JF (abst) ... 333
Doornbos J (abst) ... 401
Dorhout Mees EJ (abst) ... 291, 291, 707
Dormont J (abst) ... 872, 872
Dorsch SE (abst) ... 866, 866
Doxanidis E (abst) ... 256
Dracon M (abst) ... 382
Drake B (abst) ... 869
Dratwa M (abst) ... 324, 325, 330
Dreikorn K (abst) ... 287, 390
Dresch C (abst) ... 691
Dropsy G (abst) ... 290
Droz D (abst) ... 236, 264, 367, 692, 873
Drudi J (abst) ... 365
Drüeke T (abst) ... 240, 246, 872
Drukker A (abst) ... 296
Duarte-Silva M (abst) ... 595
Dubost C (abst) ... 240
Duc M (abst) ... 690
Ducati A (abst) ... 323
Duchateau J (abst) ... 330
Ducobu J (abst) ... 296, 330
Dudczak R (abst) ... 329
Dudek E: *see* Berlyne G et al ... S-175

Duggin GG (abst) 858, 858
Duggin GG: *see* Hall et al 178
Dukes DC (abst) 337
Dulawa J (abst) 285, 289
Dulce HJ (abst) 361
Dulka E (abst) 238, 267
Dupommereulle C (abst) 342, 342
Dupont E (abst) 326, 332, 401
Dupont M (abst) 869
Dupont P (abst) 296, 330, 330
Duran F (abst) 586
Durand C (abst) 325, 347
Durand PY (abst) 690
Duranti E (abst) 297, 330
Dusunsel R (abst) 290
Duverlie G (abst) 316
Dyson EH (abst) 278

Eaton A (abst) 303
Ebel H (abst) 305, 340, 375
Edefonti A (abst) 323, 366, 367
Edmondson RPS (abst) 267, 387
Eeckels R (abst) 295
Egbring R (abst) 707
Eggert W (abst) 286
Egidi F (abst) 394, 394
Egidi FM (abst) 385
Egido de los Rios J (abst) 586
Egido J (abst) 271, 271, 292, 586
Ehrich HH: *see* Doehring et al 520
Eibl M (abst) 267
Eigler FW (abst) 700, 708
Eisenbach GM (abst) 369
Eisenhauer T (abst) 254, 386
Eisinger DR (abst) 858
El Gammal Y (abst) 305
El Mehdi M (abst) 325, 347
El Shahat Y (abst) 305
El Sheemy N (abst) 295
El-Badry A (abst) 253
El-Belbessi S: *see* Baczynski et al 722
El-Husseini F (abst) 400
El-Yafi S (abst) 293
Elat U (abst) 296
Eliahou HE (abst) 235
Eliott JC (abst) 863
Ellims P (abst) 864
Ellis D: *see* Avner et al 447
Ellis HA (abst) 240
Elsen R (abst) 324, 325, 331, 347
Endre ZH, Kuchel PW: Proton NMR spectroscopy of rabbit renal cortex 6
Enia G (abst) 343
Era S (abst) 354
Erard D (abst) 690
Erek E (abst) 286
Erez I (abst) 256
Errasti P (abst) 590
Eschbach JW (abst) 285
Eschbach JW, Adamson JW: Anemia of end-stage renal disease (ESRD). (Editorial Review) 1
Escobar EM (abst) 244, 588
Escuin F (abst) 244, 312
Esposito A (abst) 229, 349
Esposito C (abst) 233, 234
Esposito C (abst) 233, 234
Esposito R, Betuel H, Monzo M, Cirillo D, Pluvio M, Fredel AC, Lanzetti N, Perna N, Giordano C: The effect of branch chain amino acids on proliferation of normal and uremic cells S-8
Estelberger W (abst) 350
Estenoz J (abst) 350
Ettenger RB (abst) 308
Evan AP: *see* Blantz et al 733
Evangelista M (abst) 280
Evangelisti L (abst) 224
Evans DJ (abst) 266, 365, 391
Evers WM (abst) 704
Ewing DJ (abst) 357

Faaber P (abst) 703
Faber U (abst) 229
Fabris A (abst) 232, 305, 306, 350, 357, 368, 368
Facchetti F (abst) 399
Faden D (abst) 235
Faedda R (abst) 346, 278
Falkenhagen D (abst) 331
Falkenhagen U (abst) 331
Fallon TJ (abst) 298
Fanconi A (abst) 596
Fanestil DD (abst) 597
Fantuzzi S (abst) 343
Farge D: *see* Parfrey et al 959
Farinelli A (abst) 331, 374
Farinelli R (abst) 331, 374
Farnsworth A (abst) 858
Farnsworth A: *see* Hall et al 178
Fasching I (abst) 301
Fasciolo F (abst) 323
Fassbinder W (abst) 249, 289, 386
Fassett RG (abst) 867
Fatone F (abst) 392
Fauchald P (abst) 331
Favre H (abst) 309, 592
Favre L (abst) 595, 598
Favret M (abst) 399
Fdez-Llebrez J (abst) 299, 586
Fede C (abst) 225
Federico S (abst) 258
Feduska N (abst) 372
Feehally J (abst) 261, 262, 276, 400
Feest TG (abst) 286
Feher J (abst) 238
Fehr J (abst) 377, 593
Fein PA: *see* Avram MM et al S-100
Feiner H: *see* Neugarten et al 135
Feinfeld D (abst) 394
Feldmeier H: *see* Doehring et al 520
Feletti C: *see* Bonomini V et al S-57
Fell G (abst) 292, 308, 336
Fellay G (abst) 316, 592
Fellin G (abst) 252, 349
Felsovalyi K (abst) 248
Feriani M (abst) 232, 305, 306, 368, 368
Fernandez A (abst) 244, 380, 588
Fernandez JC (abst) 332
Fernandez-Gallardo S (abst) 587
Fernandez-Munoz MD (abst) 587
Ferragut A (abst) 352
Ferran N: *see* Adler et al 932
Ferrant A (abst) 394

Ferrara R (abst) 223, 303
Ferrario F, Castiglione A, Colasanti G, di Belgioioso GB, Bertoli S, D'Amico G, Nava S: The detection of monocytes in human glomerulonephritis..... 513
Ferrario GM (abst) 300
Ferreira C (abst) 332
Ferreri A (abst) 320
Ferrero R (abst)..... 388
Ferris TF: *see* Murray et al..... 767
Fiedorowicz-Fabrycy J (abst)..... 261
Fiegel P (abst) 705
Field MJ (abst)..... 861
Fievet P (abst) 234, 234, 235, 282, 282, 293
Figueroa CD: *see* Vio et al 36
Fillastre JP (abst) 689
Finaz de Villaine J (abst) 262, 690, 694
Findon G (abst) 869
Fine RN: For children, renal transplantation is the only realistic choice S-15
Fine RN (abst) 246, 308
Fine S: *see* De Santo NG et al..... S-166
Finegold DN: *see* Avner et al..... 447
Finet M (abst)..... 281, 282, 282
Fink M (abst)..... 315
Fioni G (abst)..... 374
Fischbach M (abst)..... 286
Fischbacher A (abst) 594
Fitzner R (abst)..... 361
Flament J (abst)..... 332
Flanigan MJ: *see* Lim et al 541
Fleuren GJ (abst) 270, 702
Flynn A (abst) 318
Foellmer HG (abst)..... 695
Fogazzi GB (abst)..... 392
Fohrer P (abst)..... 365
Foidart J (abst) 690
Foidart JB (abst)..... 261, 690
Foidart JM (abst)..... 261
Fommei E (abst)..... 248, 249
Fondarai J (abst) 347
Fontan MP (abst) 307, 312
Fonteyne E (abst)..... 227
Forbes RDC: *see* Parfrey et al..... 959
Forbush III B: *see* Kashgarian et al 899
Foret M (abst)..... 339, 345
Forget D (abst) 236, 264
Fornell L: *see* Assadi et al 153
Forsstrom J: *see* Nikoskelainen et al 672
Forwell MA (abst)..... 375
Fossas P (abst)..... 381
Fourcade J (abst)..... 349
Fournier A (abst) 234, 235, 241, 242, 246, 277, 281, 282, 293, 329, 351, 365
Fowler N: *see* Hropot et al..... 477
Francasso A: *see* Bazzato G et al S-161
Frampton G (abst)..... 233
France N (abst)..... 867
Franco A (abst) 227, 367, 590
Franco D (abst)..... 692
Francois R (abst)..... 284
Frasca GM (abst) 392
Fraser C (abst)..... 858
Frattini G (abst) 305, 375
Fredel AC: *see* Esposito R et al..... S-98
Freeman RM: *see* Lim et al 541
Freemont AJ (abst)..... 239
Freestone S (abst)..... 278
Frei A (abst)..... 314
Frei D (abst)..... 309
Frei U (abst)..... 395
French MAH (abst) 260
Frey FJ (abst) 595, 596
Frey HJ (abst)..... 315
Friedman EA: Physician bias in uremia therapy..... S-38
Friedman EA: Defensive medicine in diabetic nephropathy S-120
Friedrich RA: *see* Hakim et al 936
Fries D (abst)..... 375, 377, 390, 692
Fries J (abst) 701
Frisina N (abst)..... 283
Fritschka E (abst)..... 706
Fronis H (abst) 335
Frusca T (abst) 235
Fuchs J (abst)..... 312
Fuentes J (abst)..... 284, 590
Fuentes MG (abst) 385
Fuiano G (abst)..... 229, 233, 259, 332, 345
Fujii K: *see* Kobayashi et al..... 193
Fumarola D: *see* Coratelli P et al..... S-143
Furci L (abst)..... 343
Furlong TJ (abst)..... 859

Gabas J (abst) 589
Gabl F (abst) 397
Gabriel R (abst)..... 283, 287
Gafni J (abst) 232
Gaggiotti A (abst) 295
Gaggiotti E (abst) 234
Gagnadoux M-F: *see* Niaudet P et al S-148
Gagnadoux MF (abst)..... 371
Gainza J (abst) 585, 586
Gaisl H (abst)..... 397
Gal Gy (abst) 270
Galbe M (abst)..... 239
Gallego N (abst) 588
Gallenga PE (abst) 317
Gallery EDM (abst) 861, 868
Galli F (abst) 353
Gallien M: *see* Brancaccio D et al..... S-108
Gallieni M (abst)..... 321, 321
Gallimore MJ (abst) 386
Gallo R: *see* Dal Canton A et al..... S-154
Galy C (abst)..... 241, 242, 246, 277, 365
Gammaro L (abst) 350, 357
Gan A: *see* Avram MM et al..... S-100
Gan A (abst)..... 319
Gandjbakhch I (abst) 399
Ganeval D (abst)..... 265, 295
Gangemi C (abst)..... 333
Garabedian M (abst)..... 241
Garcia F (abst) 349, 588
Garcia Hoyo R (abst)..... 586
Garcia L (abst) 299, 586
Garcia M (abst)..... 233, 588, 589
Garcia Robles R (abst)..... 584
Garcia S (abst)..... 590
Garcia-Hoyo R (abst)..... 271, 292
Garcia-Masdevall MD (abst)..... 585
Garcia-Palleiro P (abst) 381
Garcia-Riego A (abst)..... 586
Gardner B (abst) 395
Garetto A (abst)..... 233

Garin J (abst) 585
Garibotto G: *see* Tizianello A et al S-79
Garini G: *see* Cambi V et al S-54
Garovoy MR (abst) 372
Garrett P (abst) 233
Gartner H-V (abst) 262
Gastaldi L (abst) 305, 375
Gasthuisberg UZ (abst) 701
Gatell JM (abst) 241
Gatta A (abst) 223, 280
Gatti P (abst) 299
Gautschi K (abst) 593
Gavendo S (abst) 235
Gawlik D (abst) 229
Gebhart W (abst) 378, 378
Gebuhrer L: *see* Betuel H et al S-170
Geerlings W (abst) 243
Geers AB (abst) 291
Geers AB, Koomans HA, Roos JC, Mees ETD: Preservation of blood volume during edema removal in nephrotic subjects. 652
Geiger H (abst) 697
Geisert J (abst) 286
Gekle D (abst) 230
Gelfand M (abst) 306
Genin C (abst) 249, 263, 263, 372
Genin G (abst) 289
Geniteau M (abst) 694
Gennari FJ: Acid-base balance in dialysis patients (Nephrology Forum). 678
Gentili S (abst) 314
Geoghegan T (abst) 400
Georgiopoulou A (abst) 350
Gerber A (abst) 594
Gessler U (abst) 277
Geyskes GG (abst) 707
Ghidini Ottonelli A (abst) 252
Ghiggeri GM, Candiano G, Delfino G, Queirolo C: Electrical charge of serum and urinary albumin in normal and diabetic humans. 168
Ghio L (abst) 366, 367
Ghione S (abst) 248, 249
Ghiringhelli P (abst) 245
Ghonaimy E (abst) 253
Ghoneim M (abst) 400
Ghysen J (abst) 382
Giacchino F (abst) 242, 333
Giaconi S (abst) 249
Giani M (abst) 366, 367
Giannattasio M (abst) 226, 325
Giardini O (abst) 356
Gibb WR (abst) 285
Gibbons CP (abst) 376
Gibson AP (abst) 861
Giebisch G: *see* Hropot et al 477
Giebisch GH (abst) 861
Giesen-Crouse EM (abst) 693
Gigli GL (abst) 345
Gil-Vernet S (abst) 224, 225
Gilks WR (abst) 372
Gillespie CM (abst) 303
Gilli G (abst) 237
Gilli P (abst) 331
Gilliard N (abst) 401, 593
Gimenez A (abst) 588
Gimenez E (abst) 590
Ginanni A (abst) 258
Giombini L (abst) 322, 323
Gion M (abst) 237
Giorcelli G (abst) 359
Giordano C: Early dietary protein restriction protects the failing kidney S-66
Giordano C: *see* Esposito R et al S-98
Giordano C: *see* Capodicasa G et al S-112
Giordano C: *see* De Santo NG et al S-166
Giordano R (abst) 321
Giovannetti S (abst) 281
Giraudo G (abst) 242, 333
Girbau J (abst) 376
Gisinger C (abst) 267, 287
Giuliano RA (abst) 226, 230
Giusti BP (abst) 309
Glanzer K (abst) 704
Glassock RJ: Natural history and treatment of primary (idiopathic) proliferative glomerulonephritis: A review S-136
Glassock RJ: *see* Kaizu et al 629
Glavas-Boras S (abst) 351
Gleed JH (abst) 241
Glinsky GV (abst) 271, 287
Gluckman JC (abst) 399
Gmelin K (abst) 287
Gmur J (abst) 377
Gnazzo A: *see* Ritz E et al S-84
Gnazzo A (abst) 288
Gockowski K (abst) 333
Godeau P (abst) 691
Godin M (abst) 689
Goheer MA: *see* May et al 490
Gohl H (abst) 335
Gokal R (abst) 231, 259, 300, 309, 309, 334, 334, 387
Golbetz H: *see* Shemesh et al 830
Goldhoorn CA (abst) 261
Goldman M (abst) 268, 326, 332
Goldsmith HJ (abst) 239, 316, 316
Goldstein G (abst) 379
Goldstein L (abst) 327
Goldstein R (abst) 296
Golemac S (abst) 292
Golper TA (abst) 366
Gomez F (abst) 251, 262, 299, 586
Gomez J (abst) 585
Gomez-Ullate P (abst) 585, 586
Gondocs Cs (abst) 238, 267
Gonella M (abst) 326
Goni M (abst) 590
Gonthier R (abst) 249, 289
Gonzalez C (abst) 590
Gonzalez E (abst) 271, 586
Gonzalez J (abst) 271, 586
Gonzalez MT (abst) 589
Gonzalez-Cabrero J (abst) 271
Gonzalez-Carcedo A (abst) 239
Gonzalez-Lopez A (abst) 587
Gonzalo A (abst) 587, 588
Goodman A (abst) 341
Goodship THJ (abst) 310, 326
Gooren L (abst) 299
Gordge MP (abst) 297
Gordon D: *see* Wilcox et al 43
Gordon T (abst) 285
Gore S (abst) 372

Gosling C (abst) ... 395
Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS) ... 526
Goto T (abst) ... 264
Gottlieb MN: *see* Hakim et al ... 535
Gotz R (abst) ... 288
Gouyette A (abst) ... 872
Gower PE (abst) ... 322, 341
Graben N (abst) ... 227
Graefe U (abst) ... 245, 299, 351
Graf H (abst) ... 242
Grandvuillemin M: *see* Berland Y et al ... S-183
Graninger W (abst) ... 327
Granolleras C (abst) ... 349
Grantham JJ, Levine E: Acquired cystic disease: Replacing one kidney disease with another (Editorial Review) ... 99
Grantham JJ: *see* Butkowski et al ... 744
Grateau G (abst) ... 873
Grau T (abst) ... 227, 590
Grave W (abst) ... 276, 702
Gray RES (abst) ... 243
Gray RW: *see* Lemann et al ... 951
Graziani G (abst) ... 242, 281, 304, 323
Grechi G (abst) ... 288
Greenwood RN (abst) ... 327
Greger B (abst) ... 708, 709
Gregorini G (abst) ... 235
Grekas D (abst) ... 327, 334, 335, 389
Gremmel F (abst) ... 239, 401, 402
Gretz N (abst) ... 288
Grgas J (abst) ... 351
Grifel L (abst) ... 226
Griffiths P (abst) ... 858, 858
Grigg R (abst) ... 868
Grimaldi F (abst) ... 248
Grimanis A (abst) ... 337
Grino JM (abst) ... 224, 225, 395, 589
Gritzmann N (abst) ... 355
Grljusic V (abst) ... 346
Grond J (abst) ... 261
Gronhagen-Riska C (abst) ... 271, 283
Grosoli M (abst) ... 327, 353
Grossetete J (abst) ... 272, 272, 871
Groves BM: *see* Shapiro et al ... 206
Grumetto L (abst) ... 295
Grundmann R (abst) ... 385
Grünfeld JP (abst) ... 264, 692, 873
Grusendorf M (abst) ... 712
Grutzmacher P (abst) ... 249, 289
Grzegorzewska A (abst) ... 328
Grzeszczak W (abst) ... 289
Guaita MC (abst) ... 349
Gualandi G (abst) ... 331
Guarena C (abst) ... 255
Guarriello L (abst) ... 332
Guastoni C: *see* Minetti L et al ... S-116
Guastoni C (abst) ... 393
Gubler MC (abst) ... 371
Guedon J (abst) ... 691
Guerin C (abst) ... 249, 289, 372
Guerra L (abst) ... 304
Guest G (abst) ... 341
Guiberteau R (abst) ... 306
Guida B (abst) ... 295
Guignard J-P (abst) ... 594, 595, 597
Guillaume Th (abst) ... 360
Gulay H (abst) ... 334
Gulle R (abst) ... 263
Gulmen GB: *see* Mason NS et al ... S-178
Gunn-Sechehaye A (abst) ... 693
Gurland HJ: Hemoperfusion in the treatment of uremia . S-47
Gushwa LC: *see* Blantz et al ... 733
Gushwa LC: *see* Tucker et al ... 28
Gutierrez A (abst) ... 283, 289, 328
Gutierrez-Millet V: *see* Praga et al ... 69
Gutsche H-U (abst) ... 705
Guttmann RD (abst) ... 379
Guttmann RD: *see* Parfrey et al ... 959
Guziur M (abst) ... 230
Gwyn Williams D (abst) ... 272, 277
Györy AZ (abst) ... 861, 864, 865

Haberal M (abst) ... 334, 376
Haberbosch W (abst) ... 288
Haberle D (abst) ... 869
Habib M (abst) ... 295
Habib R (abst) ... 371
Hachache T (abst) ... 339, 345
Hachmoller R (abst) ... 299
Haddoum F (abst) ... 355
Hadj Aissa A (abst) ... 236
Hadjidekov V (abst) ... 339
Hadjidimitriou C (abst) ... 391
Hadorn B (abst) ... 596
Hagemann JFHM (abst) ... 703
Hahn M (abst) ... 384
Hahn W (abst) ... 315, 698
Hain H (abst) ... 306
Hainaut J (abst) ... 330, 330
Haj-Ibrahim M: *see* Niaudet P et al ... S-148
Hajibaloglou A (abst) ... 334, 335
Hakim RM, Friedrich RA, Lowrie EG, Mantilla JM, Lee C: Formaldehyde kinetics and bacteriology in dialyzers ... 936
Hakim RM, Pontzer M-A, Tilton D, Lazarus JM, Gottlieb MN: Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients ... 535
Halbwachs-Mecarelli L: *see* Monteiro et al ... 666
Hall BM (abst) ... 858, 858, 866, 866
Hall BM, Tiller DJ, Duggin GG, Horvath JS, Farnsworth A, May J, Johnson JR, Sheil AGR: Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine ... 178
Hall D (abst) ... 292, 308, 336
Hall J (abst) ... 241
Hall T (abst) ... 308
Haller H (abst) ... 697
Hamdy NAT (abst) ... 243
Hamilton JD: *see* Porter et al ... 922
Hamzeh YS (abst) ... 335
Hand CT (abst) ... 280
Hanly P (abst) ... 333
Hannan SF (abst) ... 859
Hannoun C (abst) ... 316
Hanover B (abst) ... 298
Hanover BK: *see* Stephen RL et al ... S-60
Hansanoglu A (abst) ... 290
Hansen BL (abst) ... 377
Hanson JS (abst) ... 333
Harber MJ: *see* Asscher et al ...
Harding J (abst) ... 285

Hardy M (abst) 394
Hardy TL: *see* Bach et al 605
Haring R (abst) 360
Harris DC (abst) 865
Harris K (abst) 395
Harris PJ (abst) 870
Harrison C (abst) 867, 867
Harrison P (abst) 275
Harro JJ: *see* Stephen et al S-60
Hartig F (abst) 229
Hartley B (abst) 273, 275
Hartog M (abst) 294
Hartz G (abst) 266
Hasanoglu E (abst) 290
Haschemeyer R (abst) 384, 384
Hashimoto H (abst) 364
Hassaballa A (abst) 253
Hassaballa N (abst) 295
Hassan M (abst) 253
Hastings JGM (abst) 308
Haubenstock A (abst) 319
Hauck M (abst) 341
Haworth SJ (abst) 263
Hayano S (abst) 354
Haynes WDG (abst) 860
Hayslett JP (abst) 595
Heidbreder E (abst) 288, 706
Heidland A (abst) 288, 354, 697, 706
Heierli C (abst) 335, 344
Heitz W (abst) 707
Helbing F (abst) 245
Helenon C (abst) 251
Helfrich B (abst) 306
Hemmeloff KE (abst) 335
Henderson I (abst) 292, 308, 336
Henderson IS (abst) 310, 343
Hendrix PG (abst) 230
Henny FC (abst) 371, 376, 396, 711
Henriksen I (abst) 377, 395
Henrotte G (abst) 316
Henry JA (abst) 318
Henry MA (abst) 373, 870
Henry-Amar M (abst) 236
Henze Th (abst) 296
Herbelin A: *see* Nguyen et al 158
Hermann R (abst) 304
Hernandez RM (abst) 244, 588
Hernando Avendano L (abst) 586, 587
Hernando L (abst) 271, 271, 292, 321, 586, 587
Herold C (abst) 355
Herrera J (abst) 239, 373
Herrero Beaumont G (abst) 586
Herve JP (abst) 302
Herve M (abst) 351
Herzog D (abst) 235
Heslan JM (abst) 691
Hess B (abst) 304, 592, 597
Hess T (abst) 593
Heule H (abst) 598
Heuts CCM (abst) 710
Hewitt C (abst) 239
Hicks JA (abst) 233
Hiesse C (abst) 377
Hiki Y: *see* Kobayashi et al 193
Hildebrand U (abst) 354
Hildebrand U: *see* Schrader et al 823
Hill GM (abst) 863
Hillier VF (abst) 334
Hillis AN (abst) 372, 396
Hinglais N (abst) 272, 272, 371, 871
Hirasawa Y (abst) 317
Hirschel-Scholz S (abst) 593
Hirszel P: *see* Maher et al 16
Hlaca D (abst) 292
Ho CP (abst) 859, 864
Hoberbosh W: *see* Ritz E et al S-84
Hoberg S (abst) 703, 704
Hobson SM (abst) 328
Hodler J (abst) 361, 598
Hoedemaeker Ph J (abst) 270, 696, 702, 703
Hoenich NA (abst) 326
Hofmann L (abst) 702, 703, 704, 708
Hogg RJ (abst) 863
Hoitsma AJ (abst) 700
Holdsworth SR (abst) 314, 856, 856, 857, 859, 865, 866
Holland M (abst) 385
Holton R (abst) 294
Holtz M (abst) 331
Honkanen E (abst) 283, 336
Hooke DH (abst) 866
Hopkinson G (abst) 393
Hoppe D (abst) 315, 698
Hopt U (abst) 708
Hopt UT (abst) 708, 709
Horber FF (abst) 595
Hörl WH (abst) 336, 354, 706
Hörl WH, Steinhauer HB, Schollmeyer P: Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes 791
Horsburgh T (abst) 400
Hortling L (abst) 283
Horvath JS (abst) 858, 858
Horvath JS: *see* Hall et al 178
Hosokawa S (abst) 266, 266
Howden B (abst) 867, 867
Howden BO (abst) 373
Howie A (abst) 259
Hoyer J (abst) 706, 709
Hropot M, Fowler N, Karlmark B, Giebisch G: Tubular action of diuretics: Distal effects on electrolyte transport and acidification 477
Huang W-C, Jackson CA, Navar LG: Nephron responses to converting enzyme inhibition in non-clipped kidney of Goldblatt hypertensive rat at normotensive pressures 128
Huarte E (abst) 307, 312
Huaux JP (abst) 360
Huber J (abst) 378
Hubinger A (abst) 385
Huckauf H (abst) 229
Hudson BG: *see* Butkowski et al 744
Hudson JB: *see* Mandal et al 58
Hugel U (abst) 245
Hulme B (abst) 336
Hulter HN, Peterson JC: Acid-base homeostasis during chronic PTH excess in humans 187
Hunsicker LG: *see* Bertolatus et al 467
Hunt JS (abst) 865
Hunt L (abst) 259, 334
Huotari K (abst) 237
Hurault de Ligny B (abst) 693
Hurst MJ (abst) 337

Hutteroth T (abst) 340, 340, 711

Iaccarino V (abst) 251
Iaina A (abst) 226, 235, 337
Iancu M: *see* Avram MM et al S-100
Iancu M (abst) 319
Iandolo R (abst) 284
Ibels LS (abst) 859, 862, 862, 865
Icardi A (abst) 273, 365
Idei M (abst) 369
Idrissi A (abst) 241
Iellamo D (abst) 252
Iida K (abst) 317
Ilacqua N (abst) 320
Ilic S (abst) 355
Ilstrup KM: *see* Collins AJ et al S-18
Imbs JL (abst) 693
Imperiali P (abst) 297, 330
Inarrea P (abst) 587
Ing TS (abst) 347
Ingenito A (abst) 231
Innocenti M (abst) 323
Inouye H (abst) 354
Iodice M (abst) 284
Ippen H (abst) 352, 368
Ireland H (abst) 318
Iscovici E (abst) 337
Iseki K, Massry SG, Campese, VM: Evidence for a role of PTH in the reduced pressor response to norepinephrine in chronic renal failure 11
Isklander I (abst) 295
Issad B (abst) 311
Issautier R (abst) 873
Ito K (abst) 364
Ivanova AB (abst) 271, 287
Iversen BM (abst) 249
Iwadate N (abst) 361
Iwanaga S (abst) 362
Izumi N (abst) 357, 357

Jablonski P (abst) 373, 867, 867
Jackson B (abst) 867, 868
Jackson CA: *see* Huang et al 128
Jacobs C (abst) 279, 690
Jacobsen SC (abst) 298
Jacobson HR: *see* Wingo et al 51
Jacobson SC: *see* Stephen et al S-60
Jacobson SH, Lins L-E, Svenson SB, Kallenius G: Lack of correlation of P blood group phenotype and renal scarring 797
Jacquet AF (abst) 243, 243
Jaeger Ph (abst) 243, 243, 595
Jahn H (abst) 386
Jahn H: *see* Schohn et al 814
Jahn HA (abst) 597
Jakubowski C (abst) 334
Jakubowski H-D (abst) 700
Jakubowsky HD (abst) 708
Jalkanen M (abst) 237
Janin G (abst) 293
Jann K (abst) 285
Jarvis LR (abst) 860
Jasensky N (abst) 307
Jaspers WJM (abst) 235
Jeacock J (abst) 334
Jeannet M (abst) 309
Jenkins DAS (abst) 278, 358
Jennette JC, Wall SD, Wilkman AS: Low incidence of IgA nephropathy in Blacks 944
Jenni T (abst) 338
Jessen H (abst) 380
Jessen P (abst) 383
Jesson J (abst) 337
Jilg W (abst) 712
Jirka J (abst) 384, 396
Jofre R (abst) 389
John EG: *see* Assadi et al 153
Johnson JR: *see* Hall et al 178
Johnson RWG (abst) 387
Johnston CI (abst) 868
Johnston DG (abst) 313
Johny KV (abst) 272, 307
Jones CR (abst) 244
Jones W (abst) 595
Jordan SC (abst) 308
Jover B (abst) 869
Joveva R (abst) 236
Juillerat A (abst) 592
Junco E (abst) 367, 590
Jungbluth H (abst) 290, 377, 593
Jungers P (abst) 236, 264, 265, 290, 295, 872
Junor BJR (abst) 312, 374, 375, 389
Jurkovitz CI (abst) 365
Jureidini KF (abst) 863
Justice P: *see* Assadi et al 153

Kabalan S (abst) 396
Kablitz C (abst) 298
Kafkova L (abst) 384
Kaiser F (abst) 301
Kaiser H (abst) 296
Kaizu K, Marsh D, Zipser R, Glassock RJ: Role of prostaglandins and angiotensin II in experimental glomerulonephritis 629
Kalhan S (abst) 297
Källenius G: *see* Jacobson et al 797
Kalpakoglou S (abst) 279, 279
Kamanabroo D (abst) 267
Kaminetsky B: *see* Neugarten et al 135
Kaminski E (abst) 690
Kampf D (abst) 705
Kamphoff M (abst) 705
Kandemir B (abst) 290
Kandt M: *see* Schrader et al 823
Kanfer A (abst) 355
Kanfer A: *see* de Prost et al 566
Kangarloo H (abst) 246
Kanis JA (abst) 241, 243
Kant M (abst) 354
Kaplan De-Nour A (abst) 337
Kaplan MP (abst) 398
Kapuler S (abst) 235
Karayannopoulos S (abst) 337
Kariv N (abst) 255, 255
Karlmark B: *see* Hropot et al 477
Kasanen A: *see* Nikoskelainen et al 672
Kashgarian M (abst) 595, 695
Kashgarian M, Biemesderfer D, Caplan M, Forbush III B: Monoclonal antibody to Na,K-ATPase: Immunocytochemical localization along nephron segments .. 899
Kashiwagi N: *see* Kobayashi et al 193
Katus H: *see* Rambausek et al 775

Kavetsky RE (abst) 271
Kawaguchi H (abst) 364
Kay R (abst) 376
Kazatchkine M (abst) 272, 272
Kazatchkine MD (abst) 871
Kean WF (abst) 307
Keenan TD (abst) 863
Keil K (abst) 697
Kelesi A (abst) 279
Keller F (abst) 229, 229, 265, 266, 701
Keller H (abst) 290
Kellinghaus H (abst) 245, 351
Kemenade Jv (abst) 279
Kemmerich B (abst) 229
Kendell NP (abst) 261
Kenick S: *see* Parfrey et al 959
Kennedy A (abst) 308
Kennedy AC (abst) 292, 336
Kerr DNS (abst) 241
Kershaw M (abst) 275
Keshaviah P: *see* Collins AJ et al S-18
Kessali V (abst) 872
Kessel M (abst) 317, 317
Kessler M (abst) 690, 693
Keusch G (abst) 290, 304, 338, 377, 377, 593, 594, 597 5
Khanna R (abst) 306
Khashab O (abst) 253
Khoss A (abst) 226
Kida K (abst) 259
Kiffe H (abst) 368
Kikawa K (abst) 348
Kincey J (abst) 334
Kindler J (abst) 362
Kinnaert P (abst) 401
Kinoshita M (abst) 370
Kiremitci M (abst) 338
Kirjakov Z (abst) 294, 318, 339, 339
Kirkman RL: *see* Weir et al 839
Kishimoto T (abst) 357, 357, 362
Kiskinis D (abst) 334
Kiss E (abst) 270
Klahr S: *see* Bander et al 614
Klein H (abst) 296
Klein JM (abst) 365
Kleinbloesem CH (abst) 396
Kleinknecht D (abst) 227
Kletter K (abst) 329
Klinkmann H (abst) 331
Klooker P (abst) 287
Klotman PE, Boatman JE, Volpp BD, Baker JD, Yarger WE: Captopril enhances aminoglycoside nephrotoxicity in potassium-depleted rats. 118
Klouda PT (abst) 378
Kluge R: *see* Shapiro et al 206
Kluthe R (abst) 251
Knoll O (abst) 267
Kobayashi Y, Chen X-M, Hiki Y, Fujii K, Kashiwagi N: Association of HLA-DRw8 and DQw3 with minimal change nephrotic syndrome in Japanese adults. 193
Kober M (abst) 378
Kocandrle V (abst) 371, 384, 396
Koch KM: *see* Shaldon S et al S-124
Koch KM (abst) 301, 395
Kodama N (abst) 363
Koene RAP (abst) 320, 696, 700, 702, 710
Koga N (abst) 364
Kohan R: *see* Baczynski et al 732
Kohler H (abst) 277, 340, 340, 695, 701, 711
Kois J (abst) 306
Kokko JP: *see* Wingo et al 51
Kokot F (abst) 247, 289
Kollath J (abst) 249
Komarnicki M (abst) 291
Kommerell B (abst) 287
Kong BCT (abst) 865
Konner K (abst) 338
Konstantin P (abst) 335
Koomans HA (abst) 291, 291
Koomans HA: *see* Geers et al 652
Koopman MG (abst) 291
Kopec J: *see* Wichman et al 558
Kopper L (abst) 267
Kopple JD (abst) 287
Kopsa H (abst) 239,319,355,378,379,397,397,401,402,701,709
Kopsa K (abst) 329
Kordecki H (abst) 261
Korzets Z (abst) 307, 310
Koshikawa S (abst) 317, 349
Koskela M: *see* Nikoskelainen et al 672
Köstering H: *see* Schrader et al 823
Kostic S (abst) 329, 338, 355
Kotsovasilis K (abst) 350
Koutoupi S (abst) 327
Kovaceski S (abst) 358
Kovarik J (abst) 226,242,267,301,327,369,383,400
Kovatz S (abst) 307
Kozma G (abst) 272, 307
Kozma-Malik MC (abst) 272, 307
Kraev Z (abst) 339, 339
Kraft D (abst) 229
Kramer HJ (abst) 704
Kramer W (abst) 362
Krapf E (abst) 380
Kratzmeier M (abst) 237
Kraus A (abst) 303
Krause R (abst) 278
Krause U (abst) 700
Krautwald E (abst) 340, 375
Krautwald G (abst) 340, 375
Krediet RT (abst) 291, 304, 308
Kreis H (abst) 373, 379, 692
Kretschmer G (abst) 402
Kribben A (abst) 706
Kriss JP: *see* Shemesh et al 830
Kristinsson KG (abst) 308
Krivoshiev S (abst) 318, 339
Kriz W: *see* Bouby et al 456
Krolak M (abst) 333
Kronqvist K (abst) 379
Krstanoski B (abst) 358
Kruck F (abst) 704
Krysinska I (abst) 328
Krzymanski M (abst) 273
Kuchel PW: *see* Endre et al 6
Kuentz F (abst) 339, 345, 365
Kuhl J (abst) 230
Kuhlback B (abst) 379, 387
Kuhn K (abst) 301
Kuleva V (abst) 318
Kumano K (abst) 230
Kumar MSA (abst) 397
Kuntz D (abst) 246

Kurschel E (abst) 227
Kurz P (abst) 277, 340, 340, 695, 711
Kuwata K (abst) 374

La Greca G (abst) 232, 305, 306, 368, 368
Laab C (abst) 705
Laasonen L (abst) 271, 283, 387
Labeeuw M (abst) 236, 262, 690
Laborde K (abst) 253
Lacave R (abst) 692
Lachatre G (abst) 872
Lacic N (abst) 376
Lacombe JL (abst) 331
Lacombe M (abst) 379, 872
Lacour B (abst) 281
Ladefoged J (abst) 273
Laforgia R: *see* Mastrangelo F et al S-188
Lagrue G (abst) 691
Lahera V (abst) 586
Lai KN (abst) 859, 860, 864, 867
Lalau JF (abst) 329
Lama G: *see* De Santo NG et al S-166
Lambert CI (abst) 365
Lambert PH (abst) 335
Lambert RM (abst) 373
Lambie AT (abst) 282
Lamer A (abst) 231
Lamperi S (abst) 236, 273, 307, 365, 393, 397
Lampreabe I (abst) 585, 586
Lanaro R (abst) 298
Landais P (abst) 227
Landi A (abst) 240, 323
Landini S: *see* Bazzato G et al S-161
Landini S (abst) 320, 367
Landolfo S (abst) 333
Lane DA (abst) 308
Lang E (abst) 277
Lang Ph (abst) 390
Lange H (abst) 305, 340, 375, 707
Lange WPJ (abst) 696, 702
Langhoff E (abst) 273
Lanzetti N: *see* Esposito R et al S-98
Lapalombara C (abst) 247
Lapin A (abst) 397 Lapis J (abst) 285
Lapis K (abst) 267
Laquaniti L (abst) 368
Large B (abst) 306
Largiader F (abst) 377
Lauer CS (abst) 862, 865
Laurent B (abst) 263, 263, 372
Laurent J (abst) 691
Lauterwein B (abst) 704
Lavaud S (abst) 296, 694
Lavie G (abst) 386
Laville M (abst) 262, 694
Lawler W (abst) 259, 387
Lawson L: *see* Porter GA et al S-34
Lazarides A (abst) 389
Lazaridis A (abst) 256
Lazarus JM: *see* Hakim et al 535
Le Chapois D (abst) 306
Le Couteur D (abst) 864
Le Feuvre CM (abst) 341
Le Floch V: *see* de Prost et al 566
Le Gall JY (abst) 250
Le Goff A (abst) 250
Le Petit JC (abst) 263, 263
Le Pogamp P (abst) 250
Le Treut A (abst) 250
Leatherman J (abst) 302
Lebon P (abst) 691
Lecave R (abst) 691
Lecic N (abst) 338
Ledingham JGG (abst) 241
Lee C: *see* Hakim et al 936
Lee D (abst) 307
Lee FF (abst) 340
Lee G (abst) 305
Lee I: *see* Stokes et al 640
Lee JCK (abst) 860
Leenhardt L (abst) 240
Leflon P (abst) 282, 282, 365
Legendre C (abst) 379
Legrain M (abst) 301
Leichter HE (abst) 246, 308
Leimenstoll G (abst) 363, 380, 380, 390
Leinonen M: *see* Nikoskelainen et al 672
Leitienne Ph (abst) 262
Lelievre G (abst) 382
Lemann Jr J, Gray RW, Maierhofer WJ, Cheung HS: Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations 951
Lemieux C: *see* Lemieux et al 760
Lemieux G, Berkofsky J, Quenneville A, Lemieux C: Net tubular secretion of bicarbonate by the alligator kidney Antimammalian response to acetazolamide . 760
Lenhard V (abst) 380
Lens XM (abst) 250, 264, 341
Lenz T (abst) 360, 361, 697
Leo F (abst) 254
Leonard EF (abst) 340
Leonardi M (abst) 240, 342
Leoncini F (abst) 292
Leone G (abst) 309
Leonelli M (abst) 343
Leontsini M (abst) 279
Leroux-Robert C (abst) 872
Leroy D (abst) 341
Leroy G (abst) 249, 289, 372
Lerut T (abst) 701
Lesavre P: *see* Monteiro et al 666
Leski M (abst) 693
Lethias C: *see* Nguyen et al 158
Leumann E: *see* De Santo NG et al S-166
Leumann EP (abst) 596
Leung A (abst) 292, 308, 336
Leung ACT (abst) 310
Leunissen KML (abst) 243, 397
Leuven KU (abst) 701
Levine E: *see* Grantham et al 99
Levy E (abst) 296
Levy NB (abst) 341
Lewicka S (abst) 705
Lewis EJ: *see* Schwartz et al 968
Lewis GP: *see* Wilcox et al 43
Li Calzi L (abst) 313, 313
Liano F (abst) 380, 388, 587, 588
Lieberknecht M (abst) 274
Lies A (abst) 265
Lilien Tv (abst) 308
Lillo JL (abst) 231

Lillo-Ferez M (abst) 342, 342
Lim CH (abst) 267
Lim VS, Flanigan MJ, Zavala DC, Freeman RM: Protective adaptation of low serum triiodothyronine in patients with chronic renal failure. 541
Linas SL: *see* Benedetti et al 621
Lindstrom B (abst) 387
Lins L-E: *see* Jacobson et al 797
Liosi C (abst) 320
Lis D (abst) 255
Lison AE (abst) 267, 301
Litt MH: *see* Mason NS et al S-178
Liu DT: *see* Neugarten et al 135
Livesley P (abst) 316
Llach F: Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome (Editorial Review) 429
Llach F: *see* Rodriguez et al 808
Llorach M (abst) ..... 376, k, 381, 381, 381, 382
Lloveras J (abst) 351, 376, 381, 381, 381, 382
Lloveras J-J (abst) 274
Llovet J (abst) 381
Lobatto S (abst) 381
Locatelli F (abst) 225, 228, 252, 368
Lockwood CM (abst) 263, 266, 274, 275, 275, 298
Lockwood M (abst) 267
Locsey L (abst) 342
Lode H (abst) 229
Loew H (abst) 267, 708
Lombardi M (abst) 292
Lombardo V (abst) 228
Lombini C (abst) 237
Lonati F (abst) 323
Lopez J (abst) 262
Lopez M, Tuchman M, Scheinman JI: Capillary gas chromatography measurement of exalate in plasma and urine (Technical Note) 82
Lopez Novoa JM (abst) 587
Lopez Pedret J (abst) 341
Lopez-Gomez JM (abst) 227, 367, 590
Lopez-Novoa JM (abst) 587
Lopez-Pedret J (abst) 589
Lorenzi S (abst) 23
Lornoy W (abst) 227, 321
Loschiavo C (abst) 350, 357
Losinno F (abst) 247
Losse H (abst) 301
Louis F (abst) 309, 592
Louis J (abst) 690
Lovett DH (abst) 695
Lowenstein LM: *see* Paddock et al 498
Lowrie EG: *see* Hakim et al 936
Lowry OH: *see* Burch et al 114
Lozano L (abst) 271, 292, 586
Lubec G (abst) 226
Lubowitz H: *see* Mason NS et al S-178
Lubrano R (abst) 356
Lucas PA (abst) 244, 244
Lucas SB (abst) 259
Lucatello F: *see* Bazzato G et al S-161
Lucchi L (abst) 342, 343
Luciak M (abst) 358
Luciani L (abst) 252
Ludersdorf M (abst) 697
Luger A (abst) 242, 368
Luik AJ (abst) 343
Luisoli S: *see* Marone et al 658
Lukacs B (abst) 360
Lund Hansen B (abst) 395
Lundin AP: Quality hemodialysis: A "gold standard" treatment for survival S-12
Lunghi F (abst) 281
Luno J (abst) 367, 590
Lupetti S (abst) 326
Lupo A (abst) 350, 357
Lupo L (abst) 226
Luque A (abst) 262
Lust C (abst) 690
Lusvarghi E (abst) 240, 342, 343
Luthy E (abst) 338
Lynn KL (abst) 863, 864, 865

Maass D (abst) 597
Mabadeje A (abst) 367
Mabadeje AFB (abst) 348
Mac-Moune Lai F (abst) 859, 860, 864
Macanovic M (abst) 292
MacD Agar JW (abst) 857
Mackenzie J (abst) 294
MacLaren DM (abst) 314
MacLean AB (abst) 863
MacLeod A (abst) 383
Macnicol AM (abst) 278
MacSween RNM (abst) 375
Madero R (abst) 312
Madsen S (abst) 273
Maeda A (abst) 363
Maeda T (abst) 264, 370
Maekawa M (abst) 357, 357
Maekawa T (abst) 357, 357
Magdi RF (abst) 266
Maggiore Q (abst) 252, 343
Magil AB: *see* Mavichak et al 914
Magott M: *see* Baczynski et al 722
Magri V (abst) 228
Magyarossy E (abst) 238, 267
Maher FR (abst) 266
Maher JF, Bennett RR, Hirszel P, Chakrabarti E: The mechanism of dextrose-enhanced peritoneal mass transport rates 16
Mahieu P (abst) 690, 692
Mahieu PR (abst) 261
Mahiout A (abst) 317, 317
Maierhofer WJ: *see* Lemann et al 951
Maiorca R (abst) 235, 266, 393, 399, 399, 399
Maistre-Charransol G (abst) 692
Maj M (abst) 332
Majkowska L (abst) 261, 325
Majoor GD (abst) 710
Makdassi R (abst) 242, 293
Malacarne F (abst) 331
Malavasi F (abst) 275
Malberti F (abst) 233, 233, 237
Malchesky PS: *see* Nose Y et al S-131
Maldague B (abst) 360
Malfi B (abst) 387
Mall G: *see* Rambausek et al 775
Mallamace A (abst) 320
Mallick NP (abst) 231,259,260,262,269,276,309,387
Malmusi G (abst) 343
Mampaso F (abst) 587, 588
Man in 't Veld AJ (abst) 698, 707

Man NK (abst) ... 324
Manca F (abst) ... 393
Manca N (abst) ... 393
Mandal AK, Sklar AH, Hudson JB: Transmission electron microscopy of urinary sediment in human acute renal failure ... 58
Mandet C (abst) ... 272
Mandet Ch (abst) ... 871
Mandressi A (abst) ... 281
Manente P (abst) ... 298
Manganoni A (abst) ... 266
Mangiarotti MA (abst) ... 224
Manintveld AJ (abst) ... 704
Manitius A (abst) ... 333
Manitius J (abst) ... 333
Manke HG (abst) ... 380
Mann H (abst) ... 356
Mann JFA (abst) ... 250
Manna L (abst) ... 353
Manno C (abst) ... 344, 369
Manns M (abst) ... 277, 695
Manos J (abst) ... 309
Mansour M (abst) ... 257
Mantilla JM: *see* Hakim et al ... 936
Mantovanelli A (abst) ... 248, 249
Manzi M (abst) ... 265
Marai P (abst) ... 228
Marangella M (abst) ... 252
Marcen R (abst) ... 388, 587, 588
Marchal M (abst) ... 326
Marchini P (abst) ... 237
Marciani MG (abst) ... 345, 347
Marcuccio F (abst) ... 284, 284
Marcuello E (abst) ... 351
Marie A (abst) ... 246
Marik J (abst) ... 308
Maritano M (abst) ... 388
Markert M (abst) ... 335, 344
Marone C (abst) ... 596
Marone C, Luisoli S, Bomio F, Beretta-Piccoli C, Bianchetti MG, Weidmann P: Blood sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine ... 658
Marosi L (abst) ... 329
Marra G (abst) ... 253
Marsden A (abst) ... 309
Marsh D: *see* Kaizu et al ... 629
Marsh F (abst) ... 334
Marshall VC (abst) ... 373, 867, 867
Marsili P (abst) ... 355
Marteau P (abst) ... 692
Martegani M (abst) ... 305, 375
Martin AM (abst) ... 293
Martin D: *see* Bander et al ... 614
Martin De Francisco AL (abst) ... 385
Martin Hernandez R (abst) ... 587
Martin Mateo MC (abst) ... 344
Martin R (abst) ... 588
Martin S (abst) ... 387
Martin X, Opgenorth TJ, Werness PG, Rundquist RT, Romero JC, Smith LH: Bladder secretion of inhibitors of calcium oxalate crystal growth ... 636
Martin-Comin J (abst) ... 395
Martin-Malo A (abst) ... 585
Martina G (abst) ... 260, 275, 280
Martinez A (abst) ... 350
Martinez E (abst) ... 244, 352
Martinez JA (abst) ... 341
Martinez JM (abst) ... 584
Martinez ME (abst) ... 307
Martinez-Brotons F (abst) ... 589
Martins R (abst) ... 332
Martre H (abst) ... 279
Martre H (abst) ... 690
Marumo F (abst) ... 300
Masala A (abst) ... 258
Mascart-Lemone F (abst) ... 330
Maschio G: Is phosphate more important than protein in low-protein diets? ... S-71
Maschio G (abst) ... 350, 357
Masia AM (abst) ... 223
Mason NS, Sparks RE, Skoff H, Lubowitz H, Gulmen GB, Mazumdar DC, Litt MH: A new ion exchanger with high in vivo sodium capacity ... S-178
Mason P (abst) ... 362
Mason R (abst) ... 383
Mason RS (abst) ... 859
Masramon J (abst) ... 351, 376, 381, 381, 381, 382
Massaro G (abst) ... 355
Massimetti C (abst) ... 240
Massimetti C: *see* Coen et al ... 783
Massry SG: Neurotoxicity of parathyroid hormone in uremia ... S-5
Massry SG: *see* Baczynski et al ... 722
Massry SG: *see* Iseki et al ... 11
Mastrangelo S, Rizzelli S, Corleano C, Montenary AM, De Blasi V, Alfonso L, Aprile M, Napoli M, Laforgia R: Benefits from bicarbonate dialysis ... S-188
Mastrangelo F (abst) ... 344, 345
Mastropasqua L (abst) ... 317
Matesanz R (abst) ... 244, 349, 388, 588
Mathew RJ, Rabin P, Stone WJ, Wilson WH: Regional cerebral blood flow in dialysis encephalopathy and primary degenerative dementia ... 64
Mathew TH (abst) ... 867, 868
Matl I (abst) ... 396
Matsuo H (abst) ... 348
Mattei MF (abst) ... 399
Matthews PG (abst) ... 868
Mattlinger B (abst) ... 290
Mauri J (abst) ... 589
Mauri JM (abst) ... 589
Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH: Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats ... 914
Maxwell JG: *see* Stephen et al ... S-60
Maxwell JG (abst) ... 298
May J: *see* Hall et al ... 178
May RC, Clark AS, Goheer MA, Mitch WE: Specific defects in insulin-mediated muscle metabolism in acute uremia ... 490
Mayaud C (abst) ... 692
Mayer G (abst) ... 383
Maynar M (abst) ... 352
Mayor G (abst) ... 356
Mazumdar DC: *see* Mason NS et al ... S-178
Mazzaferro S (abst) ... 240
Mazzaferro S: *see* Coen et al ... 783
Mazzarella V (abst) ... 352
McAreavey D (abst) ... 353
McCredie DA (abst) ... 857

McCullough A (abst) 297
McGiven AR (abst) 865
McGonigle R (abst) 259
McGonigle RJS (abst) 392, 393, 398
McGrath B (abst) 869
McHugh MI (abst) 293
McKenzie SI (abst) 343
McMaster P (abst) 392
McNally PG (abst) 376
McNeil NI (abst) 285
McTigue C (abst) 864
Mecca G (abst) 260
Mees ETD: *see* Geers et al 652
Meftahi H (abst) 339, 345
Mehamha H (abst) 311
Mehls O (abst) 246
Mehls O: *see* Rambausek et al 775
Meijer S (abst) 238, 711
Meisinger E (abst) 288
Melhorn N (abst) 306
Melin JP (abst) 694
Mello G (abst) 231
Meloni C (abst) 345, 347
Melzer J (abst) 372
Memoli B (abst) 332, 345
Mene P (abst) 265
Menghi R (abst) 256
Menicanti L (abst) 368
Mentasti P (abst) 232
Merke J (abst) 245, 245
Merkel C (abst) 223
Merlo A (abst) 280
Merola E (abst) 333
Merola E (abst) 588
Meroni M (abst) 300
Mery J Ph (abst) 349
Messina A (abst) 860
Messina M (abst) 381, 382
Mestdagh J (abst) 227
Metaxas P (abst) 279
Metivier F (abst) 689
Metodiev K (abst) 382
Metz U (abst) 227
Meurer KA (abst) 707
Meyer T (abst) 249
Meyer zum Buschenfelde K-H (abst) 277, 340, 340
Meyer zum Buschenfelde K-H (abst) 701
Meyer zum Buschenfelde KH (abst) 695
Meyer zum Buschenfelde KH (abst) 711
Meyrier A (abst) 693, 871
Mezger MS (abst) 293
Miailhe E (abst) 871
Michael AF: *see* Platt et al 550
Michael J (abst) 259, 392, 393, 398
Michaux JL (abst) 394
Michel C (abst) 251, 360
Michel Ph (abst) 293
Michelotti A (abst) 346
Michielsen P (abst) 701
Micossi P (abst) 313
Micucci G (abst) 228
Middeldorp JM (abst) 700
Migliardi A (abst) 356
Mignon F (abst) 251, 260
Miguel JL (abst) 244, 307
Mihatsch M (abst) 597
Mihatsch MJ (abst) 392
Milcent T (abst) 694
Mileto G (abst) 276, 313, 313
Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Cesca D, Boffo V, Casciani CU: The upper and the lower gastrointestinal tract in uremic patients on long-term hemodialysis S-157
Millar ND (abst) 293
Miller T (abst) 869
Millet VG (abst) 584
Milongo R (abst) 339, 345
Milutinovic S (abst) 297, 346
Mimran A (abst) 384, 869
Mimura K (abst) 264
Mimura N (abst) 317, 349
Minar E (abst) 401
Minetti A: *see* Brancaccio D et al S-108
Minetti L, Civati G, Guastoni C, Perego A, Teatini U: Minimal standards for hemofiltration S-116
Minetti L (abst) 233, 233, 237, 393
Minuth WM: *see* Bouby et al 456
Mioli V (abst) 228
Mioli VA (abst) 346
Mion C (abst) 322, 384, 873
Mione R (abst) 237
Miqueo C (abst) 590
Mir M (abst) 382
Miranda B (abst) 394, 350, 584
Misefari V (abst) 343
Mistry CD (abst) 309, 309
Mitch WE: *see* May et al 490
Mittal VK (abst) 398
Mitwalli A (abst) 312
Miura K (abst) 354
Miyai T (abst) 370
Mizoguchi H (abst) 349
Molenaar JC (abst) 710
Molnar V (abst) 255, 397, 346
Molzahn M (abst) 229, 254, 265, 360, 361, 705, 706
Moncada S (abst) 269
Monitz C (abst) 348
Moncrief J, Popovich R: Continuous ambulatory peritoneal dialysis best treatment for end-stage renal failure S-23
Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreira MC, Noel L-H, Berger J, Lesavre P: Charge and size of mesangial IgA in IgA nephropathy 666
Monteis J (abst) 381, 381
Monti JP (abst) 325, 347
Monti L (abst) 313
Montinaro AM (abst) 344, 345
Montenary AM: *see* Mastrangelo F et al S-188
Montoliu J (abst) 250, 264, 333, 341, 589
Monzon A (abst) 590
Moolenaar AJ (abst) 396
Moore H (abst) 306
Moore RA (abst) 280
Mooy J (abst) 276, 279, 702, 707
Mora J (abst) 395
Morabito S (abst) 252
Morachiello P: *see* Bazzato et al S-161
Morachiello P (abst) 320
Morales JM (abst) 294, 350, 584
Morales JM: *see* Praga et al 69
Morales P (abst) 385
Moreau JF: *see* Vie et al 553

Morelle V (abst) 227
Morelli C (abst) 269
Morelli E (abst) 281
Moreno A (abst) 380
Moreno E (abst) 585
Moretti P (abst) 320
Morgan AG (abst) 374
Morgan T (abst) 870
Morgan TO (abst) 869
Mori K (abst) 302
Mori R (abst) 309, 346
Moriconi L (abst) 248
Moriggi M (abst) 394
Morin JP (abst) 689
Moriniere P (abst) 241, 246, 277, 316, 351, 365
Morishita S (abst) 264
Morkrid L (abst) 249
Morley AR (abst) 696
Morosetti M (abst) 345, 347
Morris D (abst) 262
Moulonget-Doleris D (abst) 690
Moulonguet Doleris L (abst) 691, 692
Mourad G (abst) 384, 873
Mousty F (abst) 321
Movilli E (abst) 266
Mowat AM (abst) 374
Muggli F (abst) 596
Muharemi S (abst) 358
Muhlethaler K (abst) 377
Muir J (abst) 869
Mulcahy D (abst) 333
Mulder AW (abst) 235
Muller C (abst) 708
Muller G (abst) 708
Muller GA (abst) 702, 703, 704, 708
Muller GH (abst) 708, 709
Muller HG (abst) 305
Muller-Wiefel DE (abst) 237, 390
Mundo A (abst) 343
Mune M (abst) 264, 264
Munno I: *see* Coratelli P et al S-143
Muniz R (abst) 586
Munne A (abst) 381
Munoz IM (abst) 312
Munoz MC (abst) 584
Murad Z (abst) 865
Murisasco A (abst) 325, 347
Murnaghan K (abst) 691
Murphy DL (abst) 857
Murray AT (abst) 595
Murray BM, Paller MS, Ferris TF: Effect of cyclosporine administration on renal hemodynamics in conscious rats 767
Mushmov D (abst) 294
Myers BD: *see* Shemesh et al 830
Myers RR: *see* Blantz et al 733

Nadinic B (abst) 346
Nagant de Deuxchaisnes C (abst) 265
Nagaoka S (abst) 354
Nagy Z (abst) 267
Nakamura K (abst) 317
Nancollas GH: *see* Singh et al 985
Napierala K (abst) 285
Napoli M: *see* Mastrangelo F et al S-188
Napoli M (abst) 344, 345
Nardi F: *see* Milito G et al S-157
Naret C (abst) 324, 872
Naret C: *see* Nguyen et al 158
Nascimento L: *see* Rastogi et al 801
Natsheh T (abst) 279
Naughton RJ (abst) 870
Nava S: *see* Ferrario et al 513
Navar LG: *see* Casellas et al 752
Navar LG: *see* Huang et al 128
Navas JJ: *see* Praga et al 69
Navis GJ (abst) 699
Nawab ZM (abst) 347
Neale JT (abst) 871
Neale TJ (abst) 862, 866, 867, 869
Neild G (abst) 396
Neild GH (abst) 392
Neilson JM (abst) 357
Nelson EW (abst) 298
Nelson Rd (abst) 307
Nemeth J (abst) 596
Neugarten J, Kaminetsky B, Feiner H, Schacht RG, Liu DT, Baldwin DS: Nephrotoxic serum nephritis with hypertension: Amelioration by anti- hypertensive therapy 135
Neumayer H-H (abst) 254, 265, 360, 361, 705, 706
Nevarez MD (abst) 315
Ng J (abst) 867
Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood 158
Niaudet P, Haj-Ibrahim M, Gagnadux M-F, Broyer M: Outcome of children with acute renal failure S-148
Nicholls AJ (abst) 228
Nicholls KM: *see* Shapiro et al 206
Nicholson E (abst) 861
Nicolopoulos N (abst) 331, 363, 380, 380, 383, 390
Nicot G (abst) 872
Niebel W (abst) 700
Niedermayer W (abst) 705
Niederwieser A (abst) 596
Niembro E (abst) 227, 262, 590
Niemir Z (abst) 273
Nieto J (abst) 294, 584
Nikolakakis N (abst) 310
Nikolov V (abst) 347
Nikoskelainen J, Koskela M, Forsstrom J, Kasanen A, Leinonen M: Persistence of antibodies to pneumoccal vaccine in patients with chronic failure 672
Niosi F (abst) 281
Nishide I (abst) 302, 363, 370
Nishikawa N (abst) 302, 370
Nishikawa O (abst) 370
Nishio T (abst) 366, 366
Nishitani H (abst) 366, 366
Nisi MT (abst) 253
Nisi T (abst) 329
Niwa M (abst) 362
Noble B: *see* Zamlauski-Tucker et al 504
Noel Ch (abst) 382
Noel H (abst) 360
Noel L-H: *see* Monteiro et al 666
Noel LH (abst) 264, 692
Noel N (abst) 373
Nolasco F (abst) 275

Nolph K (abst) ... 306
Nolph KD, Cutler SJ, Steinberg SM, Novak JW: Continuous ambulatory peritoneal dialysis in the United States: A three-year study ... 198
Nomoto H (abst) ... 264, 264, 302, 363, 370
Nony A (abst) ... 306
Normand M (abst) ... 872
North A (abst) ... 869
Nose Y, Smith JW, Molchesky PS: Plasmapheresis holds distinct advantages for 21st century uremia therapy ... S-131
Notohamiprodjo MS (abst) ... 712
Novak JW: *see* Nolph et al ... 198
Nunez Nunez J (abst) ... 587
Nuzzi F: *see* De Santo NG et al ... S-166

Obek A (abst) ... 363
O'Brien M (abst) ... 341
Ockhuizen Th (abst) ... 710
Ocon J (abst) ... 232
O'Connor DT (abst) ... 295
O'Donovan R (abst) ... 348, 398
Odutola T (abst) ... 367
Odutola TA (abst) ... 348
O'Dwyer WF (abst) ... 333
Ody B (abst) ... 693
Oe PL (abst) ... 299, 314
Oehler S (abst) ... 703, 704
Offerman G (abst) ... 701
Offermann G (abst) ... 229, 229
Ofstad J (abst) ... 249
Ogg C (abst) ... 334
Ogg CS (abst) ... 233, 303, 303
Ogilvie R (abst) ... 312
O'Hara N (abst) ... 326
Okamoto T (abst) ... 348
Okanya D: *see* Avram MM et al ... S-100
Oko A (abst) ... 275
Okonek M (abst) ... 231
Okonek S (abst) ... 231
Oksenhendler E (abst) ... 265
Okubo M (abst) ... 300
Oldrizzi L (abst) ... 350, 357
Olgaard K (abst) ... 275
Olier B (abst) ... 689
Oliva Aldamiz H (abst) ... 587
Oliva O (abst) ... 251
Olivares J (abst) ... 590
Oliveira L (abst) ... 332
Oliver D (abst) ... 334, 334
Oliver DO (abst) ... 241
Oljans PJ (abst) ... 376
Oller L (abst) ... 381
Olmer M: *see* Berland Y et al ... S-183
Onen K (abst) ... 286, 294
Oner Z (abst) ... 334, 376
Ono K (abst) ... 348, 348
Onuzo O (abst) ... 367
Onuzo OBC (abst) ... 348
Ooms ECM (abst) ... 238
Oort J (abst) ... 238
Opelz G (abst) ... 380
Opgenorth TJ: *see* Martin et al ... 636
Orange GV (abst) ... 310
Oreopoulos DG (abst) ... 312
Orfila A (abst) ... 376, 381, 381, 382
Orko R (abst) ... 336
Orlandini GC (abst) ... 327
Orofino G (abst) ... 284
Orofino L (abst) ... 244, 587, 588
Orsanic D (abst) ... 346
Ortalda V (abst) ... 357
Orte L (abst) ... 244, 349, 588
Ortega O (abst) ... 307, 312
Orts J (abst) ... 590
Ortuno J (abst) ... 244, 349, 380, 388, 587, 588
Osadchaya LP (abst) ... 284
Ositelu S (abst) ... 367
Ositelu SB (abst) ... 348
Osnabrugge C (abst) ... 702
Osnabrugge Cv (abst) ... 270
Ota K (abst) ... 310, 314, 349
Otsubo O (abst) ... 361
Ottavioli JN (abst) ... 692
Otxaran J (abst) ... 585, 586
Oules R (abst) ... 322, 349
Ozkan K (abst) ... 363

Pablo AL (abst) ... 251
Pacchiano G (abst) ... 332
Pacini L (abst) ... 321
Paddock JK, Taddeo AR, Paddock JP, Lowenstein LM: Glycoprotein reutilization in regenerating microvilli after renal ischemia in rats ... 498
Paddock JP: *see* Paddock et al ... 498
Padovano I (abst) ... 228, 353
Pagani C (abst) ... 349
Pagliari B (abst) ... 395
Pahilan AN: *see* Avram MM et al ... S-100
Pahilan AN (abst) ... 319
Paik SS: *see* Avram MM et al ... S-100
Paillard F (abst) ... 693
Paisey R (abst) ... 294
Pajdak W: *see* Wichman et al ... 558
Palla L (abst) ... 248, 249
Paller MS: *see* Murray et al ... 767
Palmieri P (abst) ... 329
Palombo C (abst) ... 248, 249
Palop L (abst) ... 311, 311, 352
Palumbo P (abst) ... 228
Panebianco R (abst) ... 357
Paniagua J (abst) ... 239, 373
Pantano R (abst) ... 332
Panzetta G (abst) ... 350, 357
Papaconstantinou C (abst) ... 334, 335
Papadakis G (abst) ... 256
Papadimitriou M (abst) ... 279, 279, 391
Papadoyannakis NJ (abst) ... 350
Papalas A (abst) ... 256
Paparatto P (abst) ... 346
Parada J (abst) ... 586
Parfrey PS, Farge D, Forbes RDC, Dandavino R, Kenick S, Guttmann RD: Chronic hepatitis in end-stage renal disease: Comparison of HBsAg-negative and HBsAg-positive patients ... 959
Parlongo S (abst) ... 252
Parsons V (abst) ... 348, 396, 398
Pasquali S (abst) ... 268
Pasquali S: *see* Cagnoli et al ... 646
Passavanti G: *see* Coratelli P et al ... S-143
Passavanti G (abst) ... 226

Passerini P (abst) 281, 323
Passerone G: *see* Tizianello A et al S-79
Pastore A (abst) 369
Paterson AD (abst) 243
Patrikarea A (abst) 350
Patscheke H (abst) 229
Pattyn VM (abst) 230
Paul LC (abst) 371, 376, 381, 396, 401, 699, 711
Pavel P (abst) 371
Pavlovitch JM (abst) 872
Paya C (abst) 584
Paz R (abst) 332
Peach MJ: *see* Chevalier et al 891
Peach RJ (abst) 865
Peart WS: *see* Wilcox et al 43
Pecchini F (abst) 245
Pecoraro C (abst) 254, 295
Peddie BA (abst) 863, 864
Pederson JA: *see* Rodriguez et al 808
Peel MG (abst) 375
Perego A: *see* Minetti L et al S-116
Pelayo JC: *see* Blantz et al 733
Pelle-Francoz D (abst) 694
Pellegrino E (abst) 313
Peral V (abst) 375
Peratoner L (abst) 224
Perez Garcia R (abst) 389
Perez R (abst) 585
Perez Rodriguez JA (abst) 588
Perilli A (abst) 228
Perl SI (abst) 272, 856
Perna N: *see* Esposito R et al S-98
Perret G (abst) 871
Perrino ML (abst) 393
Persijn GG (abst) 699
Pertosa G (abst) 369
Petrella E: *see* D'Amico G et al S-105
Pertuiset N (abst) 265, 295
Peschke B (abst) 289
Petek W (abst) 350
Peters DK (abst) 362
Peterson JC: *see* Hulter et al 187
Peterson PK (abst) 307
Petitclere C (abst) 257
Petrarulo F (abst) 226, 325
Petrella E (abst) 281, 327, 353
Petrone A (abst) 284
Petrover M (abst) 342, 342
Pettersson E (abst) 271
Pfister L (abst) 596
Bonjour J-Ph (abst) 593
Pharmakiotis A (abst) 389
Phelps K (abst) 868
Philipp Th (abst) 697, 706
Piaza Perez JJ (abst) 586
Piazolo P (abst) 322
Piazza A (abst) 356
Piazza V (abst) 281, 353
Picardi L (abst) 353
Picazo F (abst) 590
Picca M (abst) 366, 367
Piccoli G (abst) 242, 255, 260, 275, 280, 333
Pichlmayr R (abst) 395
Pickin CA (abst) 316
Picot A (abst) 324
Piepenhagen U (abst) 361
Piera C (abst) 589
Piers DA (abst) 711
Pierucci A (abst) 252, 265
Piesco NP: *see* Avner et al 447
Pietra R: *see* Brancaccio D et al S-108
Pietra R (abst) 321
Pietrzak I (abst) 270, 291
Pignolet P (abst) 872
Pili GF (abst) 223, 303
Pill J (abst) 229
Pinet A (abst) 694
Pinggera W (abst) 327
Pinto A (abst) 254, 295
Pinto G (abst) 252
Piposki L (abst) 358
Pippi C (abst) 314
Pirie SC, Potts DJ: Application of cold flush preservation to in vitro microperfusion studies of kidney tubules (Technical Note) 982
Pirson Y (abst) 265, 382
Piskin E (abst) 338
Pistocchi E (abst) 241
Pitrone F (abst) 276, 313, 313
Piza F (abst) 402
Plans A (abst) 352
Plante GE (abst) 257
Platt JL, Sibley RK, Michael AF: Interstitial nephritis associated with cytomegalovirus infection 550
Plaza C (abst) 274, 274, 352
Plebani AM (abst) 366
Pluvio M: *see* Esposito R et al S-98
Podjarny E (abst) 254, 255, 255
Podzamzcer D (abst) 589
Poggensee U: *see* Doehring et al 520
Poggio F (abst) 353
Pogglitsch H (abst) 350
Pohanka E (abst) 383
Poignet JL (abst) 324
Poirier A: *see* Beauchamp et al 106
Poitrine A (abst) 872
Polenakovic M (abst) 356
Pomerantz A (abst) 310
Pommer W (abst) 229, 265
Pons JM (abst) 333, 588, 589
Pontchaillou Rennes CHU (abst) 873
Ponti R (abst) 225, 228, 368
Ponticelli C (abst) . 242,268,244,304,313,323,385,392,394,394
Pontzer M-A: *see* Hakim et al 535
Popovich R: *see* Moncrief J et al S-23
Porr O (abst) 290
Porter GA, Lawson L, Buss J: Bias in selecting treatment for end-stage renal disease S-34
Porter KR, Starnes DM, Hamilton JD: Reactivation of latent murine cytomegalovirus from kidney 922
Portmann L (abst) 243, 243
Posen G (abst) 354
Posen S (abst) 859
Potts DJ: *see* Pirie et al 982
Poveda R (abst) 225, 589
Powell HR (abst) 857
Power D (abst) 383
Pozet N (abst) 236, 690
Pozza G (abst) 313
Pozzato M (abst) 242, 333
Pozzi C (abst) 225, 228
Praga M (abst) 294, 350, 584

Praga M, Gutierrez-Millet V, Navas JJ, Ruilope LM, Morales JM, Alcazar JM, Bello I, Rodicio JL: Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. 69
Prager R (abst) 242
Prange H (abst) 296
Pras M (abst) 232
Pratas J (abst) 332
Pratesi G (abst) 326
Prati E (abst) 393, 399, 399, 399, 399
Precht K (abst) 300
Preis P (abst) 267, 287
Prendergast JS (abst) 861
Prescott LF (abst) 278
Prescott M (abst) 300
Priem F (abst) 300
Prieto M (abst) 251
Prieur JP (abst) 693
Prieur P (abst) 342, 342
Princi P (abst) 313
Prins FA (abst) 703
Probst W (abst) 596
Proesmans W (abst) 230, 295
Proppe D (abst) 363, 383
Proudfoot AT (abst) 278
Provoost AP (abst) 710
Prummel B (abst) 696
Puchegger R (abst) 301
Pugliese F (abst) 265
Pujo JM (abst) 324
Punzengruber C (abst) 287
Puretic M (abst) 351
Puretic Z (abst) 351
Purroy A (abst) 590
Pusey CD (abst) 263, 274, 275, 298
Pwee HS (abst) 267
Pynka S (abst) 285

Qerchi G (abst) 400
Quamme GA: *see* Mavichak et al 914
Quarello F (abst) 242, 255
Quattrocchio G (abst) 242
Queirolo C: *see* Ghiggeri et al 168
Quellhorst E: *see* Baldamus CA et al S-41
Quellhorst E (abst) 354
Quellhorst E: *see* Schrader et al 823
Quenneville A: *see* Lemieux et al 760
Quereda C (abst) 380, 388, 587, 588
Querin S (abst) 692
Quillan B (abst) 306
Quintaliani G (abst) 323
Qureshi A (abst) 289
Qvist R (abst) 857

Rabin P: *see* Mathew et al 64
Rabinovitch O (abst) 232
Radenbach KL (abst) 278
Radford SG (abst) 383
Rae D (abst) 373, 867
Rafelt M (abst) 254, 705
Raffali MJ (abst) 391
Raftery AT (abst) 243, 376
Ragaiolo M (abst) 323
Ragazzini A (abst) 248, 249
Rahn KH (abst) 279, 698, 707
Raidt H (abst) 245, 299, 351
Rainfray M (abst) 692
Raiteri M (abst) 390
Rajpal K: *see* Avram MM et al S-100
Rama H (abst) 590
Rambausek M (abst) 266, 285, 287, 695, 702
Rambausek M, Ritz E, Mall G, Mehls O, Katus H: Myocardial hypertrophy in rats with renal insufficiency . 775
Ramee MP (abst) 873
Ramos R (abst) 584
Ramperez P (abst) 322
Ramsden RT (abst) 309
Ramzy M (abst) 295
Raneri G (abst) 320
Rasoul-Rockenschaub S (abst) 400
Raspolli-Galletti M (abst) 224
Rastogi S, Bayliss JM, Nascimento L, Arruda AL: Hyperkalemic renal tubular acidosis: Effect of furosemide in humans and in rats 801
Ratcliffe PJ (abst) 280
Rathaus M (abst) 254, 255, 255, 256
Rauterberg EW (abst) 274, 274
Read DJ (abst) 248
Reanud H (abst) 241
Reddy S (abst) 861
Redlin E (abst) 386
Redman D (abst) 316
Rees AJ (abst) 266, 391
Reeve RS (abst) 374
Reichenberg Y (abst) 296
Reinert Ph (abst) 691
Reinold HM (abst) 378
Reitinger J (abst) 704
Remigolski L (abst) 325
Remmers J (abst) 301
Remmers S (abst) 301
Remuzzi A (abst) 274
Remuzzi A: *see* Remuzzi et al 21
Remuzzi G (abst) 260, 269, 274
Remuzzi G, Zoja C, Remuzzi A, Rossini M, Battaglia C, Broggini M, Bertani T: Low-protein diet prevents glomerular damage in adriamycin-treated rats. 21
Renaud H (abst) 282, 351
Reneltova I (abst) 384
Rengel M (abst) 251, 262, 299, 586
Rennke HG: *see* Baylis et al 140
Renversez JC (abst) 345
Renz M (abst) 287
Reubi FC (abst) 595
Reutter F (abst) 598
Revalderia JG (abst) 588
Reveillaud RJ (abst) 872
Revert L (abst) 250, 264, 333, 341, 588, 589
Reynaldo C (abst) 589
Riambau E (abst) 351
Ribstein J (abst) 384
Ricciardi B (abst) 320
Richardson WP: *see* Savin et al 926
Richet G: When should renal biopsy be done in acute uremia? Tomorrow could be too late S-152
Richet G (abst) 694
Riechers G (abst) 395
Riede G (abst) 335
Riegel W (abst) 336, 706
Riepenhausen J (abst) 289
Riess Ch (abst) 592
Riggio RR (abst) 384, 384

Righetto F: *see* Bazzato G et al S-161
Rigol G (abst) 373, 867, 867
Rijke T (abst) 703
Rimon R (abst) 379
Rince M (abst) 872
Ringe B (abst) 395
Ripamonti C (abst) 368
Risler I (abst) 709
Risler T (abst) 702, 703, 704, 708
Rits E (abst) 351
Ritsema van Eck HJ (abst) 698
Ritter ME (abst) 286
Ritz E, Augustin J, Bommer J, Gnasso A, Hoberbosh W: Should hyperlipemia of renal failure be treated? ... S-84
Ritz E (abst) 245, 245, 250, 266, 270, 270, 285, 287, 288, 319, 695, 702, 711, 712
Ritz E: *see* Rambausek et al 775
Rivera F (abst) 590
Rivera JM (abst) 586
Rivetti V (abst) 245
Rivolta E (abst) 385, 394
Rizzelli S (abst) 344, 345
Rizzelli S: *see* Mastrangelo F et al S-188
Rizzica M (abst) 321
Robaudo C: *see* Tizianello A et al S-79
Robert D (abst) 240
Roberts NB (abst) 396
Robertson DB (abst) 857
Robinson CJ (abst) 241
Robson JS (abst) 282
Roca M (abst) 395
Roccatello D (abst) 260, 275, 280
Rocchi G (abst) 269
Rocher Martin A (abst) 344
Roddis S: *see* Wilcox et al 43
Rodger RSC (abst) 241, 310
Rodicio JL (abst) 294, 350, 584
Rodicio JL: *see* Praga et al 69
Rodinger K (abst) 390
Rodriguez FJ (abst) 586
Rodriguez L (abst) 388
Rodriguez M, Pederson JA, Llach F: Effect of dialysis and ultrafiltration on osmolality, colloid osmotic pressure, and vascular refilling rate 808
Rodriguez-Perez JC (abst) 311, 311, 352
Rodriguez-Roza R (abst) 239
Roels L (abst) 701
Roger V (abst) 251
Rogerson M (abst) 348
Rogez P (abst) 282, 282
Rohr N (abst) 395
Rolli H (abst) 338
Rollier A (abst) 227
Rollin PE (abst) 693
Rollino C (abst) 260, 275, 280
Roma J (abst) 351
Romani F (abst) 240
Romano G (abst) 234
Rombola G (abst) 233
Romero JC: *see* Martin et al 636
Romero R (abst) 230, 590
Ronco C (abst) 232, 305, 306, 368, 368
Ronco P (abst) 694, 696, 871
Ronconi M (abst) 314
Rondana M (abst) 280
Rondeau E (abst) 692
Roodvoets AP (abst) 360
Roos JC (abst) 707
Roos JC: *see* Geers et al 652
Roque-Barreira: *see* Monteiro et al 666
Rosati C (abst) 255
Roseler E (abst) 300
Rosenberger J (abst) 385
Rosenfeld J (abst) 256
Rosenfeld JB (abst) 257, 373
Rosenman H (abst) 226, 337
Rosenmann E (abst) 296
Ross C (abst) 862
Ross MR (abst) 861
Rossetti M (abst) 387
Rossi L: *see* Cagnoli et al 646
Rossini M (abst) 274
Rossini M: *see* Remuzzi et al 21
Rossini PM (abst) 345, 347
Rossmann P (abst) 384, 396
Rotellar C (abst) 692
Rotellar E (abst) 352
Roth P (abst) 315
Rothenbuhler A (abst) 594
Rother U (abst) 695, 712
Rothgordt S (abst) 380
Rotolo U (abst) 352
Rotondo S (abst) 228, 320, 353
Rottembourg J (abst) 311, 399
Roujouleh H (abst) 296, 694
Roullet JB (abst) 281
Roulot D (abst) 872
Rovelli E (abst) 252
Rowe J (abst) 868
Royer-Moreau MJ (abst) 690
Roza M (abst) 239
Rubin JE: *see* Berlyne GM et al S-175
Rubinstein M (abst) 296, 330, 330
Rudigoz Ch (abst) 236
Rudolf L (abst) 371
Ruedin P (abst) 309, 592
Rugiu C (abst) 350, 357
Ruilope L (abst) 350, 584
Ruilope LM (abst) 294, 584
Ruilope LM: *see* Praga et al 69
Ruiz JC (abst) 246
Ruiz Munoz LM (abst) 385, 385
Rumpf KW (abst) 296, 352, 368
Rundquist RT: *see* Martin et al 636
Russi E (abst) 290
Russo D: *see* Dal Canton et al S-154
Russo D (abst) 251
Rutkowski B (abst) 333
Ryan CJ (abst) 274
Ryan GB (abst) 860
Rylance PB (abst) 297

Saad A-M (abst) 366
Saba M (abst) 237
Sabate I (abst) 395
Sabatier JC (abst) 249, 289, 372
Sabbatini M (abst) 234
Sabbioni E: *see* Brancaccio D et al S-108
Sabbioni E (abst) 321
Sacca L (abst) 284
Saccaggi A (abst) 367
Sacchi G (abst) 260, 266

Sachs C (abst) 253, 341
Sack K (abst) 708, 709
Saenz de la Calzada C (abst) 350
Saguer T (abst) 587
Saint-Brieuc CH (abst) 873
Saint-Remy M (abst) 690
Saito T (abst) 866
Saitou S (abst) 361
Sakai T (abst) 250
Sakellariou G (abst) 391
Salerni B (abst) 399
Salgia P (abst) 309
Salmon J (abst) 269
Salusky IB (abst) 246, 308
Salvadeo A (abst) 281, 353
Salvado M (abst) 376, 382
Salvadori M (abst) 292, 358
Salvatierra O (abst) 372
Salvatorelli G (abst) 374
Salvini P (abst) 353
Salwa W (abst) 261
Samaja B (abst) 235
Samarzija I (abst) 255
Sanchez Crespo M (abst) 321, 587
Sanchez Heras M (abst) 389
Sanchez M (abst) 367, 587, 590
Sanchez Sicilia L (abst) 244
Sanchez-Tapias JM (abst) 381
Sancho J (abst) 271, 271, 292, 584, 586, 589
Sancho S (abst) 589
Sandilands GP (abst) 375
Sandoz P (abst) 597
Sandrini S (abst) 393, 399, 399, 399
Santopietro A (abst) 229, 259
Santos I (abst) 350
Santos JC (abst) 587
Sanz De Castro S (abst) 385
Sanz E (abst) 587
Sapikas I (abst) 334, 335
Saponaro R (abst) 281
Saracho R (abst) 585, 586
Saravo MT (abst) 254, 295
Sargent JA: *see* Gotch et al 526
Sari R (abst) 279, 690
Sarrias X (abst) 224,589
Sasdelli M (abst) 297, 330
Sato G (abst) 361
Sato N (abst) 300
Satta A (abst) 256, 258, 278
Saulino C (abst) 355
Savage COS (abst) 266, 275
Savazzi AM (abst) 327, 353
Savic V (abst) 356
Savica V (abst) 228, 320, 363
Savige JA (abst) 275
Savin S (abst) 297
Savin VJ, Beason-Griffin C, Richardson WP: Ultrafiltration coefficient of isolated glomeruli of rats aged 4 days to maturation 926
Savoldi S (abst) 266, 399, 399, 399, 403
Sawada S (abst) 364
Sawanishi K (abst) 366
Sawanishi S (abst) 366
Sbarbati A (abst) 346
Scaini P (abst) 266, 403, 399, 399, 399
Scalamogna A (abst) 314
Scanferla F: *see* Bazzato G et al S-161
Scatizzi A (abst) 311, 364, 364, 364
Schacht RG: *see* Neugarten et al 135
Schaefer RM (abst) 288, 354
Schafferhans K (abst) 288
Schalekamp MADH (abst) 698, 704, 707
Schali C (abst) 597
Schandene L (abst) 326
Schareck W (abst) 708
Schareck WD (abst) 709
Scharer K (abst) 223, 237, 290, 390
Scheinman JI: *see* Lopez et al 82
Scheler F (abst) 254, 296, 301, 352, 354, 368, 386
Scheler F: *see* Schrader et al 823
Schellekens P Th A (abst) 711
Schemper M (abst) 378
Schena FP (abst) 354, 369
Schernthaner G (abst) 242
Scheuermann E-H (abst) 386
Schiavina G (abst) 223
Schicht IM (abst) 359, 359
Schifferdecker E (abst) 289
Schiffl H (abst) 251
Schilling H (abst) 312
Schindler J (abst) 401, 402
Schirmeister J (abst) 704
Schmid G (abst) 697
Schmidt JB (abst) 378
Schmidt P (abst) 329, 701
Schmidt R (abst) 709
Schmidt U (abst) 708
Schmidt-Gayk H (abst) 223
Schneider H (abst) 378, 698
Schneider N (abst) 256
Schneider R (abst) 337
Schober O (abst) 301
Schoeppe W (abst) 249, 289, 315
Schohn D (abst) 386, 597
Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C: Norepinephrine-related mechanism in hypertension accompanying renal failure 814
Schollmeyer P (abst) 251, 314, 336
Schollmeyer P: *see* Hörl et al 791
Scholz K (abst) 254
Scholz P (abst) 301
Schorderet D (abst) 592
Schrader J (abst) 354, 386
Schrader J, Valentin R, Tonnis H-J, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Köstering H, Quellhorst E, Scheler F: Low molecular weight heparin in hemodialysis and hemofiltration patients 823
Schreiber M (abst) 297, 312
Schreiner E (abst) 703
Schrier RW: *see* Shapiro et al 206
Schrijver G (abst) 702
Schudrowitsch L (abst) 706
Schulenburg WE (abst) 298
Schultze G (abst) 705, 706
Schultze Kool L (abst) 401
Schulz E (abst) 708, 709
Schumacher R (abst) 695
Schwartz J (abst) 693
Schwartz M (abst) 383
Schwartz MM, Lewis EJ: Focal segmental glomerular sclerosis: The cellular lesion 968
Schwarz A (abst) 229, 229

Schwarz M (abst) 267
Schwietzer G (abst) 705
Scolari F (abst) 266, 393, 399, 399, 399
Scolari MP: *see* Bonomini V et al S-57
Scott DF (abst) 314, 859
Scott SJ (abst) 293
Sear JW (abst) 280
Sebert JL (abst) 241, 246, 365
Segagni S (abst) 353
Segal GM (abst) 285
Segasothy M (abst) 865
Segoloni GP: *see* Vercellone A et al S-29
Segoloni GP (abst) 387, 388
Segre GV (abst) 595
Seidl G (abst) 327
Seidman M: *see* Berlyne GM et al S-175
Seitz R (abst) 707
Sekse I (abst) 249
Selgas R (abst) 244, 307, 312
Sells RA (abst) 372, 396
Selwood NH (abst) 372, 378
Sennesael J (abst) 252
Sensi G (abst) 231
Separovic D (abst) 297
Sequino L (abst) 345
Serban I (abst) 235
Serdengecti K (abst) 286, 294
Seron D (abst) 589
Serra SR: *see* Arbeit et al 440
Serrano M (abst) 373
Serrano S (abst) 381
Servadio C (abst) 386
Sessa A (abst) 300
Setoain J (abst) 589
Settas L (abst) 256
Setti G (abst) 393
Seubert A (abst) 352, 368
Seubert S (abst) 352, 368
Seveso M (abst) 393
Shaffer J (abst) 369
Shaldon S, Koch KM: Are standards and checklists needed in uremia therapy? S-124
Shaldon S (abst) 322, 369
Shapira J (abst) 254, 255
Shapira Z (abst) 373, 386
Shapiro F: *see* Collins AJ et al S-18
Shapiro MD, Nicholls KM, Groves BM, Kluge R, Chung H-M, Bichet DG, Schrier RW: Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients 206
Sharman VL (abst) 400
Shehab El-Din A (abst) 400
Sheikh HA (abst) 272
Sheil AGR (abst) 858, 858, 862
Sheil AGR: *see* Hall et al 178
Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients 830
Sherry L (abst) 862
Shigemi J (abst) 354
Shinkai Y (abst) 275
Shmueli D (abst) 373, 386
Shmueli I (abst) 386
Shneider R (abst) 226
Shohat J (abst) 256, 257
Short CD (abst) 260, 262, 269, 276, 387
Shortland JR (abst) 228, 260
Shushan J (abst) 310
Sibert A (abst) 355
Sibley RK: *see* Platt et al 550
Sicilia LS (abst) 307, 312
Siegel RK: *see* Williams et al 146
Silberbauer K (abst) 287
Silverberg DS (abst) 247
Silvert C (abst) 296
Simmons A (abst) 868
Simon G (abst) 334
Simon Gy (abst) 369
Simon P (abst) 354, 871, 873
Simonetti BM (abst) 252, 265
Simpson D (abst) 278
Sindoni M (abst) 228
Singer D (abst) 362
Singer DRJ (abst) 298, 298
Singh RP, Nancollas GH: Determination of urinary citrate by high performance ion chromatography (Technical Note) 985
Singlas E (abst) 279, 690
Sipila R (abst) 237, 283, 379, 387
Sitzmann C (abst) 596
Skinner SL (abst) 870
Sklar AH: *see* Mandal et al 58
Skoff H: *see* Mason NS et al S-178
Slade R (abst) 294
Slapak M (abst) 395, 400
Slater PA: *see* Avram MM et al S-100
Slaviero G (abst) 313
Slooff MJH (abst) 711
Sluiter WJ (abst) 238, 359, 711
Smacchi A (abst) 240
Smacchi A: *see* Coen et al 783
Smetisko A (abst) 351
Smith C (abst) 315
Smith GD (abst) 246
Smith J (abst) 269
Smith JD: *see* De Fronzo RA et al S-88
Smith JW: *see* Nose Y et al S-131
Smith LH: *see* Martin et al 636
Smith PS (abst) 860
Smith WGJ (abst) 312, 313
Smolen J (abst) 327
Smolenski O: *see* Wichman et al 558
Sobbrio GA (abst) 276, 313, 313
Sobh M (abst) 257, 257, 400
Sogami M (abst) 354
Solares J (abst) 227, 590
Soler J (abst) 589
Soliman M (abst) 253
Solomon LR (abst) 387
Solomon M (abst) 295
Solomon RJ: *see* Weinberg et al 975
Solsona JF (abst) 381
Somia NV (abst) 392
Sommer G (abst) 355
Sorgato G (abst) 349
Sorgel F (abst) 277
Soskolne V (abst) 337
Soulillou JP: *see* Vie et al 553
Southwood J (abst) 304
Southwood TR (abst) 863
Spalding CT (abst) 315

Sparano G (abst) 322
Sparks RE: *see* Mason NS et al S-178
Spencer ES (abst) 391
Spencer RC (abst) 308
Spencer S (abst) 333
Spieker C (abst) 267
Spisni C (abst) 317
Spitz B (abst) 256
Spitzenberg R (abst) 695
Splendiani G (abst) 355
Spona J (abst) 378
Spotti D (abst) 313
Spragg J, Denney DL, Tilney NL, Austen KF: Kallikrein excretion in renal transplant recipients and in uninephrectomized donors 75
Squadrito F (abst) 283
Squerzanti R (abst) 331
Squiccimarro E (abst) 344
Squiccimarro G (abst) 387
Squifflet JP (abst) 382
Sraer J (abst) 692
Sraer JD (abst) 691, 692
Stabile C (abst) 372
Stamatakis G (abst) 355
Stanek B (abst) 400
Stankiewicz H (abst) 296
Stantchev J (abst) 294
Stanziale P (abst) 229, 259
Starck E (abst) 249
Starnes DM: *see* Porter et al 922
Starzl TE: Protecting the patient's interests S-31
Staub JJ (abst) 594, 700
Stauffer JC (abst) 401
Stefanidis CJ (abst) 350
Stefanovic V (abst) 329, 338, 355, 356
Stefoni S: *see* Bonomini V et al S-57
Stegmeier K (abst) 229
Stehle C (abst) 703
Stein JH: The pathogenetic spectrum of Bartter's syndrome (Nephrology Forum) 85
Steinberg SM: *see* Nolph et al 198
Steinbrunn W (abst) 338
Steinhauer HB (abst) 314, 336
Steinhauer HB: *see* Hörl et al 791
Steinhausen D (abst) 245
Steinhoff J (abst) 708
Stella A (abst) 247
Stella M (abst) 344
Stenstrom J (abst) 331
Stenzel KH (abst) 384, 384, 388
Stephen RL, Maxwell JG, Harro JJ, Jacobson SC, Hanover BK: Intervention in nephropathy due to insulin-dependent diabetes mellitus (IDDM) S-60
Stephen RL (abst) 298
Sterzel RB (abst) 695
Stevens D (abst) 396
Stevens J (abst) 870
Stewart K (abst) 383
Stibbe W: *see* Schrader et al 823
Stilinovic K (abst) 346
Stiller S (abst) 356
Stirati G (abst) 252, 265
Stitz M (abst) 380
Stokes JB, Lee I: Mineralocorticoid effect on K+ permeability of the rabbit cortical collecting tubule 640
Stone J (abst) 398
Stone WJ: *see* Mathew et al 64
Stormi M (abst) 224
Stout JP (abst) 334
Stratta P (abst) 238, 387
Strauch M (abst) 288, 361
Streicher E (abst) 378
Strippoli P (abst) 311
Strom TB: *see* Weir et al 839
Stubenbord W (abst) 384, 384
Stummvoll HK (abst) 301, 369, 383, 400
Sturani A (abst) 247
Subias R (abst) 250
Suh HJ (abst) 307
Suleiman AB (abst) 865
Summerton CB (abst) 376
Sunder Plassmann G (abst) 239
Sundram FX (abst) 387
Suranyi MG (abst) 858
Surian M (abst) 233, 233, 237, 252, 321
Susanna F (abst) 298
Suter P (abst) 592
Suthanthiran M (abst) 384, 384, 388
Sutton RAL: *see* Mavichak et al 914
Suzuki E (abst) 354
Svendsen V (abst) 395
Svenson SB: *see* Jacobson et al 797
Swainson CP (abst) 858, 858, 862, 863, 863, 864, 870
Swart JM (abst) 238
Swartz R (abst) 356
Sweeney WE Jr: *see* Avner et al 447
Swift PGF (abst) 261
Syre G (abst) 267
Syrganis C (abst) 327
Szalay L (abst) 267
Szepeshazy K (abst) 267

Taburet AM (abst) 279, 690
Taccone-Gallucci M: *see* Milito G et al S-157
Taccone-Gallucci M (abst) 345, 347, 256
Tacquet A (abst) 382
Taddeo AR: *see* Paddock et al 498
Taga Y (abst) 363
Taggi F (abst) 252
Taggi F: *see* Coen et al 783
Takai N (abst) 361
Takuma T (abst) 364
Talia B (abst) 240
Talin A (abst) 306
Tan-Tjiong HL (abst) 707
Tanaka H (abst) 357, 357
Tanaka S (abst) 362
Tange J (abst) 867, 867
Tange JD (abst) 373, 870
Tangelder MM (abst) 696, 702
Tanke HJ (abst) 376
Tannen RL: Diuretic-induced hypokalemia (Nephrology Forum) 988
Tantow J (abst) 338
Tapia L (abst) 384, 384
Taraba I (abst) 248, 369
Tarantino A (abst) 385, 392, 394
Tarchini R (abst) 346
Tardanico R (abst) 399
Tarpey P (abst) 276
Tartini R (abst) 338
Tataranni G (abst) 331

Taylor DJ (abst) 858
Taylor GT (abst) 372
Taylor J (abst) 400
Taylor JY (abst) 859
Taylor WH (abst) 396
Tchernia G (abst) 872
Tchorzewski H (abst) 358
te Strake L (abst) 401
Teatini U: *see* Minetti L et al S-116
Tegzess AM (abst) 238, 359, 401, 700, 710, 711
Teodori T (abst) 299
ter Wee PM (abst) 257
Terracciano V (abst) 284
Terribile M (abst) 233
Teruel JL (abst) 380, 388, 587, 588
Teschner M (abst) 288
Tesio F (abst) 328
Tessarin C (abst) 324
Tessier J (abst) 375
Tessitore N (abst) 350, 357
Testa A (abst) 332, 351
Testa T (abst) 300
Tetta C (abst) 238
Tevar F (abst) 373
Teyssou H (abst) 375
The TH (abst) 700, 710
Theilmann L (abst) 287
Thiel G (abst) 594, 597, 700
Thienpont L (abst) 227
Thoenes GH (abst) 703
Thomas E (abst) 692
Thomas J (abst) 692
Thomas MAB (abst) 859, 862, 862, 865
Thomson BJ (abst) 357, 358
Thomson D (abst) 282, 282
Thomson NM (abst) 314, 857, 859, 864, 865, 866
Thonney M (abst) 597
Thormann J (abst) 362
Thoua Y (abst) 268
Thune S (abst) 351
Thurner J (abst) 701
Tiebosch A (abst) 276, 702
Tielemans C (abst) 324, 325, 330
Tiller DJ (abst) 858, 858
Tiller DJ: *see* Hall et al 178
Tilney NL: *see* Spragg et al 75
Tilney NL: *see* Weir et al 839
Tilton D: *see* Hakim et al 535
Timio M (abst) 314
Tinaztepe B (abst) 276
Tinaztepe K (abst) 276
Tipping PG (abst) 856, 857, 866
Tirelli S (abst) 253
Tizianello A, Deferrari G, Gariboto G, Robaudo C, Canepa A, Passerone G: Is amino acid imbalance harmful to patients in chronic renal failure? S-79
Todde PF (abst) 223
Tokuda M (abst) 354
Tolani M (abst) 293, 329
Toledo-Pereyra LH (abst) 388, 398
Tomanoski V (abst) 358
Tomoyoshi T (abst) 366, 366
Tompson P (abst) 396
Tonini G (abst) 399
Tönnis H-J: *see* Schrader et al 823
Tönnis HJ (abst) 354
Tooth A (abst) 309
Tornroth T (abst) 271
Torras A (abst) 264
Torras J (abst) 224, 224, 230, 395, 589, 590
Torre F (abst) 320
Torrella T (abst) 382
Torrents J (abst) 351
Torres A (abst) 585
Toscano A (abst) 353
Tosi P (abst) 231, 358
Toth M (abst) 270
Toth S (abst) 270
Toulon J (abst) 249, 289, 372
Toupance O (abst) 296, 694
Tourkantonis A (abst) 256, 327, 389
Toussaint C (abst) 401
Toutain H (abst) 689
Traeger J: *see* Betuel J S-170
Traeger J (abst) 391, 694
Trebbin WM: *see* Weinberg et al 975
Treille M (abst) 349
Treissede D (abst) 349
Trepo C (abst) 293
Tresguerres JAF (abst) 586
Trevico S: *see* Dal Canton A et al S-154
Tribout B (abst) 234, 234, 235, 282, 282
Trimarchi F (abst) 276, 313, 313
Trinchieri A (abst) 281
Trinh-Trang-Tan M-M (abst) 689
Trinh-Trang-Tan M-M: *see* Bouby et al 456
Triolo G (abst) 387, 388
Triolo L (abst) 309, 346
Trounson W (abst) 286, 691
Trpenoski LJ (abst) 358
Trube A (abst) 859
Trznadel K (abst) 358
Tsakiris D (abst) 312, 374, 389
Tsobanelis T (abst) 279, 279
Tuchman M: *see* Lopez et al 82
Tucker BJ, Gushwa LC, Wilson CB, Blantz RC: Effect of leukocyte depletion on glomerular dynamics during acute glomerular immune injury 28
Turan M (abst) 376
Turci F (abst) 241
Turgan C (abst) 232
Turner A (abst) 343
Turner DR (abst) 275
Turner JG (abst) 858
Turner S (abst) 371
Turney JH (abst) 328
Turrini F (abst) 258, 278

Uccello F (abst) 234
Uehling DT: *see* Chesney RW et al S-75
Ulmann A (abst) 689
Ulmer H (abst) 290
Ulrich W (abst) 267
Umeda M (abst) 362
Umemura K (abst) 366, 366
Umimoto K (abst) 357, 357
Unal S (abst) 232
Ungaro B (abst) 258
Urbain J (abst) 268
Urra M (abst) 585
Urti DA (abst) 320
Usberti M (abst) 254, 258, 295

Uten M (abst) 394
Uttendorfsky O Th (abst) 238
Uyttebrouck A (abst) 394

v Baak M (abst) 698
v Burgers J (abst) 702
v d Meiracker A (abst) 698
v d Wal AM (abst) 703
v Hooff M (abst) 698
v Kemenade J (abst) 698
v Kemenade J (abst) 707
Vaccaro S: *see* Capodicasa G et al S-112
Vacha GM (abst) 359
Vagelli G (abst) 326
Vagnoli E (abst) 297, 330
Vaj M (abst) 388
Valcke Y (abst) 321
Valderrabano F (abst) 227, 367, 389, 590
Valentijn RM (abst) 359, 359
Valentin R (abst) 354
Valentin R: *see* Schrader et al 823
Valeri M (abst) 356
Valeyre D (abst) 693
Vallance-Owen J (abst) 859, 864
Vallotton MB (abst) 595
Vallotton MB (abst) 598
Valvo E (abst) 252, 350, 357
van Aanholt PCT (abst) 359
van Ballegooie E (abst) 257
van Berlo A (abst) 360
van Bockel JH (abst) 699
van Breda Vriesman P (abst) 276, 702
van Breda Vriesman PJC (abst) 710
Van Damme B (abst) 295
Van Damme-Lombaerts R (abst) 230, 295
van De Wall Bake AWL (abst) 695
van de Wiel Th (abst) 702
Van der Groen G (abst) 284
van der Hem GK (abst) 261, 343, 359, 699, 710
van der Muelen J (abst) 299, 314
van der Wiel Th (abst) 276
van der Woude FJ (abst) 238, 710, 711
Van Dijck M (abst) 230
van Es A (abst) 699
van Es LA (abst) 270, 371, 376, 381, 396, 696, 711
Van Es LA (abst) 695
van Gemert GW (abst) 371, 711
van Gestel WCFTM (abst) 314
Van Hoof R (abst) 284
van Hooff JP (abst) 243, 397
Van Landuyt H (abst) 321
Van Lierde M (abst) 382
Van Liew JB: *see* Zamlauski-Tucker et al 504
van Oers MHJ (abst) 711
van Rie H (abst) 702
van Schilfgaarde R (abst) 699
van Son WJ (abst) 238, 710, 711
Van Steenberge R (abst) 227
van Ypersele de Strihou C (abst) 360, 382, 394
Vandenbroucke D (abst) 321
Vandenbroucke JM (abst) 265, 360
Vandepitte J (abst) 321
VanderWerf BA (abst) 389
Vanek I (abst) 371
Vangelista A (abst) 392
Vanherweghem JL (abst) 326, 332
Vanrenterghem Y (abst) 701
Varanese L (abst) 318
Varela C (abst) 584
Vargas F (abst) 586
Vargas-Z P (abst) 299
Vasileri H (abst) 327
Vasiliou S (abst) 389
Vasmant D (abst) 691
Vassilaki-Grimani M (abst) 337
Vasta E (abst) 332
Vazelov E (abst) 318, 339, 339
vd Wal AM (abst) 696
Vecsei P (abst) 705
Vedevato M (abst) 374
Vegeto A (abst) 374, 385, 390
Veillon B (abst) 689
Veitch PS (abst) 400
Velazquez ML (abst) 585
Velkovski T (abst) 339
Velkovski Z (abst) 318
Venanzi S (abst) 314
Vendemia F (abst) 252
Veniero P (abst) 234
Venning MC (abst) 298
Venuto R (abst) 697
Verbeelen D (abst) 252
Verbi V (abst) 398
Verbic D (abst) 292
Verbrugh JA (abst) 314
Vercellone A (abst) 238, 387, 388
Vercellone A, Segoloni GP: The need for dialysis S-29
Vereerstraeten P (abst) 401
Vergnaghi D (abst) 223
Vermylen J (abst) 295, 701
Verpooten GA (abst) 226, 230
Verroust P (abst) 269, 694, 696, 871
Vester U: *see* Doehring et al 520
Veterova LJ (abst) 347
Vetter W (abst) 262
Veyret C (abst) 249
Viberti GC (abst) 258
Vichi GF (abst) 288
Vidt DG (abst) 312
Vie H, Bonneville M, Cariou R, Moreau JF, Soulillou JP: Interleukin 2 production by peripheral blood lymphocytes in allograft patients during acute rejection episodes 553
Villa G (abst) 281, 353
Villada G (abst) 390
Villari D (abst) 288
Vincent HH (abst) 704
Vincent M (abst) 236, 690
Vincenti F (abst) 372
Vining R (abst) 863
Vinnitsky VB (abst) 287
Vinuesa MG (abst) 227
Vinuesa SG (abst) 367, 590
Vinzia G (abst) 589
Vio CP, Figueroa CD: Subcellular localization of renal kallikrein by ultrastructural immunocytochemistry 36
Viola E (abst) 366
Viotte G (abst) 689
Viron B (abst) 360
Virto R (abst) 590
Vischedyk M (abst) 245, 351
Visconti G (abst) 352

Vismans F-JFE (abst) ... 243
Visser GHA (abst) ... 238
Vita G (abst) ... 353
Vites NP (abst) ... 300
Vlachojannis J (abst) ... 315, 698
Vlek LMF (abst) ... 710
Vlietinck R (abst) ... 295
Vogt K (abst) ... 304, 597
Voisin MC (abst) ... 246
Volpi A (abst) ... 300
Volpp BD: *see* Klotman et al ... 118
von Lilien T (abst) ... 246
Vondra K (abst) ... 371
Vyzantiadis A (abst) ... 391

Wadepuhl B (abst) ... 598
Wagner H (abst) ... 368
Wagner K (abst) ... 254, 265, 360, 361, 705, 706
Wagner L (abst) ... 239, 361
Wagner U (abst) ... 226
Wahren J (abst) ... 328
Wakabayashi Y (abst) ... 300
Walb D (abst) ... 705
Waldek S (abst) ... 276
Waldherr R (abst) ... 223, 266, 695, 702, 711
Walker R (abst) ... 870
Walker RJ (abst) ... 862, 863, 864
Wall SD: *see* Jennette et al ... 944
Wallace M (abst) ... 867, 869
Wallington TB (abst) ... 315
Walls J (abst) ... 258, 261, 400
Walter R (abst) ... 704
Wambach G (abst) ... 707
Wang XL (abst) ... 326, 698
Wanic-Kossowska M (abst) ... 328
Ward M (abst) ... 334
Ward MK (abst) ... 240, 241, 310, 326
Wartha R (abst) ... 230, 390
Watanabe T (abst) ... 361
Waterlot Y (abst) ... 321, 332
Watson M (abst) ... 858
Watson ML (abst) ... 278
Waugh J (abst) ... 858
Wauters JP (abst) ... 316, 335, 344, 401, 593
Webb DB (abst) ... 315
Webb J (abst) ... 865
Weber A (abst) ... 245
Weber M (abst) ... 255, 277, 340, 340, 695, 701, 711
Weber MH (abst) ... 301
Weening JJ (abst) ... 696, 703, 708
Wegmuller E (abst) ... 261, 598
Weidmann P (abst) ... 594, 597
Weidmann P: *see* Marone et al ... 658
Weidmann P: *see* Schohn et al ... 814
Weiller F (abst) ... 704
Weinberg MS, Azar P, Trebbin WM, Solomon RJ: The role of urinary kininogen in the regulation of kinin generation ... 975
Weininger J (abst) ... 226
Weir MR, Kirkman RL, Strom TB, Tilney NL: Liver disease in recipients of long-functioning renal allografts 839
Weissel M (abst) ... 301
Wells JV (abst) ... 862, 865
Welsch C (abst) ... 693
Wens R (abst) ... 324, 325, 330
Wenting GJ (abst) ... 698, 707
Werner E (abst) ... 315
Werness PG: *see* Martin et al ... 636
Wernze E (abst) ... 706
Weseley S (abst) ... 341
Westedt ML (abst) ... 371
Westervelt F (abst) ... 371
Weston MJ (abst) ... 297
Westphal E (abst) ... 383, 390
Wetzels JFM (abst) ... 700
Wheeler J (abst) ... 696
White AG (abst) ... 397
White C (abst) ... 371
White D (abst) ... 294
Whitford J (abst) ... 867
Whitten J (abst) ... 388
Wichman Z, Pajdak W, Smolenski O, Kopec J: Detection of plasma proteins during sequential ultrafiltration/dialysis ... 558
Wicht C (abst) ... 598
Wiedenmann B (abst) ... 287
Wieliczko W (abst) ... 285
Wierusz-Wysocka B (abst) ... 362
Wijnen M (abst) ... 287
Wilcox CS, Roddis S, Peart WS, Gordon D, Lewis GP: Intrarenal prostaglandin release: Effects of arachidonic acid and hyperchloremia ... 43
Wild D (abst) ... 869
Wilhelms H (abst) ... 319
Wilkinson A (abst) ... 856
Wilkinson AH (abst) ... 272, 277
Wilkinson R (abst) ... 310, 334
Wilkman AS: *see* Jennette et al ... 944
Will EJ (abst) ... 248
Willebrand Ev (abst) ... 271
Williams AJ (abst) ... 258, 318
Williams DG (abst) ... 233, 303, 303, 856
Williams G (abst) ... 298, 391
Williams LC (abst) ... 859
Williams SK, Siegel RK: Preferential transport of non-enzymatically glucosylated ferritin across the kidney glomerulus ... 146
Willoughby JJ (abst) ... 392
Wilmink JM (abst) ... 711
Wilson CB (abst) ... 871
Wilson CB: *see* Tucker et al ... 28
Wilson I (abst) ... 395
Wilson WH: *see* Mathew et al ... 64
Winchester JF, Ash FR: Hemoperfusion for uremia: Past, present, and future ... S-127
Winchester J (abst) ... 306
Windeck R (abst) ... 700, 708
Winearls CG (abst) ... 266, 362
Wingen A-M (abst) ... 274, 274
Wingo CS, Kokko JP, Jacobson HR: Effects of in vitro aldosterone on the rabbit cortical collecting tubule ... 51
Winkler E (abst) ... 379, 709
Winney RJ (abst) ... 246, 357, 358
Winterberg B (abst) ... 267, 301
Wiseman MJ (abst) ... 258
Witteck CH (abst) ... 301
Witting Ch (abst) ... 267
Wizemann V (abst) ... 362
Wokke JMP (abst) ... 320
Wolf C (abst) ... 692
Wolf S (abst) ... 286
Wolff ED (abst) ... 710

Woloszczuk W (abst) 383
Wolters H (abst) 276, 702
Wong CC (abst) 868
Wong NLM: *see* Mavichak et al 914
Wonigeit K (abst) 395
Woo KT (abst) 267
Wood C (abst) 859
Wood CJ (abst) 864
Wood K (abst) 276
Woodhead JS (abst) 244, 244
Woods CG (abst) 241
Woods RL (abst) 861
Wronski R (abst) 221
Wu AYT (abst) 267
Wu G (abst) 312
Wust J (abst) 315
Wuthricp RP (abst) 598
Wybran J (abst) 332
Wykretowicz A (abst) 362
Wynckel A (abst) 694
Wyndham R (abst) 857
Wynen A (abst) 868
Wysocki H (abst) 362

Yamagami S (abst) 362
Yamagata J (abst) 364
Yamagata Y (abst) 364
Yan KW (abst) 859, 864
Yarger WE: *see* Klotman et al 118
Yokota S (abst) 250
Yong SL (abst) 711
Yoshida O (abst) 366, 366
Youinou P (abst) 302
Young GA (abst) 328
Young J (abst) 398
Yu H (abst) 334
Yukawa S (abst) 264, 264, 302, 363, 370
Yurtkuran M (abst) 363
Yussim A (abst) 273, 386
Yuste P (abst) 388

Zabel P (abst) 363, 380, 380, 383
Zaccuri F (abst) 343
Zager PG (abst) 315
Zahorsky R (abst) 705
Zaletok SP (abst) 271
Zamlauski-Tucker MJ, Van Liew JB, Noble B: 504
Zamora C (abst) 587
Zanetti U (abst) 399
Zaniol P (abst) 240
Zannier A (abst) 391
Zarola F (abst) 347
Zastava V (abst) 396
Zavala DC: *see* Lim et al 541
Zazgornik J (abst) 239, 319, 329, 355, 378, 378, 379, 397, 401, 402, 701, 709
Zbinden M (abst) 363, 592
Zech P (abst) 236, 262, 690
Zegla O (abst) 327
Zemer D (abst) 232
Zepcevska Z (abst) 347
Zeppenfeldt B (abst) 276, 702
Zeromski J (abst) 261
Ziak E (abst) 350
Zielinski CC (abst) 287
Zielinski Ch (abst) 267
Zimmerman E (abst) 301
Zingraff J (abst) 240, 246, 872
Zingraff J: *see* Nguyen et al 158
Zinner G (abst) 331
Zipser R: *see* Kaizu et al 629
Zlatarska S (abst) 339
Zoccali C (abst) 252
Zoellner K (abst) 286
Zoerle C (abst) 349
Zoja C (abst) 274
Zoja C: *see* Remuzzi et al 21
Zouabi M: *see* Avram MM S-100
Zozulinska M (abst) 291
Zuber K (abst) 361
Zubimendi JA (abst) 385, 385
Zucchelli P (abst) 247, 268, 268
Zucchelli P: *see* Cagnoli et al 646
Zumkley H (abst) 301
Zuyderhoudt FMJ (abst) 308
Zyman HJ (abst) 397

Subject Index for Volume 28

Abnormal renal function
early detection in sick neonate by FEb2M 153
Abortion and acute renal failure (abst) 232
Abumins, glomerular sieving of 467
Abuse, protecting patients S-31
Acetazolamide, antimammalian response 760
Acid base
balance in dialysis patients 678
cellular renal response to respiratory 845
homeostasis during PTH excess 187
Acidosis
evidence for a voltage-dependent acidification defect (abst) 862
hyperkalemic renal tubular 801
renal, infusion of PTH excess 187
Acquired cystic disease
in dialysis patients 99
hemodialysis (abst) 358
Acute immune injury
polymorphonuclear leukocytes in mediating decrease ... 28
Acute Ischaemic Renal Failure (abst) 279
Acute renal failure
after radiologic contrast (abst) 230
and new treatments in septic abortion (abst) 232
children S-148
comparative dialysis study (abst) 289
cortex and medullary proton NMR (abst) 226
diuretics (abst) 278
drug associated, a multicenter report (abst) 227
enzymes (abst) 284
functional basis, glomerular alterations in uranyl nitrate 733
glycerol-induced by thromboxane-antagonist BM 13.505 (abst) .....
Hantaan virus nephropathy (abst) 292
in adults over 70 332
in children (abst) 299
Intra-arterial verapamil prevents ischemia-induced (abst) 858
Newborn, by continuous arteriovenous hemofiltration (abst) 368
post ischemic calcium antagonists improve (abst) 254
reversible during enalapril treatment (abst) 872
sequential changes in, nephrotoxic tubular necrosis (abst) 870
transmission electron microscopy of urinary sediment study 58
1,2-Dichloropropane nephrotoxicity, trilene (abst) 228
Acute renal respiratory failure (abst) 293
Acute tubular necrosis
newborns Beta 2-microglobulin clearance tubular maturation 153
studied using transmission electron microscopy 58
transmission electron microscopy non-invasive study ... 58
ADH-induced hypertrophy in rats 456
ADR glomerulopathy
low-protein diet prevents development 21
Adrenal function in transplant (abst) 385
Adrenal suppression
steroid-induced, risk factor for kidney graft (abst) 700
Adrenergic system
in pregnancy-induced hypertension (abst) 234
Adrenoceptor
responsiveness during dialysis and uremia (abst) 332
Adriamycin-treated rats
low protein diet prevents glomerular damage 21
Adult minimum change nephrotic syndrome
corticosteroid demand, benign outcome (abst) 261
Adult-onset nephrotic syndrome
HLA-DRw8 and DQw3 may be primary genetic marker in Japanese 193
Adults over 60
nephrotic syndrome (abst) 262
Adults, ARF over 70 (abst) 332
Albumin
chromatographic studies on nonmercapt/mercapt (abst) 354
substitution in plasmafiltration (abst) 294
nephropathy intervention IDDM S-60
nonenzymatic glycosylation of main determinant into urine 168
Albuminuria, glomerular sieving 467
Alcohol, hypertension related (abst) 248
Alcoholism
Rhabdomyolysis and myoglobinuria in (abst) 296
Aldosterone
in vitro effects of in rabbit cortical collecting tubule 51
on Na^+, K^+ permeability 640
Alfacalcidiol
and parathyroidectomy for renal bone disease (abst) .. 241
Alkalosis, mild metabolic, PTH induced 187
Allograft
are cyclosporine deposits significant? (abst) 399
filtration fraction and ^{99m}Tc-DMS clearance (abst) 711
HLA-DR antigen on endothelial cells in (abst) 380
kidney, prolonged administration of OKT_3 (abst) 379
persistence of antibodies to pneumococcal vaccine in CRF 672
prediction of failure time (abst) 384
renal, conversion cyclosporin to azathioprine (abst) ... 395
renal, cyclosporin A in treatment of rejection (abst) ... 393
renin-angiotensin-aldosterone system, cyclosporin A (abst) 400
skin class I MHC antigens on vascular endothelium (abst) 710
survival, cyclosporine (abst) 384
Alloimmunity, T-cell activation (abst) 388
Allotransplant, renal
CMV infections in (abst) 391
lymphocyte subset, LEU7-LEU3 (abst) 379
Alport's syndrome (abst) 275, 692
Aluminum
concentrations in body during long-term hemodialysis (abst) 301
content and histology in bone of HD and HF (abst) ... 365
Desferrioxamine induce during hemodialysis? (abst) ... 361
induced osteomalacia, and hyperparathyroidism (abst) 247
injestion of aluminium hydroxide in CRF 240
intoxication iron-transferrin complex link between HLA-B40 and dialysis encephalophy (abst) 333
of erythroid and lymphoid cells (abst) 273

oral phosphorus binders and Al content of bone (abst) 245
osteodystrophy Desferrioxamine ocular toxicity (abst) 330
osteodystrophy in uremia S-183
osteomalacia due to cellular $1,25(OH)_2D_3$ resistance (abst) 244
plasma levels and bone aluminum content (abst) 351
removal between 69-S membrane and charcoal filter (abst) 359
spinal fluid levels in hemodialyzed uremic patients (abst) 321
toxicity, microcytic anemia a marker (abst) 356
toxicity and analgesic nephropathy in renal (abst) 229
Aluminum Hydroxide, absorption
Vitamin D metabolites, hyperparathyroidism & iron (abst) 239
anemia in (abst) 354
Amiloride
voltage-dependent acidification defect in dRTA (abst) 862
Amino acid
infusion, and mechanism of glomerular function (abst) 254
essential converted from branched-chain ketoacids in BCAAT 114
imbalance in CRF S-79, S-98
Aminoglycoside nephrotoxicity
in potassium-depleted rats 118
(abst) 228
(abst) 224
Aminoglycosides, 4 compared (abst) 226
Ammonia
removed from branched-chain amino acids 114
Amyloid nephropathy
effect of pregnancy in familial mediterranean fever (abst) 232
Amyloidosis, renal
due to gastric plasmozytoma (abst) 704
Analgesic
consumption vs. nephropathy (abst) 229
Nephropathy and aluminum toxicity (abst) 229
-associated renal necrosis relevance of animal models to 605
Anaphylatoxin
inhibition of within dialyzer (abst) 343
Anemia
and renal cyst formation absence in HD (abst) 348
end stage renal disease 1
in regular hemodialysis, effect of biotin (abst) 348
microcytic and Al (abst) 356
Nandrolone Decanoate therapy on HD (abst) 349
Anephric patients
production of $1,25(OH)_2D_3$ and $24,25(OH)_2$ (abst) 242
Angiography
in A-V fistulas (abst) 338
in A-V fistulas and PTFE grafts for HD (abst) 339
Angiotensin
effects in converting enzyme inhibition in hypertensive rats 128
converting enzyme activity heredity in CRF 250
converting enxyme inhibition in hypertension (abst) 868
Angiotensin II
-converting enzyme inhibitor, artery stenosis (abst) 690
glomerular & tubular actions of (abst) 257
in glomerulonephritis 629
in patients undergoing regular hemodialysis (abst) 252
sensitivity and prostaglandin excretion in pregnancy (abst) 235
Anion gap
acid-base status and dialysis in uremics (abst) 357
Anionic electrical charge
in serum and urinary albumin in normal and diabetic humans 168
Antibodies
anti-BSA idiotypes in IgA nephropathy (abst) 271
anti-DNA in ESRF (abst) 356
monoclonal to NA,K-ATPase, immunocytochemical in nephron 899
titers in transplant patients virus-specific evaluation (abst) 709
Anticoagulation, hemodialysis (abst) 324
Antidiuretic suppressed
effect of acute NaCl load on urinary excretion (abst) 256
Anti-GBM disease
-GBM-GN, PCA (abst) 856
inhibition of throboxane synthetase worsens (abst) 275
manipulation of the splenic plaque-forming cell (abst) 275
Antigen
brush border 330 kilodalton, study of (abst) 871
class I MHC in skin (abst) 710
Goodpasture's disease (abst) 276
tissue typing pitfalls S-170
Antihypertensive therapy
effects of on glomerular dynamics 134
effect calcium entry blockers, nifedipine, verapamil (abst) 706
nephrotoxic serum nephritis with hypertension 135
pindolol, propranolol, monitoring, hemodynamic (abst) 698
Antiinflamatory drug
Lonazolac (abst) 277
Sulindac (abst) 858
Antimammalian response to acetazolamide 760
Antinatriuresis
aldosterone produces significant 51
Antithrombin III and CAPD (abst) 309
Antithrombotic therapy
in childhood hemolytic uremic syndrome (abst) 295
Antithymocyte globulin
complement activation, renal allograft rejection (abst) 381
Anti-thymote-globulin, tolerance (abst) 377
Antituberculosis chemotherapy (abst) 278
Anyloid deposits
in carpal tunnel syndrome (abst) 343
Arachidonic acid
effects of in intrarenal prostglandin release 43
ARF after Triaminic administration
new syndrome different from HUS (abst) 223
Arterial blood volume, cirrhotic patient 206
Arteriolar C3 disease, familial (abst) 862
Artery lesions, renal
in accelerated or malignant hypertension 249
Artificial kidney
new urea adsorbent and dialysate regeneration (abst) 361
Ascites, absense in treated normotensive 135
Asians
high incidence of minimal change nephrotic syndrome (abst) 261
Aspirin and sulindac
in rabbit nephrotoxic nephritis (abst) 269
Atenolol
to prevent preeclampsia in hypertensive patients (abst) 235, S-84
Atherosclerotic cardiovascular disease
concentrations of selenium in hemodialysis (abst) 337

(abst) 320
Atrial natriuretic factor (abst) 870
Auric
regulation of plasma phosphate concentration (abst) ... 350
Australia, hyponatremia (abst) 864
Autoclaving for dialyzer re-use (abst) 868
Autoimmune response
regulation of in active Heymann's nephritis, T-cells (abst) 696
autonomic nervous system dysfunction, PTH in CRF .. 11

Bacteria, urinary pathogens 717
Bacteria, cystitis (abst) 863
Bacteriology
Formaldehyde kinetics and, in dialyzers 936
Bartter's syndrome
Enalapril therapy ameliorates the hypokalemia (abst) . 294
pathogenetic spectrum 85
three sisters treated with Captopril 300
Basal
evoked potentials in uremia (abst) 329
Basophils, degranulation (abst) 319
benzoic acid, loop diuretics of (abst) 693
Beta blockers
lack of on parathyrod hypersecretion in uremics (abst) 242
Beta 2-microglobulin clearance, neonates
index of tubular maturation 153
beta-adrenoceptor blockers (abst) 698
Beta 2-receptor blockade
effects of on plasma noradrenaline, renin and BP (abst) 704
Bicarbonate
net tubular secretion of, by alligator kidney 760
dialysis S-188
dialysis composition (abst) 361
Bioenergetics, PTH and muscle 722
Biofiltration vs hemofiltration (abst) 365
Biopsy
needle in transplantation (abst) 708
renal ultrasonography (abst) 283
Blacks, IgA nephropathy in 944
Blood
access, alternative for chronic hemodialysis patients (abst) 872
chemiluminescence of 158
detoxification new sorbents for (abst) 338
flow, reduced renal may ameliorate glomerular damage 135
hemoperfusion S-127
lowered tissue-fluid oncotic pressure protects in NS (abst) 291
management of kidney transplant recipients (abst) 390
membrane without dialysis and protein catabolism (abst) 328
microvascular reactivity, perfused juxtamedullary nephrons 752
pressure control vasopressor and prostglandin interactions 697
preservation during edema removal in nephrotic subjects 652
pressure norepinephrine-related in hypertension, PF . 814
pressure status progression of renal failure in IgA GN (abst) 702
pressure, volume effects dietary K, parathyroidectomy (abst) 250
reducing risk of hepatitis B exposure in (abst) 373
tranfusion importance in hypersensitivity in ESRD (abst) 308
volume expansion during sodium restriction (abst) 291
Bone
Al containing oral phosphorus binder and Al content (abst) 245
aluminum content, chronic HD and HF (abst) 365
amyloidosis complications (abst) 360
disease, renal and child S-71
GLA, predialysis CRF 783
GLA protein in hemodialyzed patient (abst) 246
necrosis, aseptic (abst) 389
resorption inhibition 1,25-dihydroxyvitamin D elevated serum 951
Branched chain amino acid
metabolism in CRF and dialysis 297
aminotransferase along rabbit and rat nephron 114
Buffers
lactate/acetate base cocktail for HD (abst) 347
acetate, lactate ultrafiltration rate during CAPD 311
BUN predialysis S-100

Cadaveric renal allograft
improvement of renal function during pregnancy 238
Cadmium nephropathy in rats (abst) 228
Caeruloplasmin, pre operative
age and outcome of renal transplantation 383
Caffeine, acute withdrawl (abst) 318
Calcitriol receptors in uremia (abst) 245
Calcium
absorption in thoracic sarcoidosis 693
antagonist effect of nifedipine (abst) 249
antagonist effect, post-ischemic acute renal failure (abst) 705
antagonist improve course of post-ischemic AFC (abst) 254
changes in intracellular, after nifedipine (abst) 697
cyclic AMP-, interaction in tubuloglomerular signals .. 728
entry blockade with nifedipine, sodium-blood volume state 658
exogenous support on blood parameters in dialysis (abst) 245
metabolism hormonal regulation mechanisms, pregnancy (abst) 237
nephrolithias, prevalence of hypertension in (abst) 252
nifedipine, verapamil, antihypertensive treatment (abst) 706
oxalate crystal growth bladder secretion of inhibitors of 636
oxalate calculi transient hyperoxaluria (abst) 239
serum levels determinants after renal transplantation . 244
serum levels, posttransplant hyperparathyroidism (abst) 243
stone formers soft vs. hard water in (abst) 282
transport during hypertonic dialysis (abst) 304
Calcium carbonate as phosphate binder in hemodialysis (abst) 343
effect of on nitrogen metabolism in HD (abst) 350
Vascular calcinosis risk factors in hemodialysis (abst) 351
Calorimetry
effect of peritoneal dialysis on energy turnover (abst) . 305
cAMP
calcium interaction 728
concentration effect of parathyroid hormone, calcium (abst) 697
Cancer
Neuropeptides, peptide hormones as humoral mediator (abst) 287
proteinuria in (abst) 287

Candida albicans
intracellular survival of in peritoneal macrophages (abst) ... 307
CAPD
alter immune function? (abst) ... 315
amino acid solutions after peritonitis (abst) ... 312
analysis of dialysate (abst) ... 869
antibiotic therapy for undiagnosed peritonitis (abst) ... 310
associated peritonitis, prostglandin effect (abst) ... 314
best treatment ... S-23, S-38, S-112
CCPD, better ... S-26
coagulase negative staphylococci in (abst) ... 308
computer data retrieval lists infection & treatment (abst) ... 312
developing countries (abst) ... 305
diabetic, glycemic and metabolic control (abst) ... 313
dialysance of adrenocorticoids (abst) ... 315
endogenous sympathetic activity in ... 312
exercise capability (abst) ... 867
flame-lock system improvement of the joint (abst) ... 310
fluid substitution of sodium bicarbonate (abst) ... 306
fungal peritonitis treatment (abst) ... 311
fungal peritonitis, high morbidity (abst) ... 312
glucose polymer as osmotic agent (abst) ... 309
influence of changes in plasms and red cell volume (abst) ... 315
insulin and diabetics (abst) ... 303
iron and iron binding protein losses in (abst) ... 305
long-term dialysis ... S-41
measurements, ultrafiltration & peritoneal clearance (abst) ... 310
multi-center study of, and hemodialysis (abst) ... 334
Netilmicin, Vancomycin in treatment of peritonitis (abst) ... 309
optimal treatment for ESRD (abst) ... 314
peritoneal membrane defense mechanism in (abst) ... 304
peritoneal membrane failure a determinant of future (abst) ... 307
peritoneum permeability, proteins, systemic disease (abst) ... 308
peritonitis (abst) ... 303
peritonitis prevention by local defence (abst) ... 314
peritonitis requirements for staphylococcus epidermis (abst) ... 303
psycological aspects (abst) ... 693
post-transplant incidence of lymphocele (abst) ... 390
prevention of peritonitis, y-connected double bag (abst) ... 315
prophylaxis of staphylococcus (abst) ... 311
reversal of hypertrophy in uremics (abst) ... 314
sclerosingencapsulating peritonitis in (abst) ... 311
six year experience (abst) ... 859
transfer from hemodialysis (abst) ... 303
trace metal abnormalities in (abst) ... 308
ultrafiltration, role of acetate, lactate buffers (abst) ... 311
US, 3-year study ... 198
working capacity of patients vs hemodialysis ... 338
Y-connector & disinfectant (abst) ... 304
Capillary filters, polysulfon (abst) ... 363
Capsulo snovial complications HD (abst) ... 360
Captopril
enhances aminoglycoside nephrotixicity in rats ... 118
in Barter's syndrome ... 300
in hypertension (abst) ... 707
Carbamazepine therapy
for induced nephropathy in child (abst) ... 225
Carbohydrate
intolerance, uremia (abst) ... 328
metabolism during physical activity, renal insufficiency (abst) ... 300
Carboxylic acid, quinolone (abst) ... 864
Cardiac
parasympathetic activity in hemodialysis (abst) ... 357
damage, Iatrogenic (abst) ... 347
dysrhythmias, child (abst) ... 290
output, vascular resistance arterial blood volume in cirrhotic ... 206
rhythm, bicarbonate HD (abst) ... 344
Cardiovascular complications
in adult polycystic kidney disease (abst) ... 288
Carpal Tunnel syndrome
amyloid deposits in hemodialysis (abst) ... 342
amyloid deposits of dialysis patients (abst) ... 352
diagnosis by electromyogram, hemodialysis (abst) ... 342
in hemodialysis (abst) ... 346
Catheter
drainage of uremic pericardial effusion, tamponade (abst) ... 290
short peritoneal, clinical experience (abst) ... 305
subclavian venous using long term single needle (abst) 336
uremic cardiomyopathy (abst) ... 362
Cell
amino acid effect ... S-98
B and T abnormalities, primary IgA nephropathy ... 646
dysfunction, B and T in primary IgA nephropathy ... 268
proliferation in anti-GBM GN (abst) ... 696
T, in idiopathic membranous nephropathy ... 269
T, regulation of autoimmune response in HN (abst) ... 270
T, activity during dialysis/HD in chronic uremics (abst) 358
Cellular lesion
focal segmental glomerular sclerosis ... 968
Cellulose, membrane, modified (abst) ... 331
Cerebral blood flow
in dialysis encephalopathy and primary degenerative dementia ... 64
Cerebral nervous system
disorders of, significance in early posttransplant (abst) 709
Chemiluminescence
evaluation of dialysis membrane biocompatibility effective ... 158
polymorphonuclear leukocytes index, biocompatibility (abst) ... 342
Child
absense of cardiac dysrhythmias on hemodialysis (abst) ... 290
acute renal failure (abst) ... 299, S-148
bacterial infections and polymorphonuclear, CRF (abst) ... 366
bilateral nephrectomy in (abst) ... 251
CAPD/CCPD vs hemodialysis in transplantation (abst) 308
computer program to supply dietary menus in RF child (abst) ... 286
decreased risk of iron overload in HF (abst) ... 367
dialyzed, parathyroid glands by ultrasound (abst) ... 246
extra cellular volume and blood pressure (abst) ... 341
folic acid in CRF (abst) ... 286
hemolytic uremic syndrome antithrombotic therapy in (abst) ... 295
idiopathic nephrotic syndrome (abst) ... 262
membranous GN "De Novo" in transplanted (abst) ... 371
nephrotic syndrome, decreased activity thymic hormone (abst) ... 691

obstructive uropathy in (abst) ... 857
overhydration in renal disease, treatment (abst) ... 351
renal bone disease ... S-71
renal dysplasia (abst) ... 276
renal function during urography (abst) ... 254
renal transplantation ... S-15
standards for dialysis ... S-112
urinary stones in (abst) ... 288
visual evoked responses vs. biochemical indexes (abst) 323

Chimerism
anti-arsonate response and immunopathology, neonatal (abst) ... 268

Chlorthalidone
optimal dosage in prevention of nephrolitrhiasis (abst) 243

Chromatography
determination of urinary citrate by high performance ion ... 985
isoelectric points of albumin in serum and urine of humans ... 168
of oxalate in plasma and urine ... 82

Chromogranin, plasma in RF (abst) ... 293

Chronic renal failure
accumulation of aluminum due to injestion (abst) ... 240
amino acid in ... S-79
analgesic abuse ... 605
and glomerulonephritis, changes in S.A.C.E. ... 250
biopsy ... S-152
blood pressure reduction, preservation of funtion (abst) ... 867
branched chain amino acid metabolism in (abst) ... 297
changes of cyclic nucleotides after dopamine (abst) ... 256
changes of plasma lipids (abst) ... 289
correlation between serum phosphate and rate of (abst) 288
diet, low-protein (abst) ... 863
Digoxin-like activity in hemodialysis (abst) ... 350
effects of fish oil on lipid metabolism ... 363
factors affecting progression (abst) ... 280
factors in low erythrocyte alpha tocopherol in (abst) . 302
hemodialysis VHF ... S-18
human cytomegalovirus in urine (abst) ... 287
immune status in (abst) ... 340
in predialysis, effects of $1,25(OH)_2D_3$ on bone GLA (abst) ... 240
increased dietary fiber (abst) ... 343
influence of meat-free diet on urinary excretion (abst) 289
is parathyroid hormone a uremic toxin (abst) ... 242
lead exposure ... 212
menstrual disturbances in adolescent girls (abst) ... 237
myocardial beta adrenergic receptor response (abst) ... 250
oral dose of $1,25(OH)_2D_3$ not suppress PTH ... 241
persistence of antibodies to pneumococcal vaccine ... 672
PTH role in reduced pressor response to norepinephrine ... 11
reduced $1,25(OH_2D_3$ and hyperparathyroidism ... 244
renal response to pregnancy in nephrectomized rats (abst) ... 235
serum corticothopin/ACTH/and cortisol/cort in HD (abst) ... 325
serum oxalate in, higher in patients on dialysis (abst) . 867
serum 25 Hydroxyvitamin D concentration in (abst) ... 859
sites of defective regulation of prolactin (abst) ... 284
therapy, choosing ... S-54
tubular nephrotoxicity after i.v. urography (abst) ... 223

Ciclosporin in ESRF (abst) ... 380

Cimetidine, verapamil influence (abst) ... 279

Circadian rhythm
of peptide content in blood plasma ... 271
in hypertensive (abst) ... 247

Circulating immune complexes
in glomerulonephritic patients (abst) ... 273

Cirrhosis
absence of IgA in glomerular deposits of patients (abst) 264
alcoholic, cell defect (abst) ... 692
liver phosphate clearance and proximal tubular sodium (abst) ... 280
patients determinants of effective arterial blood volume 206

Cirtrate, urinary
measurement in renal stone formers (abst) ... 243

Cis-platinum
cumulative nephrotoxicity enzymuria detecting cancer (abst) ... 226
induced hypomagnesemia in rats ... 914
overdose inefficiency of early hemodialysis in (abst) ... 872
side effects (abst) ... 227

Citrate, urinary shown in chromatography ... 985

CMV infection, renal allograft (abst) ... 700

CNS involvement in hemodialysis (abst) ... 344

Colchicine
effect on nephrotic syndrome of Mediterranean fever (abst) ... 294

Cold flush preservation
in vitro microperfusion studies of kidney tubules ... 982

Colloid scans, renal rejection (abst) ... 387

Complement
and the direct mediation of immune glomerular injury 879
activation for renal allograft rejection episodes (abst) . 381

Computer
applications in renal (abst) ... 360
tomography (abst) ... 693

Continuous arteriovenous hemofiltration
treatment in newborn ARF (abst) ... 368

Copolymeric membrane for HD (abst) ... 335

Corpulence index, cyclosporin A (abst) ... 709

Cortical accumulation kinetics
of Gentamicin in CRF rat model (abst) ... 230
of Gentamicin, Netilmicin, Amikacin & Tobramicyn (abst) ... 226

Cortical collecting tubule
aldosterone added to adrenalectomized animals increased Na ... 51
effects of in vitro aldosterone ... 51
mineralocorticoid effect on K^+ permeability, rabbit ... 640

Corticothropin, cortisol in CRF (abst) ... 325

Cortisol, serum
diurnal pattern of in nephrotic syndrome (abst) ... 285

Creatinine
limitations of as a filtration marker in glomerulopathic 830
clearance in hemodialysis (abst) ... 358
clearance, no urine (abst) ... 283
predialysis BUN ... S-100

Crescent forming cells
in rapidly progressive glomerlonephritis (abst) ... 702

Cryoglobulinaemia, mixed
cell surface Fc receptor defective function (abst) ... 275
mixed essential features and response to treatment (abst) ... 298
mixed IgA/IgG, rapid progressive glomerulonephritis (abst) ... 701

CSA to AZA
renal allotransplantation with conversion protocol (abst) ... 398

Cuprophan, cellulose acetate (abst) ... 327
analysis of a limulus-positive substance in (abst) ... 362
Cyclophosphamide dependent nephritis
in Wegener's Granulomatosis (abst) ... 261
Cyclosporin A
and prednisolone in renal re-transplantation (abst) ... 392
and steroids in transplantation (abst) ... 708
and the ischemic kidney (abst) ... 867
and urine glutathiones-transferase (abst) ... 394
blood trough levels a tool in immunosuppression (abst) 399
conversion to azathioprine (abst) ... 400
deposits in allografts significant? (abst) ... 399
doses (abst) ... 393
dosage in kidney transplant based on body or Broca wt (abst) ... 701
DSD-electrophoresis of urinary proteins (abst) ... 397
effect of on renal hemodynamics in conscious rats ... 767
enhanced allograft survival rates (abst) ... 384
ERA analysis of preservation method (abst) ... 398
hypertrichosis (abst) ... 378
immunosuppression (abst) ... 378
improved graft survival with high levels (abst) ... 398
in allograft rejection steroid refractory (abst) ... 397
in combination with azathioprine, steroids (abst) ... 400
induced gingival hyperplasia ... 399
induced hypertension in bone marrow transplantation (abst) ... 394
inhibition of renal gluconeogenesis in rats (abst) ... 223
less rejection vasculopathy? (abst) ... 396
measurement in blood by HPLC (abst) ... 396
modulation by of toxin-induced autoimmune reactions (abst) ... 696
murine SLE (abst) ... 703
need for steroid in for transplant recipients (abst) ... 394
nephrotoxicity comparison of biopsy (abst) ... 396
ocular side effects of immunosuppression (abst) ... 709
post transplant ARF ... 178
prevention of nephrotoxic peak contrations (abst) ... 402
reduce blood pressure, preserve renal funtion (abst) ... 867
renal graft rejection (abst) ... 392
renin, angiotensin, aldosterone system in (abst) ... 400
serum levels, required dosage and corpulence index (abst) ... 709
sole immunosuppressive treatment in renal allograft (abst) ... 395
steroid resistant rejection episodes (abst) ... 400
successful conversion from, to azathioprine (abst) ... 395
transplantation (abst) ... 700
treatment of steroid resistant rejection, renal (abst) ... 393
uric acid (abst) ... 397
vascular lesions in renal transplants (abst) ... 392
vs conventional therapy, dermatologic side effects (abst) ... 701
worsen pneumocystis carinii infection? (abst) ... 398
Cytolytic antibody responses
to cytomegalovirus during CMV infection (abst) ... 700
Cytomegalovirus
retinitis (abst) ... 299
murine reactivation of from kidney ... 922
Cytometry, flow in kidney (abst) ... 372
C3
and Bf in IgA GN (abst) ... 695
congenital deficiency (abst) ... 272
C3D
by capillary hemodialysis (abst) ... 712
in glomerular diseases (abst) ... 274
C5b-9
complex in diseased kidneys (abst) ... 871
in human kidneys (abst) ... 272
in normal kidney (abst) ... 272

D, 1,25-dihydroxyvitamin
elevated serum, hydrochlorothiazide inhibits bone resorption ... 951
Data on 7,000 patients with CAPD ... 308
Decompensated, hyponatremic cirrhotic
patients with ascites demonstrate normal sodium excretion ... 206
Dehydration
drinking inhibits vasopressin release in sheep (abst) ... 861
Delta agent transmission
renal transplation with severe hepatitis induction (abst) 381
Dermatology
cyclosporin vs conventional immunosuppression (abst) 378
Desaggregation, prevention of toxemia
Evening primrose oil may decrease blood pressure (abst) ... 234
Desferrioxamine, Al in HD (abst) ... 361
Diabetes
insipidus Brattleboro
effect of potassium loading on urinary prostglandin (abst) ... 255
PGE_2-9 ketoreductase activity in kidney ... 255
insipidus, neonatal (abst) ... 230
mellitus effect of Dopamine on renal function in (abst) 257
Diabetic
accumulation of protein due to transglomerular transport ... 146
CAPD optimal treatment for ESRD? (abst) ... 314
defensive medicine ... S-120
glycemic and metabolic control in CAPD (abst) ... 313
insulin dependent ... S-60
insulin dependent effect of protein loading, high GFR (abst) ... 259
metformine treated, bicarbonate hemodialysis in LA (abst) ... 329
microangiopathy, proteinuria transglomerular permeability ... 146
nephropathy effect of intraperitoneal insulin regimens (abst) ... 298
non, in renal failure (abst) ... 313
under CAPD, insulin administered (abst) ... 303
Dialysate
Acetate or bicarbonate, effect on red blood cell pH (abst) ... 325
CAPD (abst) ... 869
portable hemodialysis system, sorbent regeneration (abst) ... 873
peritonitis indicator (abst) ... 307
reuse in UK (abst) ... 326
Dialysers
automatic reuse program, interference factors (abst) ... 332
formaldehyde kinetics and bacteriology in ... 936
hollow fiber, automatic reuse programe (abst) ... 332
hollow fiber, urethanes as ethylene oxide reservoirs (abst) ... 340
inhibition of anaphylatoxin by cooling blood (abstr) ... 343
membranes, effects on plasma levels, granulocyte elastase ... 791
re-use, autoclaving for (abst) ... 868
re-use improve membrane biocompatability? (abst) ... 335
re-use of polysulfon capillary filters ... 363

rinsing procedure for cuprophan hollow-fiber(abst) 345
standardization S-105
Dialysis
acid-base balance in patients 678
acquired cystic disease, factors influencing (abst) 358
adjustment, home to center (abst) 337
aluminium containing phosphate binders and (abst).... 321
amyloid deposits in carpal tunnel syndrome of (abst) . 352
and transplanted evoked potentials in patients (abst) . 349
and UF, effect on osmolality, colloid osmotic pressure 808
benefits, early initiation S-57
bicarbonate recirculating, tolerance of elderly (abst)... 343
bicarbonate, composition of (abst) 361
CaCO3 supplements on serum oxalate (abst) 326
carpal tunnel syndrome (abst) 711
children visual evoked responses, EEG & Biochemical (abst) 323
comparative treatment of ACF (abst) 289
comparison of ssychosocial adjustment in types of (abst) 341
chronic uremic, transplant, production of lymphocytes (abst) 270
creatinine BUN S-100
double lumen single needle 323
duration vs. no dialysis on kidney graft survival (abst) 373
effectiveness of after chromatography, spectrometry (abst) 342
encephalopathy and primary degenerative dementia 64
encephalopathy, link between HLA-B40 (abst) 333
Eosinophylia, elevated IgE, antibodies (abst) 352
Epstein-Barr virus infection in (abst) 296
essentials of sodium modelling (abst) 356
ETO enduced IgE-mediated degranulation of basophils (abst) 319
glucose intolerance improved with Carnitine (abst) 350
glutathione peroxidase activity in red blood cells (abst) 337
hemoperfusion uremic S-47
heparin free regional and low dose (abst) 324
hyperchromiumemia in chronic (abst) 336
hypersensitivity reactions to extract & ETO (abst) 324
hypertonic dextrose increases peritoneal mass transport rate 16
hypertonic peritoneal calcium transport during (abst) . 304
hypotension S-161
hypoxemia during acetate (abst) 352
immune complexes in transfusion sera of (abst) 380
induced changes in uric acid/UA/concentration...(abst) 328
intolerance, prevention by bicarbonate recirculating (abst) 323
intraocular pressure (abst) 317
life satisfaction (abst) 334
long term outcome S-41
long term single needle using SVC (abst) 336
low molecular wt heparin in hemodialysis and hemofiltration 823
malignancy, incidence and outcome (abst) 351
membrane biocompatibility, chemiluminescence blood samples 158
membrane biocompatibility study electron microscopy (abstr) 346
membrane, serum B_2-microglobulin in (abst) 338
need, world-wide S-29
needle, double lumen single (abst) 323
oxalosis, customize through chromatography measurement 82
peritoneal 5-years (abst) 307
peritoneal effect of on the energy turnover 305
phychiatric and psychosocial adjustment after 10 yr (abst) 341
plasma pheresis S-131
pre-, chronic renal failure 783
response to influenza vaccine 316
re-use of blood lines, heparin administration sets (abst) 316
selenium deficiency in chronic uremia and (abst) 292
serum oxalate in CRF higher than on (abst) 867
Theophylline metabolites in serum, toxicity risk (abst) 872
tolerance of elderly to bicarbonate recirculating (abst) 343
treatment of ESR disease leads to acquired cystic disease 99
tuberculosis in Jordan (abst) 335
urgent, 3-year survey (abst) 362
ventilation in ARRF (abst) 293
Diet
children in CRF (abst) 863
dairy restriction and idiopathic hypercalciuria (abst)... 281
dependant idiopathic hypercalciuria, hypertension (abst) 252
dialysis early S-51
fiber intake in CRF (abst) 343
gluten-free reduce levels of IgA immune complexes (abst) 260
increased calcium intake and parathyroidectomy (abst) 250
low nitrogen, on lipid metabolism in uremia (abst) 280
low-protein©prevents glomerular damage in adriamycin-treated rats 21
low-protein increases serum albumin in nephrotic (abst) 299
low protein protects kidneys S-66
meat-free influence on urinary excretion in CRF (abst) 289
microalbuminuria, protein, unilateral nephrectomy (abst) 280
moderate protein restriction with fiber (abst) 285
protein and andriamycin glomerulopathy (abst) 274
sodium and calcium, blood pressure control (abst) 252
Diltiazem
on renal function (abst) 706
ischemic heart disease (abst) 353
Diphosphonates
in postz—transplant hypercalcaemia 243
Disequilibration, caffine (abst) 318
Dissection
isolated bilateral renal artery (abst) 251
Distal tubular mass
may be reflected in renal kallikrein excretion 75
Diuretics
induced hypokalemia 988
in post-ischemic ARF (abst) 279
potassium substitution for hypertensive patients (abst) 248
preservation of blood volume during edema, nephrotic subject 652
therapy & renal failure (abst) 224
therapy, uremic S-154
tubular action of, distal effects on electrolytes 477
DNCB skin test, transplantation (abst) 390
Donor
after 10 years 387
influence on graft survival (abst) 395
protect patient rights S-31
psychic reaction (abst) 379
selection for sensitized patients (abst) 378
Dopamine
effect of on insulin dependent diabetes millitus (abst) . 257

infusion changes of cyclic nucleotides after in CRF (abst) ... 256
D-penicillamine-induced CG (abst) ... 265
DR-matching and sharing (abst) ... 389
Drug
associated ARF (abst) ... 227
induced ARF (abst) ... 293
interactions with verapamil (abst) ... 707

ECG
prolonged QT-interval in, uremic polyneuropathy (abst) ... 339
Echocardiographic
assessment of cardiac size in hemodialysis (abst) ... 333
plasmapheresis (abst) ... 287
right ventricular function in hemodialysis (abst) ... 355
Eclamptogenic gestosis
investigation of kidney function and morphology ... 238
Edema removal, blood volume preservation ... 652
Eicosanoid production
in immune complex glomerulonephritis (abst) ... 269
Electrical charge of albumin in humans ... 168
Electrolyte
transport, acidification tubular action of diuretics ... 477
Verapamil effect (abst) ... 256
Electromyogram
usefulness in carpal tunnel syndrome on hemodialysis (abst) ... 342
urinary sediment in acute renal failure ... 58
Electrophysiological in uremia (abst) ... 318
ELIZA method
used to demonstrate antibodies vs. antigens of GBM (abst) ... 695
Employment, computer, renal unit (abst) ... 360
Enalapril
hemodynamic effects on neonatal partial ureteral obstruction ... 891
treatment reversible acute renal failure (abst) ... 872
acute effects of (abst) ... 707
End stage renal disease
anemia ... 1
blood tranfusions in delayed hypersensitivity (abst) ... 309
comparison of HBsAg-negative and HBsAg-positive patients ... 959
antituberculosis chemotherapy (abst) ... 278
changing trends in modalities of therapy in Canada (abst) ... 354
patterns of absorption of ciclosporin A (abst) ... 380
Endralazine vs. hydralazine
in renal failure and on renal replacement therapy (abst) 248
Energy metabolism
effect of parathyroid hormone on, skeletal muscle ... 791
Enhanced glomerular injury
antihypertensive treatment may be responsible ... 135
Environmental exposure
Organic solvents and end stage renal failure (abst) ... 282
Enzyme
activity hereditary, high levels serum angiotensin (abst) 250
inhibition in non-clipped kidney ... 128
inhibition, angiotensin in rats ... 128
Enzymuria
detecting Cisplatin cumulative nephrotoxicity (abst) ... 226
(abst) ... 230
Epidemiologic study
France, membranoproliferative glomerulonephritis (abst) ... 264
Epidemiology of glomular disease (abst) ... 276
Epstein-Barr virus in dialysis (abst) ... 296
Erythrocyte alpha tocopherol
ghosts cyclic enzymatic determines Na, K, ATPase (abst) ... 297
low concentrations in chronic renal failure (abst) ... 302
mediated renal donor, organ-specific phenomenon (abst) ... 710
morphology in renal disease investigation of hematuria (abst) ... 263
Erythrocytosis
post kidney allotransplantation (abst) ... 377
Erythroid and Lymphoid cells
aluminium in vitro effect (abst) ... 273
Erythropoietic inhibitors in CRF (abst) ... 285
Erythropoietin
following kidney transplantation (abst) ... 374
(EP) release into system ... 1
ESRD
anti-DNA antibodies in (abst) ... 356
best treatment: CAPD ... 23
bias and treatment ... S-34
child, transplantation ... S-15
defensive medicine and diabetes ... S-120
dialysis outcome ... S-41
standards ... S-124
Ethylene oxide-albumin complexes (abst) ... 352
Evening primrose oil
Effects of during pregnancy and high risk toxemia (abst) ... 234
Extracellular fluid volume
red blood cell Na^+, K^+ cotransport in normal (abst) ... 255
edema ... 652

Fabry's Disease, ESRF secondary (abst) ... 375
Factor VIII related antigen
levels in renal allograft, cyclosporine treated (abst) ... 392
Familial glomerulonephritis (abst) ... 266
Fc receptors (abst) ... 275
Felodipine, haemodynamics (abst) ... 278
Ferritin
carbohydrate-free transport across kidney glomerulus ...
glucosylation of ... 146
Fibrinolytic impairment
potention and mission trotein C increase in rejection (abst) ... 707
Filtration
drug removal by Amicon-20r diafilter (abst) ... 366
fraction, allograft (abst) ... 711
marker, limitations of creatinine ... 830
Fine needle aspiration cytology
monitoring response to treatment of renal allograft (abst) ... 374
Immunopathology of, renal allografts (abst) ... 858
Fine-needle aspiration biopsy (abst) ... 271
Fish oil, lipid metabolism, CRF (abst) ... 363
Fistula
arteriovenous (abst) ... 327
A-V complications of for hemodialysis ... 339
A-V percutaneous transluminal angioplasty therapy (abst) ... 355
Brescia-Cimino (abst) ... 335
proximal forearm, HD (abst) ... 360
snuff box (abst) ... 334
snuffbox/bresciacimino (abst) ... 319
transvenous digital subtraction angiography (abst) ... 338

Flucloxacillin in renal failure (abst) ... 277
Focal glomerular sclerosis (abst) ... 866, 968
Folic acid, CRF in children (abst) ... 286
Formaldehyde kinetics
and bacteriology in dialyzers ... 936
Foscarnet and CMV Hyperimmune
treatment in cytomegalovirus retinitis (abst) ... 298
Furosemide
on peritoneal transport of guanidines (abst) ... 270
acute effects of (abst) ... 707
renal tubular acidosis ... 801

Gastric plasmozytoma
renal amyloidosis due to (abst) ... 704
Gastroduodenal disease, uremics (abst) ... 331
Genetic marker for nephrotic syndrome ... 193
Genital tract in transplantations ... 863
Gentamicin
captopril in rat kidneys ... 118
cortex and medullary proton NMR in induced ARF (abst) ... 226
induces increase in calcium, magnesium, phosporus (abst) ... 689
nephrotoxicity in pyelonephritic rats ... 106
Gestation
uric acid renal handling (abst) ... 237
GFR
angiotensin involved in regulation of (abst) ... 254
protein loading effect in diabetics (abst) ... 258
angiotensin-mediated influences ... 128
ultrafiltration coefficient in rats ... 926
Gingival hyperplasia
cyclosporine induced (abst) ... 399
GLA, bone
protein in predialysis chronic renal failure ... 783
Glomerular
alterations functional basis for, in uranyl nitrate ARF 733
-anti basement membrant antibodies in human sera (abst) ... 695
basement laminal abnormalities in idiopathic hematuria (abst) ... 860
capillary pressure microvascular reactivity, ... 752
cells rat epithelial and mesangial produce cytokine (abst) ... 690
C3 deposition characteristic of membranous nephropathy (abst) ... 260
damage in adriamycin-treated rats with low protein diet 21
disease C3D a marker in (abst) ... 274
dynamics effect of leukocyte depletion ... 28
epithelial cell abnormalities kidney isografts (abst) ... 373
epidemiology of immunologically mediated (abst) ... 276
filtration rate ureteral obstruction on renal function in rats ... 614
filtration rate, pregnancy, not lead to renal deterioration ... 140
filtration rates hypertensive levels reduced in rats ... 128
glucagon-mediated modification of (abst) ... 253
hemofiltration chloride distal flow may contribute to (abst) ... 253
inflammatory disease sex and age as determinants (abst) ... 702
inherited properties (abst) ... 269
injury
and depletion glomerular polyanion in proteinuria (abst) ... 860
complement mediation of immune ... 879
leucocyte-independent (abst) ... 856
kallikrein-kinin system involvement in chronic (abst) . 265
lesions, focal segmental, IgA nephritis (abstr) ... 262
lesions, historical treatment ... S-136
morphology in pregnant rats
no measured difference in GFR compared to virgin rats ... 140
pregnancy, renal functional reserve (abst) ... 232
procoagulant activity in glomerulonephritis (abst) ... 856
sclerosis, focal segmental ... 968
sieving of anionic and neutral bovine albumins in rats 467
tubular actions of angiotensin II (abst) ... 257
urinary polar lipids newly detected (abst) ... 264
Glomerulonephritis
anti-GBM (abst) ... 696
arteriolar C3 autotransplantation for loin pain (abst) ... 862
circulating immune complexes in (abst) ... 273
crescent-forming cells in (abst) ... 702
crescentic D-penicillamine-induced (abst) ... 265
disappearance of mesangial IgA deposits in (abst) ... 873
glomerular lymphocyte infiltration in (abst) ... 866
familial (abst) ... 266
IgA deficiency and (abst) ... 260
IgA genetic polymorphism of C3 and Bf in mesangial (abst) ... 695
immune complex eicosanoid production in (abst) ... 269
immuno-electron microscopy in experimental (abst) ... 703
immunosuppression and anticoagulation with arvin (abst) ... 865
membranoproliferative rarefaction of (abst) ... 264
membranous, antigenic targets in antibody-mediated (abst) ... 695
membranous predictive factors renal failure progression (abst) ... 259
mixed IgA/IgG cryoglobulinemia with (abst) ... 701
modulation of cyclosporin A, toxin-induced autoimmune (abst) ... 696
of Schonlein-Henoch purpura in adults (abst) ... 691
pregnancy (abst) ... 238
(abst) ... 231
primary membranous immunogenetics of (abst) ... 263
primary membranous T-lymphocytes subpopulations in (abst) ... 263
prognosis (abst) ... 265
rapidly progressive recovery, juicy crescents (abst) ... 266
role of prostaglandins and angiotensin II in ... 629
survey (abst) ... 859
survival (abst) ... 266
treated by plasmapheresis and immunosuppression (abst) ... 267
treatment with streptokinase and ancrod (abst) ... 857
Type III lesion membranoproliferative, morphogenesis of (abst) ... 259
treatment history ... S-136
Glomerulopathic patients
limitations of creatinine as a filtration marker ... 830
Glomerulopathy
absence of IgA in glomerular deposits of (abst) ... 264
protein diet affect (abstr) ... 275
autoimmune mercuric chloride induced (abst) ... 270
Mercuric chloride-induced in mice (abst) ... 702
Glomerulus, kidney
preferential clearance of glucosylated ferritin ... 146
Glomular disease
superimposed nephritis: a separate entity (abst) ... 260

Glomular dynamics
effects of antihypertensive therapy 135
Glucagon-mediated modifications
of GFR induced by essential amino acids (abst)..... 253
Glucose intolerance
harmful for uremic patients..... S-88
improvement of post-dialysis, Carnitine in dialysis (abst) 350
in uremia (abst) 284
Glucose metabolism
acute uremia, defects in insulin-mediated muscle metabolism..... 490
Glucose polymer in CAPD (abst)..... 309
Glucose transport
influence of prostaglandinF2a on in renal tubule (abst) 255
Glucosylated ferritin, non-enzymatic
preferential transport across kidney glomerulus..... 146
Glutamine synthase in rabbit nephron 114
Glutathione peroxidase
activity in red blood cells of dialysed (abst) 337
Glutathione-Stransferase
and cyclosporin (abst) 394
Glycoprotein
hypothetical intracellular processing pathway for kallikrein..... 36
reutilization in regenerating microvilli after renal ischemia 498
Tamm Horsfall (abstract)..... 285
(abst) 865
Gold labelling
of immune complexes and tissue antigens, kidney (abst) 860
Gonadal, parathyroid hormone, HD (abst) 355
Goodpasture antigen
abnormal expression of in Alport's syndrome (abst)... 275
specific immunoabsorption (abst) 274, 267, 277
Graft
monitoring serum neopterine levels post tranplant (abst) 383
survival, imported cadaver (abst)..... 376
Graftectomy, renal (abst)..... 384
Granulocyte elastase
plasma levels during hemodialysis, effects of membranes 791
during HD (abst)..... 336
Granulomatosis, Wegener's (abst)..... 704
Granulopenia
influence of indomethacin pretreatment on HD (abst). 362

Haemodynamics, Felodipine effect (abst)..... 278
Hantavirus
sero-epidemilogical study in Belgian military (abst).... 284
HbsAg positive
long term survival of HD and Tx (abst) 359
HBsAg-negative, HBsAg-positive chronic hepatitis in end state renal disease, comparison of..... 959
Head-out water immersion
in decompensated cirrhotic patiets to correct sodium & water 206
influence of Naloxone on in head-out water-immersion 247
Heart
Myocardial hypertrophy in rats with renal insufficiency 775
Hematocrit and cerebral blood flow
inverse correlations in dialysis patients 64

Hematuria
erythrocyte morphology in renal disease (abst) 263
evaluation by phase-contrast microscopy (abst)..... 290
familial, studies in arteriolar C3 disease (abst) 862
idiopathic glomerular basement laminal abnormalities (abst) 860
syndrome, loin pain intradermal skin testing..... 282
Hemocath vascular access device (abst) 337
Hemodiafiltration
acid-base imbalance correction, dialysis hypoxemia (abst) 364
A-V increase urea removal during C.A.V.H. (abst).... 368
hypertonic (abst) 364
Hemodialysis
absence of anemia and renal cyst formation (abst) 348
acetate and bicarbonate comparison (abst) 330
acute alpha and beta adrenoceptor regulation (abst) ... 326
alternative means of blood access for chronic (abst)... 872
amino acid..... S-98
anemia, Nandrolone Decanoate therapy on (abst)..... 349
angiography in A-V fistulas and PTFE grafts (abst).... 339
arterial hypertension as cardiovascular risk factor (abst) 348
atherosclerotic disease determined by velocity wave (abst) 320
bias in treatment S-34, S-54
bicarbonate..... S-88
bicarbonate as alternative to dichloroacetate (abst).... 329
bicarbonate, effect on cardiac rhythm..... 344
bone GLA-protein in 246
calcium carbonate as phosphate binder in (abst) 343
cardiac parasympathetic activity (abst)..... 357
Carpal tunnel syndrome in (abst)..... 346
changes in plasma, heparin vs epoprostenol (abst) 328
children, extra cellular volume and blood pressure (abst) 341
chromatographic studies on mercapt/nonmercapt (abst) 354
clearance optimized hyperoxaluric patients..... 82
complications of reverse A-V fistula..... 339
Creatinine clearance, treatment (abst) 358
Cuprophan and cellulose acetate membranes during (abst) 327
dialytic symptoms (abst) 333
digoxin-like activity in CRF (abst)..... 350
echocardiographic assessment of cardiac size in (abst) 333
Ecocardiographic study (abst) 355
effect of angiotensin converting enzyme on (abst)..... 252
effect of biotin on anemia and dry skin 348
effect of calcium carbonate on nitrogen metabolism (abst) 350
effect of extracorporeal on energy turnover (abst)..... 340
effect of iron overload, superoxide anion production (abst) 332
erythropoietic inhibitors in CRF (abst)..... 285
experimental vascular access for (abst) 334
Fistula, snuffbox or classic bresciacimino (abst) 319
gastrointestinal tract S-157
generation of C3d by duprophane and polycarbon (abst) 712
gold standard S-12
Hemocath vascular access device (abst) 337
high bleeding risk, Nafamstat Mesilate in (abst)..... 317
high efficiency (abst)..... 344
hypersensitivity reactions during (abst) 339
iatrogenic cardiac damage during (abst)..... 347
immune status (abst)..... 711

induced acute changes in T-subsets (abst) 330
insulin resistance in (abst) 242
interleukin I hypersensitivity during (abst) 333
iron-transferrin complex and microcytic anemia (abst) 354
K^+ modeling in ESRD (abst) 347
lactate/acetate buffer base cocktail (abst) 347
L-carnitine treatment lipids and hematocrit (abst) 320
left ventrical funtion in uremia (abst) 867
leukocyte elastase, biocompatibility marker (abst) 353
leukokinetics in cuprophane (abst) 317
long-term aluminium concentrations in bone, plasma (abst) 31
low molecular wt heparin in, and hemofiltration 823
lymphocyte function in chronic (abst) 340
machine standards S-105
management of post parathyroidectomy hypocalcemia (abst) 240
measured and predicted inter, intradyalytic sodium (abst) 330
membrane biocompatibility of, complement and leukopenia (abst) 361
mixed vascular access (abst) 335
modification of neutrophil metabolism during (abst) ... 344
mononuclear cell membrane lipid peroxidation (abst) . 356
multi-center study of CAPD 334
NA and H_2O kinetics in (abst) 324
Nifedipine kinetics (abst) 279
normotensive myocardial function (abst) 698
once a week, 6 hours (abst) 352
osteoarticular lesions and amyloid infiltration (abst) ... 246
parathyroid hormone and gonadal function in males (abst) 355
performance of new copolymeric membrane, gambrane (abst) 335
peritoneal combo S-50
persistence of antibodies to pneumococcal vaccine in CRF 672
phagocyte oxidative metabolism detected in whole blood 158
Plasma levels of granulocyte elastase during 791
plasma levels of granulocyte elastase during (abst) 336
plasma refilling rate, ultrafiltration in edema (abst) 331
platelet cyclo-oxygenase in (abst) 357
platelet volume distribution (abst) 357
Portable system, sorbent regeneration of dialysate (abst) 873
primary hypothyroidism and amyloidosis in (abst) 330
procedures on blood febronectin (abst) 369
programmed removal of fluids, unstable hemodynamics (abst) 318
progression of vascular calcifications in 244
prophylactic, in cis-platinum overdose (abst) 872
proximal forearm fistula (abst) 360
quality gold standard S-12
regional anticoagulation with sodium citrate (abst) 324
renal transplant effect multimodality evoked potentials (abst) 347
septicemia in (abst) 341
serum B_2-microglobulin in (abst) 338
snuff box fistula (abst) 334
standards, are they needed S-124
stenotic lesions, treatment of (abst) 352
stimulation of lipoxygenase activity of platelets (abst) 690
Thallium 2o1 myocardial study (abst) 329
thermography use for vascular access (abst) 358
thyroid hormone levels, multi-center trial (abst) 301
trace element binding to plasmatic proteins (abst) 344
tranfer from CAPD (abst) 303
transplant long term survival of HbsAg positive (abst) 359
ultrafiltration (abst) 327
vascular calcinosis risk factors evaluated (abst) 351
vs hemofiltration S-18
vs hemoperfusion (abst) 349
working capacity of patients vs CAPD 338
yersinia enterocolitica bacteraemia in (abst) 321
3-years experience in Nigeria (abst) 348
Hemodynamic effects of enalapril
on neonatal chronic partial ureteral obstruction 891
Hemodynamic monitoring
and antihypertensive effect of pindolol, propanolol (abst) 698
Hemodynamic, hormonal, renal
responses to acute protein feeding in normal (abst) 870
Hemodynamics and Na excretion
effects of increased spanchnic resistances (abst) 256
Hemodynamics, phosphate effect (abst) 257
Hemodynamics, renal
and function after converting enzyme inhibition (abst) 384
Hemofilter, permeable plate (abst) 694
Hemofiltration
chelation, treatment water induced plumbism (abst) ... 690
continuous arteriovenous, management of ARF (abst) 367
continuous arterivenous, option for non-renal units (abst) 366
continuous pumpdriven venovenous, CRF (abst) 369
decreased risk of iron overload in children (abst) 367
gravity (abst) 367
glycosylated uremia (abst) 294
low molecular wt heparin in, and hemodialysis 823
outcome S-41
prepared substitution fluid vs commercial infusate (abst) 369
removal of middle molecules in (abst) 369
standards S-116
to eliminate porphyrins in PCT (abst) 368
treatment of manganese intoxication 366
vs hemodialysis S-18
vs. biofiltration in uremics 365
without Heparinisation in high bleeding risk uremic (abst) 365
Hemoglobinuria in drummers (abst) 871
Hemolytic uremic syndrome S-148
Hemoperfusion, uremic S-47, S-50, S-127
Hemoperfusion vs. hemodialysis (abst) 349
Hemorrhagic fever
acute tubular necrosis in renal biopsies of (abst) 292
in RS (abst) 693
Hemostasis, HFD, RH & LDH (abst) 324
Heparin in hemodialysis (abst) 318, 354
hemofiltration 823
Hepatic failure in renal allografts 839
Hepatitis
B vaccine in non dialyzed uremic patients (abst) 290
delta agent transmission in renal transplation (abst) in end stage renal disease 959
reducing risk of in pretransplant blood transfusion (abst) 373
serum markers of, steroid regimen (abst) 386
vaccination of patients on hemodialysis (abst) 363
vaccination (abst) 359
Hepatorenal syndrome
"Natural killer" cell defect in alcoholic cirrhosis (abst) 692

new trends S-143
Herpes simplex virus
transplantation, evidence with other symptomatology (abst) 708
HEVAC B vaccine, immune response (abst) 293
Heymann nephritis
pathophysiology 504
regulation of autoimmune response in active, T-cell (abst) 695
(abst) 866
HLA DR7, onset of Idiopathic NS (abst) 691
HLA-DR
antigen in allograft (abst) 380
HLA-DR/DP/DQ antigens on tissue (abst) 708
HLA-DR2 in dialysis (abst) 383
HLA-linked nephritis (abst) 869
HLS-DRw8 & DQw3 in Japanese
primary genetic marker for adult-onset nephrotic syndrome 193
Holocaust survivors
Hypertension in (abst) 247
Hormone replacement therapy
Ep circulation to validate tests for inhibitors 1
hormone, thyroid S-166
Humoral mediator
neuropeptides and peptide hormones in cancer (abst) . 287
Hyalinosis, focal segmental
treatment with cyclosporin in corticoresistant (abst) ... 871
Hydralazine vs. endralazine
in renal failure and on renal replacement therapy (abst) 248
Hydrochlorothiazide
in calcium stone formers, soft vs. hard water (abst) ... 282
inhibits bone resorption in men 951
oxalate absorption in calcium stone formers (abst) 282
Hydroxyvitamin D in CRF (abst) 859
Hyocardial hypertrophy
evolution of after renal transplantation 388
Hypercalcaemia
use of diphosphonates in post-transplant (abst) 243
Hyperchoremia
effects of in intrarenal prostglandin release 43
Hyperchromiumemia in dialysis (abst) 336
Hypercoagulability
renal vein thrombosis, complications of nephrotic syndrome 429
Hyperendorphinism (abst) 289
Hyperfiltration and chloride handling
during amino acid and glucose infusion 253
Hyperlipemia S-84
Hyperimmunoglobulin, prophylactic
Cytomegalovirus after renal transplant (abst) 386
Hyperkalemia
and steriod hormones on renal potassium handling (abst) 861
Hyperlipidemia in uremic (abst) 296
Hypermagnesemia, hemodialysis (abst) 316
Hyperolaluria, transient
post-injestion of food rich in oxalic acid (abst) .....
Hyperoncotic albumin
during sodium restriction and reduced urine flow (abst) 291
Hyperoxaluric states
chromatography useful to measure oxalate for diagnosis 82
Hyperparathyroidism
Aluminum-induced osteomalacia effect on 246
effect of parathyroid hormone on energy metabolism, skeletal 722
insulin resistance in chronic hemodialysis (abst) 242
reduced $1,25(OH)_2D_3$ responsible for in CRF 244
post-transplant treatment ADP to lower calcium levels (abst) 243
renal acidosis 187
secondary uremic thrombodytopathy in (abst) 241
Hyperpermeability, capillary
in vitro synthesis of leukotriens by leukocytes (abst) . 692
Hyperphosphataemia
is controlled by oral magnesium carbonate (abst) 348
Hyperprolactinemia
in uremia, hemodialysis and parathormone (abst) 346
Hypersensitivity, delayed type (abst) 389
Hypertension
alcohol related (abst) 248
arterial evidence as cardiovascular risk factor in HD (abst) 348
comparison of essential and malignant in IgA neph. (abst) 250
decreased urinary kallikrein in pregnancy induced (abst) 237
effect of potassium depletion on renovascular, in rat .. 621
effects of enalapril on sodium balance in (abst) 699
essential urinary kallikrein activity not altered in (abst) 252
exaggerated natriuresis in pregnancy (abst) 233
glomerular dynamics in nephrotoxic serum nephritis .. 135
in renal transplant recipients (abst) 373
kidney scintigraphy after ace inhibition (abst) 248
low-level lead exposure 212
nephrotoxic serum nephritis and antihypertensive therapy 135
norepinephrine related mechanism in, accompanying RF 814
Prednisolone in, allogenic transplantation (abst) 710
pregnancy-induced renin angiotensin & adrenergic (abst) 234
pregnancy-induced roll¯over test theophilline (abst) ... 234
proximal renal artery lesions in (abst) 249
renal function during angiotensin converting enzyme (abst) 868
renal venous, the "Nutcracker Syndrome" (abst) 857
renovascular renal arterial acleroembolisation (abst) ... 251
renovascular renal ischemia, the true problem 247
renovascular, use of captopril in diagnostic (abst) 707
risk in human uninephrectomy (abst) 863
role of renin-angiotensin system in allograft (abst) 386
salt preference in pregnant rats (abst) 234
sympathetic nervous system, reninangiotension system (abst) 698
tetrahydro-aldosterone-glucuronide in (abst) 705
Hypertensive
Atenolol to prevent preeclampsia (abst) 235
changes in free intracellular calcium post nifedipine (abst) 697
cyclosporin induced, bone marrow transplantation (abst) 394
effect of oral penbutolol on renal hemodynamics (abst) 862
effect of parathyroid hormone and calcium intake (abst) 697
effects of urapidil in (abst) 707
essential dietary sodium and calcium in BP control (abst) 252
GFR reduced in rats 128
in holocaust (abst) 247

patients potassium substitution in, diuretics (abst)..... 248
plasma renal activity, circadian rhythm in..... 247
renal parenchymal serum lipoproteind diuretic therapy (abst)..... 251
Hypertrichosis, cyclosporin (abst)..... 378
Hypertrophy, myocardial in rats with renal insufficiency 187
Hypocitraturia, nephrolithiasis (abst)..... 298
Hypokalemia
in Bartter's Syndrome..... 85
Bartter's syndrome Enalapril therapy ameliorates (abst)..... 294
diuretic-induced..... 988
Hypomagnesemia, cisplatin-induced..... 914
Hyponatremia (abst)..... 864
Hypotension
temperature-monitoring..... S-161
Hypotensive
on hemodialysis, acute a and b-andrenoceptor (abst) . 326
Hypothyroidism
and amyloidosis in hemodialysed patients (abst)..... 330
Hypotriiodothyoxinemia
in chronic hemodialysis patients (abst)..... 363
Hypoxemia
during acetate dialysis..... 353

IgA
absence in cirrhosis of liver and glomerulopathy (abst) 264
B and T cell dysfunctions in (abst)..... 268
deficiency (abst)..... 260
factors in Dextran-induced nephropathy (abst)..... 271
glomerulonephritis blood pressure status, RF progression (abst)..... 702
IgG production in GN (abst)..... 856
immunochemical characterization of light chains in (abst)..... 859
immunoglobulin production by lymphocytes (abst)..... 272
macroscopic hematuria and reduction of renal function 69
malignant esential hypertention in..... 250
membrane attack complex (abst)..... 274
mesangial deposits, glomerulonephritis (abst)..... 873
nephrotic range proteinuria, predictive index of (abst)..... 864
nephritis focal segmental glomerular lesions (abst)..... 262
nephritis factors (abst)..... 267
nephropathy and pregnancy (abst)..... 236
nephropathy in Blacks..... 944
nephropathy, B & T cell abnormality..... 646
nephropathy, charge and size IgA..... 666
nephropathy gluten-free reduce levels immune complexes (abst)..... 260
nephropathy, mesangial (abst)..... 865
polymorphism of C3 and Bf in, glomerulonephritis (abst)..... 695
tonsillectomy decreases synthesis of polymeric IgA (abst)..... 292
IgG
effect of pre-transplant transfusion (abst)..... 374
fixation of along glomerular and tubular membranes (abst)..... 692
immunochemical characterization of (abst)..... 269
response tetanus toxoid in membranous nephropathy (abst)..... 262
serum and biopsy subclasses in MN (abst)..... 276
IgM associated
primary mesangial proliferative glomerulonephritis (abst)..... 259

Immune
function and CAPD (abst)..... 315
glomerular injury complement and the direct mediation of..... 879
response dialysis patients, improvement HEVAC B vaccine (abst)..... 203
hepatitis B allow prediction to kidney allograft (abst) . 383
response in MCN (abst)..... 277
status type analysis (abst)..... 382
status, hemodialysis (abst)..... 711
Immunoabsorption in GBM (abst)..... 274
Immuno-electron microscopy in GN (abst)..... 703
Immunogenetics of MGN (abst)..... 263
Immunological injury
in stage 2 Heymann nephritis, impairment proximal function..... 504
Immunological mechanisms
occurrence of adult-onset MCNS in Japanese immunogenetic..... 193
Immunosuppression
and plasmapheresis in glomerulonephritis (abst)..... 267
cyclosporin (abst)..... 378
dermatologic side effects of (abst)..... 701
hemodialysis and gold standard..... S-12
in glomerulonephritis, treatment (abst)..... 865
in preserved grafts, azathioprine vs. cyclosporin A (abst)..... 397
therapy virus-specific evaluation of antibody titers (abst)..... 709
treatment and Goodpasture's syndrome (abst)..... 267
treatment of microscopic polyarteritis (abst)..... 266
triple drug, low dose, for risk renal graft (abst)..... 391
Indium-111-oxine labelled platelets
diagnosis, renal allograft rejection, cyclosporine (abst) 395
Indometacin treatment
loss of RBF-autoregulation in old SHR (abst)..... 249
Indomethacin pretreatment on HD (abst)..... 362
increase of GFR following aminoacid infustion (abst) . 254
Infection
bacterial polymorphonuclear function in children (abst) 366
CMV in transplants (abst)..... 391
CMV kidney transplantation, cyclosporin/prednisolone (abst)..... 709
cytomegalovirus (abst)..... 386
cytomegalovirus renal transplant, transplant rejection (abst)..... 710
fungal urinary, in renal transplantation (abst)..... 383
herpes in renal transplant recipients, cyclosporine (abst)..... 393
latent reactivation latent murine cytomegalovirus from kidney..... 922
peritoneum (abst)..... 306
propionhydroxamic acid vs acetohydroxamic in urea (abst)..... 281
urinary no correlation of P phenotype and renal scarring..... 797
urinary tract single-dose Tobramycin treatment (abst) 297
urinary two quinolone carboxylic acid derivatives (abst)..... 864
viral in transplants (abst)..... 376
virulence-urinary pathogens..... 717
Inhibition of calcium oxalate growth..... 636
Insulin
dependent diabetes..... S-60
effect of on renal sodium handling, diabetic/normal (abst)..... 253

mediated muscle metabolism in acute uremia 490
regimens, intraperitoneal effect of on diabetic nephropathy 298
Interferon, alpha, gamma
production of lymphocytes (abst)..... 270
Interleukin-1
glomerular cells (abst) 690
hypersensitivity reactions during hemodialysis..... 333
Interleukin-2
inhibition by cyclosporin A, lymphocyte proliferation (abst) 711
normalization of uremic lymphocytes by (abst) 273
Interstitial nephritis
acute idiopathic leucocyte interstitial infiltrate (abst) .. 695
aminoglycoside nephrotoxicity, review of 480 cases (abst) 228
mefenamic acid nephropathy renal lesions (abst)..... 229
Intigenic targets
in antibody-mediate membranous glomerulonephritis (abst) 696
Intoxication, uremic S-2
Intraocular pressure in dialysis (abst)..... 317
Intravascular coagulation
in acute renal failure, pregnancy related (abst)..... 238
Intrinsic sympathomimetic activity
of beta-adrenoceptor blockers (abst)..... 698
Ion chromatography, urinary citrate 985
Ion exchanger..... S-108
Iron
aluminum loading reversal of osteomalacia (abst) 239
overload on superoxide anion production in HD (abst) 332
transferrin complex (abst) 354
Ischaemic and aminoglycoside
effect of Verapamil in ARF (abst) 279
Ischemia
glycoprotein reutilization in regenerating microvilli.... 498
heart disease diltiazem in treatment of (abst) 353
heart disease myocardial imaging in pre-dialysis (abst) 301
induced acute renal failure, verapamil prevents (abst) 858
kidney, Cyclosporin A and (abst) 867
post, kidneys effect of ketanserin on function of (abst) 705
preservation of renal function, verapapamil 371
reduced dialytic program for uremics? (abst) 345
Isografts, renal
glomerular epithelial cell abnormalities (abst)..... 373
Isotonic acid..... S-178

Jaundice
child, steriod-induced (abst) 226
kidney damage (abst) 223
neonate risk of nephrotoxicity in physiologic (abst) ... 224
Juicy crescents
recovery of renal function in glomerulonephritis (abst) 266
Juxtamedullary nephron
microvascular reactivity of perfused blood 752

Kallikrein
activity not altered in essential hypertension (abst).... 252
early indicators in transplant rejection (abst) 386
excretion in pregnancy induced hypertension (abst) ... 237
in normotensive rats..... 440
in renal transplant recipients & uninephrectomized donors .....
kinnin effects on renal function 118
kinin system involvement in chronic glomerular disease (abst) 265
ultrastructural immunocytochemistry localizes..... 36
urinary decreased total in normotensive salt susceptible 440
Ketanserin
effect of, function of post-ischemic kidneys (abst)..... 705
Ketoanalogues and amino acids
glucagon-mediated modificationf of GFR induced by (abst) 253
Kidney
functional behavior (abst) 388
preservation, new solution 867
low-protein diet S-66
uremic therapy, global perspective S-133
Kinin generation
role of urinary kinogen in regulation of 975

L-carnitine
on lipids of uremics (abst)..... 359
treatment lipids and hematocrit in hemodialysis (abst) 320
Lead nephropathy..... 212
Leptospirosis & CRF, evaluation (abst)..... 299
Leucocyte
depletion during acute glomerular immune injury 28
elastase, hemodialysis (abst)..... 353
glomerular injury (abst) 856
interstitial infiltrate idiopathic interstitial nephritis..... 695
Leucokinetics
in cuprophane hemodialyzers (abst) 317
Leukopenia
Verapamil blunts hemodialysis-induced (abst) 321
Leucotriene C_4 and 5-Lipoxygenase
in aminonucleoside nephrosis (abst) 264
Leukotrienes
in vitro synthesis, capillary hyperpermeability (abst) .. 692
Levamisole in NS (abst) 295
Lha-DR2 in dialysis (abst)..... 383
Light chain disease (abst) 266
immunochemical characterization of, IgA nephropathy (abst) 859
Lipid abnormalities in RF (abst) 288
Lipid metabolism, CRF, fish oil (abst) 363
Lipoprotein
lipase inhibitory mechanism of uremic toxin (abst) 370
serum during chronic diuretic therapy (abst)..... 251
Lipoxygenase activity during HD (abst)..... 690
Lithiasis, secondary oxalic (abst)..... 692
Lithium
clearance, renal (abst) 278
therapy during pregnancy, neonatal diabetes insipidus (abst) 230
Liver
veno-occlusive disease of (abst)..... 380
disease in renal allograft patient..... 839
Lonazolac, antiinflamatory drug (abst)..... 277
LpA reduction
reduction of leukocytes prevented decrease in LpA 28
Lupus erythematosus (abst) 865
Lupus nephritis (abst) 864
and pregnancy (abst) 233
plasma exchange (abst) 263
Lymphocyte
function in chronic hemodialysis (abst) 340
function of transfusion related serum factors (abst).... 375
function, zinc (abst) 295
glomerular infiltration in glomerulonephritis (abst)..... 866
IgA and IgG production, in IgA glomerulonephritis (abst) 856

immunoglobulin production in IgA disease 272
in dialysed patients alpha gamma interferon production (abst) 270
LEU7-LEU3 subset (abst)..... 379
proliferation inhibition cyclosporin A $Il^{-}2$ production (abst) 711
T, hemodialysis induced changes in subsets (abst) 330
T, macrophage involvement in glomerular lesions (abst) 273
T, phenotypic and functional alterations of in HD (abst) 326
Lymphocytotoxins, CMV infections (abst) 711
in renal transplant recipients (abst)..... 711

Machine, hemodialysis standards..... S-105
Magnesium
Cisplatin-induced hypomagnesemia in rats 914
induced neurpathy (abst)..... 316
renal handling during pregnancy (abst)..... 233
repletion in Bartter's syndr. 85
Magnetic resonance imaging
in renal transplants (abst) 401
Malignant Proteinuria syndrome
life-threatening syndrome, management options (abst) 319
Manganese intoxication
treatment with hemofiltration caused by (abst)..... 366
Marker, filtration
limitations of creatinine as, in glomerulopathic patients 830
Mediterranean fever
effect of colchicine on nephrotic syndrome of (abst)... 294
familial effect of pregnancy on amyloid nephropathy .. 232
Medullary thick ascending limbs
of Henle's loop, quick isolation and characterization (abst) 689
Membrane
Attack Complex (abst)..... 274
biocompatibility leukocytes chemiluminescence (abst) 342
basement linear fixation of IgG in glomerular, tubular (abst) 692
Membranous GN De Novo, child (abst)..... 371
Menstrual disturbances
in adolescent girls with chronic renal failure (abst) 237
Mercuric chloride
induced autoimmune glomerulopathy in mice (abst) ... 270
induced autoimmune glomerulopathy in mice (abst) ... 702
Mercury exposure
renal function and extrenal damage (abst)..... 225
Mesangial cells
deposition IgA, idiopathic IgA..... 666
deposition of IgA factors Dextran-induced nephropathy (abst) 271
history of treatment S-136
IgA nephropathy (abst) 865
immunocytochemical examination of matrix component of (abst)..... 695
Metal, trace in CAPD (abst)..... 308
Methotrexate therapy
neprotoxicity in juveniles with osteosarcoma (abst) ... 230
Microalbuminuria, diet (abst)..... 280
Micro-ELISA (abst)..... 695
Microperfusion study of kidney tubules..... 201
Microscopic polyarteritis
immunosuppressive treatment of (abst) 266
Microscopy
in evaluation of glomerular hematuria (abst)..... 290
Microvilli regenerated
post-renal ischemia in rats, with glycoprotein reutilization..... 498
Microwave fixation, renal tissue (abst)..... 860
Mineralocorticoid effect on potassium 640
Moderate renal failure
prevention of osteodystrophy..... 241
Modified cellulose membrane (abst) 331
Monoclonal anti T_3 cell antibody
to kidney allograft patient (abst) 379
Monoclonal antibodies
against Tamm-Horsfall protein (abst) 694
characterization of cultured parenchymal cells and (abst) 703
immunological monitoring, renal transplant patients (abst) 376
renal antigen (abst) 704
Mononuclear cell
membrane lipid peroxidation in HD (abst)..... 356
markers immunopathology renal allograft rejection (abst) 858
Mononuclear leucocyte, FGS (abst) 866
Morphine transport in kidney (abst) 280
Morphology
of post partum renal biopsies 238
Motor nerve comparison
as marker of uremic polyneupathy (abst)..... 299
MPGN type III morphogenesis (abst)..... 259
Multimodality evoked potentials, serial
effect of hemodialysis and renal transplant on (abst)... 346
Murine kidney tissue
reactivation of latent murine cytomegalovirus in 922
Murine SLE, cyclosporine (abst)..... 703
Myeloma
multiple, renal failure (abst) 864
multiple, RF in (abst)..... 295
Myocardial
beta adrenergic receptor response coupling in CRF rat (abst) 250
function comparison hemodialysis & healthy patients (abst) 698
hyperlipidemia, renal failure S-84
hypertrophy in rats with renal insufficiency..... 775
imaging, pre-dialysis (abst) 300
Myoglobinuria, in alcoholics (abst) 296

Na absorption
increase without change in voltage or K secretion with aldosterone added in vitro collecting tubules in rabbits 51
Na diffusion
effects of thyroid hormones on (abst) 258
Na,K-ATPase, monoclonal antibody..... 899
NaCl load
effect of in antidiuretic supressed dogs (abst)..... 256
Nafamstat Mesilate
in high bleeding risk hemodialysis (abst) 317
Naloxone, influence of
in head-out water-immersion for hypertension (abst) .. 247
Necrosis, acute tubular
in renal biopsies of hemorrhagic fever patients (abst) . 292
Necrosis, renal papillary
relevance of animal models to analgesic-associated.... 605
Needle, double lumen, single (abst) 323
Neonatal, transplantation tolerance
persistant chimerism, anti-arsonate response (abst).... 268

Neonates, physiologic jaundice (abst) ... 224
Neoterin in transplantation (abst) ... 382
Nephrectomy, bilateral
in children with hypertension in hemodialysis (abst) ... 251
Nephrectomy, unilateral
microalbuminuria and high protein diet (abst) ... 280
Nephritis
congenital C3 deficiency (abst) ... 272
anti-GBM in mice (abst) ... 702
anti-TBM interstitial (abst) ... 703
children, outcome in ... S-148
Henoch Schonlein Purpura, complex of IgA nephritis (abst) ... 274
Heymann, pathophysiology ... 504
Heymann's regulation of autoimmune response in (abst) ... 270
Heymann's (abst) ... 866
Heymann's, role (abst) ... 871
Heymann's, T-cell (abst) ... 866
hypokalemic interstitial ESRF, HLA-linded familial (abst) ... 869
interstitial leucocyte interstitial infiltrate (abst) ... 695
lupus (abst) ... 864
nephrotoxic effect of aspirin and sulindac ... 269
superimposed (abst) ... 260
Nephrolithiasis
diagnosis oxalic acid measurement useful for ... 82
Hypocitraturia (abst) ... 298
optimal chlorthalidone dosage in prevention of (abst) . 243
oxalic stones and prirdoxilate (abst) ... 872
transient hyperoxaluria after injection of food (abst) ... 239
Nephron
branched-chain amino acid aminotransferase ... 114
cold flush preservation in microperfusion studies of ... 982
microvascular reactivity, blood perfused juxtamedullary ... 752
segments monoclonal antibody to Na, K-ATPase ... 899
Nephropathy
analgesic (abst) ... 229
defensive medicine ... S-120
diabetic kidney transplantation in (abst) ... 700
Hantaan virus first case in Italy (abst) ... 292
idiopathic membranous, predictions (abst) ... 268
IgA, B & T cell abnormality ... 646
IgA, charge and size of mesangial IgA in ... 666
IgA in Blacks ... 944
lead ... 212
light chain (abst) ... 266
membranous
immunochemical characterization of IgG in (abst) ... 269
impaired IgG response to tetanus toxoid in (abst) ... 262
serum and biopsy IgG subclasses (abst) ... 276
(abst) ... 260
minimal change (abst) ... 277
Nephrosis, aminonucleoside
role of 5-lipoxygenase products in (abst) ... 264
Nephrotic syndrome
adult minimal change corticosteroid demand (abst) ... 261
Antithrombin III and CAPD ... 309
association between proteinuria and histologic type (abst) ... 286
corticoresistant idiopathic, cyclosporin treatment (abst) 871
diurnal pattern of serum cortisol in (abst) ... 285
genetic marker ... 193
hypercoagulability, renal vein thrombosis, complications ... 429
ideopathic, defect of peripheral monocyte phagocytic (abst) ... 691
idiopathic, and HLA DR7 (abst) ... 691
idiopathic in children, diffuse mesangial proliferation (abst) ... 262
in adults over 60 (abst) ... 262
levamisole in treatment of frequently relapsing (abst) . 295
lowered tissue-fluid oncotic pressure, blood volume (abst) ... 291
minimal change high incidence in Asians (abst) ... 261
platelets are hyperaggregable to ristocetin (abst) ... 268
thrombo-embolic complications in (abst) ... 265
Nephrotic, edema and blood volume ... 652
Nephrotoxic
avoided with low-dose cyclosporine (abst) ... 401
cyclosporin peak concentration, prevention (abst) ... 402
environmental exposure ... 212
high dose methotrexate therapy in juveniles (abst) ... 230
no relationship in cyclosporine levels and at biopsy (abst) ... 394
nonsteroidal antiinflamatory drugs & renal failure (abst) ... 225
of cyclosporin in renal transplant (abst) ... 396
of paraquat after percutaneous poisoning (abst) ... 231
of gentamicin in rats ... 106
tubular nectosis changes in ACF from (abst) ... 870
Neutrophil
metabolic activation effect of ultrafiltration (abst) ... 346
metabolism in HD (abst) ... 344
New Zealand glomerulonephritis (abst) ... 859
Nifedipine
effect of on blood pressure, urine and electolytes (abst) 249
kinetics (abst) ... 279
on AIRF (abst) ... 279
parmacokinetics of, in patients on hemodialysis (abst) 690
sodium-blood volume state ... 658
uremia (abst) ... 706
Non-cytotoxic alloantibody formation
HLA-DR2 in dialysis patients is associated with (abst) 383
Nonsteroidal antiinflamatory drugs
NSAID nephrotoxitity, monitoring renal function (abst) 225
induced acute renal failure ... 293
Norepinephrine
mechanism in hypertension acompanying renal failure 814
role of PTH in reduced pressor response to ... 11
Nutcracker Syndrome (abst) ... 857

Obstruction, ureteral
long-term effects of 24-hr on renal function in the rat . 614
Occlusion, renal artery
revascularisation of using transluminal angioplasty (abst) ... 249
Ocular
compare cyclosporin vs conventional immunization (abst) ... 379
toxicity, DFX (abst) ... 330
OKT_3.Pan
rescue or resistant rejection with (abst) ... 385
Oliguria and cyclosporine ... 178
Oral gold therapy (abst) ... 327
Organic solvents
occupational exposure leads to ESRF (abst) ... 282
Organ-specific phenomenon
donor erythrocyte-mediated prolonged renal allograft (abst) ... 710

Osteoarticular lesions
and amyloid infiltration in hemodialysis (abst) 246
Osteocalcin, serum levels
biochemical determinant factors in uremic patients (abst) 244
Osteodistrophy
aluminum and renal..... S-83
exogenous calcium support on blood parameters (abst) 245
prevention, CaCo3 and hypercalcemic doses of 25(OH)D_3 (abst)..... 241
phosphate on protein diet S-71
renal transplant (abst)..... 378
Osteomalacia
cellular 1,25$(OH)_2D_3$ resistance responsible (abst)..... 245
(abst) 238
Otoneurological analysis
of brain-stem auditory functions in HD uremics (abst) 345
Oubain binding sites
of red blood cells in non-dialyzed CRF patients (abst) 301
Oxalate
measured in plasma and urine by chromatography 82
Oxalate absorption
in calcium stone formers, hydrochlorothiazide (abst) . 282
Oxalic Acid, effect on plasma (abst)..... 224
Oxalic stones, piridoxilate (abst)..... 872

P-blood group
no correlation of phenotype, and renal scarring..... 797
Pancreas transplant (abst)..... 385
Pancreatic B cell
in non diabetics with renal failure (abst) 313
Papillary collecting duct
transepithelial, transmembrane potential difference (abst..... 869
Papillary necrosis, animal modeling 605
Paraquat percutaneous poisoning (abst)..... 231
Parathyroid
adenomas on RDT, scintigraphy and ultrasonography (abst) 240
hormone effect of on energy metabolism of skeletal muscle 722
hormone neurotoxicity..... S-5
Parathyroidectomy
after renal transplant (abst)..... 689
citrate anticoagulation, HD patients, bleeding risk (abst) 325
for renal bone disease, effects of alfacalcidiol (abst)... 241
Parenchyma
Tc-Aprotinin uptake test indicator of (abst)..... 281
Parenchymal cells
characterization of cultured, monoclonal antibodies (abst) 703
Pathogens, urinary, virulence..... 717
Penbutolol, oral
effect of on renal hemodynamics of hypertensive (abst) 862
Peptide, circadian rhythm (abst) 271
Peritoneal
CAPD S-23, S-112
dialysis thyroid function tests and evaluation of (abst) 313
diffusion capacity (abst)..... 312
membrane failure determinant of CAPD future (abst) . 307
transport mechanism whereby hyopertonic dextrose affects 16
transport, effects on (abst)..... 306
treatment increase ultrafiltration with LPS (abst)..... 310
Peritoneum (abst) 306
Peritonitis
CCPD, better than CAPD S-26
CAPD (abst)..... 303
effects of prostglandins on in CAPD (abst) 314
efficacy of Y-connector and disinfectant in CAPD (abst) 304
fungal in CAPD (abst) 311, 312
Netilmicin and Vancomycin in treatment (abst) 309
prevention during CAPD using Y-connected double bag (abst) 315
prevention: UV-system or filter? (abst) 304
sclerosingencapsulating in CAPD..... 311
undiagnosed CAPD, initial antibiotic therapy (abst) ... 310
use of amino acid containing solutions in CAPD (abst) 312
Permselectivity, glomerular..... 467
Phagocyte oxidative metabolism
in uremic patients on hemodialysis monitored by blood sample 158
Phagocytic function in INS (abst) 691
Phenotype, P blood group, renal scarring 797
Phosphate
aluminum containing binders and dialysis (abst)..... 321
clearance proximal tubular sodium in cirrhosis (abst) . 280
decreased urinary, lithogenic risk factor (abst)..... 281
effect of inorganic, on serum ionized calcium concentration 932
on hemodynamics (abst) 257
plasma concentration regulation in anuric patients (abst) 350
protein on diet S-71
removal in uremics (abst) 320
serum concentration and rate of CRF (abst)..... 288
Phosphorus, serum
control and P binders in vitamin D treatment (abst) ... 239
Physical activity
influence of renal insufficiency on carbohydrates (abst) 300
Piperacillin interaction in RF (abst)..... 277
Piridoxilate
secondary oxalic lithiasis due to (abst)..... 692
Plasma
amino acid and CRF..... S-79
chromogranin in RF (abst)..... 293
effect of regular dialysis and hemofiltration on..... 808
exchange in Goodpasture's syndrome (abst)..... 267
exchange treatment (abst)..... 276
exchange, lupus nephritis (abst)..... 263
free fatty-acid in HD (abst)..... 328
lipids during CRF (abst)..... 289
noradrenaline, renin and BP effects of beta 2-receptor (abst) 704
oxalate decrease may predict success of transplantation 82
platelet rich effect of oxalic acid (abst)..... 224
red cell volume, CAPD (abst)..... 315
renal flow calculation (abst) 858
renin activity changes, with plasma exchange..... 692
trapping effects of increased splanchnic resistances (abst) 256
volume estimation of exchange in plasmafiltration (abst) 294
Plasmafilter reuse (abst)..... 365
Plasmapheresis
and immunosuppression in glomerulonephritis (abst) .. 267
double filtration on systemic lupus erythematosus (abst) 364
echocardiography (abst)..... 287

for ciclosporin induced hemolytic uremic syndrome ... 377
Plasmatic proteins
trace element binding to in hemodialysis (abst) 344
Platelet
cyclo-oxygenase in HD (abst)..... 357
function in uremia (abst) 297
volume distribution how hemodialysis affects..... 357
glicoproteids content of (abst) 291
Plumbism in anuric hemodialysis (abst) 690
Pneumococcal vaccine, antibodies in CRF 672
Polyarteritis, microscopic (abst)..... 273
Polycystic disease
(abst) 288
Tubular basement membrane changes in 744
Polycythemia, renal transplant (abst) 691
Polymorphonuclear cells
impaired, chemotaxis in uremia (abst) 302
Porphyria cutanea tarda
hemofiltration in elimination of porphyrins (abst)..... 368
Post-parathyroidectomy Hypocalcemia
management in hemodialysis (abst)..... 240
Post-transplant acute renal failure
cadaver renal recipients treated with cyclosporine 178
Potassium
depletion effect of captopril in rats receiving gentamicin..... 118
effects of depletion on renovascular hypertension in the rat..... 621
excessive urinary loss in Bartter's syndrome 85
loading on urinary prostglandid E_2, F2a excretion (abst) 255
maintenance therapy, diuretic therapy 988
mineralocorticoid effect on permeability of tubule, rabbit..... 640
renal handling of, hyperkalemis and steriods (abst).... 861
Pre-eclampsia and pregnancy (abst) 236
toxicity as nephrotic syndrome 231
Pregnancy
amyloid nephropathy in familial mediterranean feaver (abst) 232
angiotension II sensitivity during sodium balance (abst) 235
blood pressure control in, vasopressor & prostglandin- (abst) 697
effect of cyclical hormonal on transport mechanisms (abst) 868
exaggerated natriuresis in chronic hypertension (abst) 233
glomerulonephritis (abst)..... 238
glomerulonephritis (abst)..... 231
hormonal regulation mechanism of calcium metabolism (abst) 237
Iga nephropathy on course of renal disease (abst)..... 236
intravascular coagulation in acute renal failure (abst) . 238
lupus nephritis (abst) 233
magnesium renal handling during (abst)..... 233
post tranplantation, graft and fetus risks (abst)..... 382
pre-eclampsia, immunological patterns (abst) 236
pre-eclampsia as NS (abst) 231
renal evaluations (abst) 236
renal and glomerular hemodynamics no different than virgin 140
renal function improved with renal allograft (abst) 238
renal functional reserve (abst) 232
renal response in 5/6 nephrectomized CRF in rats (abst) 235
with hypertension, maternal and fetal prognosis (abst) 233
Preservation solution, new (abst)..... 867
Pressor response
norepinephrine in chronic renal failure..... 11
Pressure measurement, intrarenal (abst)..... 376
Pressure, recirculation
fistula assessment technique (abst) 327
Procurement, organ (abst)..... 381
Prolactin secretion in CRF (abst)..... 284
Prolactine
effect of on Na,K,ATPase activity in renal tubule (abst) 253
Prominent peaks assignments
high resolution spin-echo spectra rabbit renal cortex 6
Propionhydroxamic acid in urine (abst) 281
Prostaglandin
E_2 effect of angiotension II, adrenaline on (abst)..... 254
F2a influence of on glucose transport in renal tubule (abst) 255
glomerulonephritis..... 629
glomerulonephritis..... 629
release effects of arachidonic acid and hyperchloremia. 43
synthesis inhibitors in SIDAH 296
Protein
anionic, glucosylation in transglomerular permeability 146
catabolism (abst) 328
creatinine ratio inaccuracy of proteinuria estimations (abst) 291
feeding, renal hemodynamic and hormonal responses to (abst) 870
loading renal response in insulin-dependent diabetics (abst) 258
low protects kidney..... S-56
phospate in S-71
Proteinuria
animals fed low protein diet did not develop..... 21
anti-GBM nephritis (abst) 702
cancer 287
diabetic microangiopathy permeability of anionic proteins 146
cancer 287
EPH gestosis (abst)..... 230
Heymann nephritis 504
inaccurate estimations from protein/creatine ratio (abst) 291
levels in primary glomerulonephritis with NS (abst) ... 286
malignant (abst)..... 319
protamine sulphate-induced, glomular injury (abst).... 860
reduced in low protein diet in nephrotic patients (abst) 299
Proton NMR spectroscopy
rabit renal cortex©spin-echo spectra..... 6
PTH
and left ventricular funtion in HD patients (abst)..... 325
effect of on energy metabolism of skeletal muscle..... 722
excess results in biphasic renal and acid-base response 187
is it a uremic toxin? (abst)..... 242
neurotoxicity and uremic..... S-5
pathogenetic role in uremic autonomic neuropathy (abst) 352
role in reduced pressor response to norepinephrine in CRF 11
1,25 Dihydroxycholecalciferol not suppress in CRF (abst) 241
PTH excess in humans..... 187
Pulmonary function in CAPD (abst) 867
Pyelonephritic rats
increased nephrotoxitity of gentamicin..... 106
Pyelonephritis, acute (abst)..... 693
host resistance (abst) 869

Rabbit renal cortex
Proton NMR spectroscopy 6
Radio-immunoassay
used to examine rate of tissue kallidrein excretion 75
Radiologic contrast in ARF (abst) 230
Ranitidine
not influence blood ciclosporin levels in transplant (abst) 401
RBF, ultrafiltration coefficient in rats 203
RBF-autoregulation
in old SHR during indometacin treatment 249
RDT
ultrasound finds decreased spleen volume post-HD (abst) 355
Red blood cell cotransport
Na^+, K^+ during volume expansion in normal subjects (abst) 255
Rejection
allograft urinary interleukin-1 activity in kidney (abst) 393
cyclosporine A for acute vascular (abst) 391
graft, combined plasma-lymphapheresis effective (abst) 386
immunopathology of renal allograft, mononuclear (abst) 858
indium-111-oxine labelled platelets in diagnosis (abst). 395
kidney graft, steroid-induced adrenal suppression (abst) 700
less vasculopathy with cyclosporin? (abst) 396
percutaneous renal biopsy lesion, outcome (abst) 381
renal, late acute interstitial cellular 387
renal, ^{99m} Tc. Sn colloid scans in diagnosis (abst) 387
renal allograft (abst) 374
rescue or resistant (abst) 385
Renal
biopsy in acute uremia S-152
effections, pregnancy (abst)..... 236
allografts immunopathology of fine-needle aspirate of (abst) 858
allografts, liver disease..... 839
antigen immunochemical identification (abst) 704
arterial scleroembolisation treatment renovascular hypertension 251
artery dissection (abst)..... 251
bone and children S-75
diabetic IDDM S-60
disease
fine-needle aspiration biopsy (abst) 271
mechanism of hypertension in kidney damage 136
polycystic 744
Polynesian (abst) 862
dysplasia, childhood (abst) 276
failure
bias in treatment S-34
calcium antagonists effect post-ischemic acute (abst) 705
diet..... S-66, S-71
hepatorenal S-143
hyperlipemia..... S-84
Hypertension, norepinephrine-related mechanism in 814
in multiple myeloma (abst) 864
kinetics gentamicin, "remnant kidney method" (abst) 230
lipid abnormalities..... 288
moderate dietary protein restriction (abst)..... 285
multiple myeloma patients (abst) 295
non-dialated obstructive (abst) 694
silicon metabolism..... S-175
tuberculosis in ethnic minority groups 336
vaccination policy (abst) 712
function
acute worsening during episodes of macroscopic hematuria 203
captopril deteriorate in renovascular disease? (abst) 705
chronic mercury exposure and extrarenal damage (abst) 225
effect of atrial natriuretic factor in rat (abst)..... 870
effect of diltizem on (abst)..... 706
effects of 24-hr unilateral ureteral obstruction..... 614
gluconeogenesis, inhibition of by cyclosporin A (abst) 223
graft CMV, leukocytoxins and rheumatoid factors in (abst) 371
hemodynamics cyclosporine administration on conscious rats..... 767
infection increased susceptibility of kidney to aminoglycosides..... 112
injury Mitomycin-induced (abst) 225
insufficiency myocardial hypertrophy in rats with 775
lesions Mefenamic acid nephropathy spectrum (abst) . 228
medulla binding (3H)-piretanide to membranes of (abst) 693
plasma flow calculation (abst)..... 858
scarring lack of correlation of P blood group phenotype and 797
selectivity properties in humans..... 168
stone formers indications urinary citrate (abst)..... 243
tissue HLA-DR/DP/DQ antigens, differential expression (abst)..... 708
tissue 860
transplant recipients kallikrien excretion 75
transplantation, after determinants calcium levels (abst) 244
tubular acidosis, hyperkalemic effect of furosemide ... 801
tubule cells found in urinary sediment in ARF 58
tumors frequency in acquired cystic kidney disease & dialysis..... 99
vascular resistance arachidonic acid caused ipsilateral fall 43
Renin
aldosterone system in pregnancy (abst) 861
aldosterone system increase in pregnancy renal disease (abst) 232
angiotensin system, nervous system in hypertensin (abst) 698
cellular response to respiratory acid-base disorders ... 845
in pregnancy-induced hypertension (abst) 234
plasma changes in activity..... 692
Renovascular disease
does captopril deteriorate renal function in (abst) 705
Renovascular hypertension, K depletion 621
Respiratory acid-base disorders..... 845
Rhabdomyolysis in alcoholics (abst)..... 296
Ristocetin
platelets in nephrotic syndrome are hyperaggregable (abst) 268
Rights, protecting patient..... S-31

Saline diuresis & alkaline diuresis
in lithium clearance (abst)..... 278
Saline volume expansion, isotonic
anti-natriferic activity of proximal tubular fluid (abst). 861
Salt
preference in pregnant hypertensive rats (abst) 234
sarcoidosis, thoracis
calcium absorption in (abst) 693
Schonlein-Henoch purpura in adults..... 691

Scintigraphy
possible test for diagnosis of hypertension (abst) 248
ultrasonography localization of parathyroid adenomas (abst) 240
Sclerosis, focal segmental glomerular 968
SDS-electrophoresis
urinary proteins in renal transplants (abst) 396
SDS-page, rapid technique (abst) 390
Selenium
concentrations during hemodialysis (abst) 337
deficiency in chronic uremia and dialysis (abst) 292
Sepsis
cause of death in renal vasculitis (abst) 259
Septicemia in hemodialysis (abst) 341
Serum
electrical charge in humans 168
electrical charge of albumin 168
SIADH and PGI (abst) 296
Sickle cell trait
Hemoglobinuria in bare handed drummers (abst) 871
silicon metabolism in RF S-175
Single nephron filtration rate
AGBM-Ab shown to decrease this and LpA 28
Skeletal muscle energy metabolism, PTH 722
Skin testing
intradermal in loin pain hematuria syndrome 282
Sodium
& blood volume after calcium entry blockade, nifedipine 658
and water kinetics in hemodialysis (abst) 324
chloride, water, renal handling after transplantation (abst) 385
depletion, interaction of vasopressin, antiotensin (abst) 869
effects of enalapril on, in hypertension (abst) 699
ion exchanger S-178
ionized, kinetics during isolated ultrafiltration (abst) ... 368
measured and predicted intradialytic in HD (abst) 331
modelling, essentials of (abst) 356
potassium ATPase activity mediates cyst formation ... 447
transport capacity selective ADH-induced hypertrophy in rats 456
urinary kallikrein in normotensive salt susceptible rats 440
water retention in decompensated cirrhotic patients ... 206
Spectroscopy, Proton NMR 6
Splenic plaque-forming cell (abst) 275
Staphylococcus
coagulase negative in CAPD (abst) 308
Epidermidis opsonic requirements, CAPD peritonitis (abst) 303
prophylaxis of, in CAPD (abst) 311
Stenosis
arterial study digital substraction angiography on (abst) 375
percutaneous transluminal angioplasty, therapy (abst) 355
renal artery, detection (abst) 690
transplant renal artery (abst) 699
venous (abst) 360
Stenotic lesions
vascular access for hemodialysis, treatment of (abst) . 352
Steroid,
renal transplant (abst) 375
Streptokinase and ancrod
fibrin-related experimental glomerulonephritis (abst) ... 857
Subcellular organelles
description of kallikrein involved with glycoproteins ... 36
Sulindac, renal sparing? (abst) 858
Survival, graft
delayed type hypersensitivity on (abst) 389
hemodialysis gold standards S-13
imported cadaver (abst) 376
Systemic disease
permeability of peritoneum to proteins in CAPD (abst) 308
study of double filtration plasmapheresis on (abst) 364
Systemic vascular resistance
in decompensated cirrhotic patients 206

Tamm-Horsfall glycoprotein (abst) 285, 865
monoclonal antibodies against human (abst) 694
Tamponade
catheter drainage of uremic pericardial effusion (abst) 290
Tc-Aprotinin test (abst) 281
T-cell activation, alloimmunity (abst) 388
T-cell, Heymann's nephritis (abst) 866
Tetrahydro-aldosterone-glucuronide
in hypertension diagnostic (abst) 705
Thallium 2o1 myocardial in HD (abst) 329
Theophilline
Roll¯over test in pregnancy-induced hypertension (abst) 234
Therapy, CAPD in USA 198
Thermography
for vascular access in HD (abst) 358
vascular access in hemodialysis 358
Throboxane synthetase, anti-GBM (abst) 275
Thromboembolic complications
in cyclosporine A treated cadaveric kidney recipients (abst) 701
in nephrotic syndrome 265
(abst) 429

Thromboxane B_2
effect of angiotensin II, adrenaline on (abst) 254
production in rats 118
antagonist BM 13.505 prevention of glycerol-incuded ARF .....
Thymulin in children with NS (abst) 691
Thyroid function
in hepatitis B virus carriers on hemodialysis (abst) 329
in uremic child S-166
tests evaluation of in peritoneal dialysis 313, 276
Thyroid hormone levels
in hemodialysis patients (abst) 301
Thyroid hormones
effects of on Na diffusion on tubular brush border (abst) 258
tissue typing, pitfalls S-170
Tissue damage in kidneys
study of C5b-9 complex in diseased (abst) 871
T-lymphocytes subpopulations
in primary membranous glomerulonephritis (abst) 263
Tobramycin
treatment in urinary tract infections 297
Tonsillectomy
and polymeric IgA by blood lymphocytes in IgA (abst) 292
Toxicity
in rats susceptible to nephrotoxic potential of gentamicin 106
cyclosporine 178
hemoperfusion S-127
renal monitoring of cisplatinum by urinary enzymes (abst) 226
uremia intoxication S-3

Transfusion
effect on Lymphocyte function (abst) 375
Transluminal angioplasty
revascularization of complete renal artery oclusion (abst) 249
Transluminal angioplasty (abst) 360
Transplant, heart
renal function & blood pressure in, with cyclosporine (abst) 399
Transplantation
allo-, cyclosporin A or azathoprine and prednisone (abst) 398
analysis of recipients' immune status type (abst) 382
anti-thymocyte-globulin tolerance in rats (abst) 377
aspiration cytology in hypersensitized, renal graft (abst) 391
blood transfusions in management of post renal (abst) 390
child S-15
child, complications of CAPD/CCPD vs hemodialysis (abst) 308
comparison of ALG and ATG for renal 388
comparison of cyclosporin, prednisolone, renal (abst). 401
cyclosporin A (abst) 707
cyclosporin dosage based on body or Broca wt (abst) 701
cyclosporin in combination with azathioprine, steroid (abst) 400
cyclosporine A doses in cadaveric kidney justified? (abst) 700
cyclosporine A in treatment of steroid resistant (abst) 400
cytomegalovirus infection in, absence in rejection (abst) 710
development of renal osteodystrophy after (abst) 378
dialysis, need world-wide S-29
dialysis duration vs no dialysis, kidney graft (abst) 372
disorders of cerebral nervous system in early post- (abst) 709
donor selection for sensitized patients (abst) 378
DR-matching and sharing for cadaveric renal (abst) ... 389
effect of steroids 375
erythrocytosis after kidney (abst) 377
female, colposcopic assess (abst) 863
graft monitoring with serum neopterine levels (abst)... 383
hemodialysis, gold standard S-12
hepatitis in ESRD, HBsAg-negative and HBsAg-positive patient 959
hypertension in renal recipients (abst) 373
hypertension, prednisolone in kidney (abst) 710
incidence of CMV infections, kidney (abst) 709
inferior results in patients on CAPD vs hemodialysis (abst) 306
intrarenal pressure measurement in (abst) 376
kidney, evidence of herpes simplex virus in urine (abst) 708
kidney, with diabetic nephropathy (abst) 700
kidneys, damage indicated by urine protein pattern (abst) 708
kidneys, damage to by urine protein patterns (abst) ... 708
liver disease in recipients of renal allografts 839
lymphocytotoxins associated with acute CMV infection (abst) 711
necrokidney, urinary RBP as best viability test (abst). 374
Neopterin in serum and urine after kidney (abst) 382
nephrotoxicity of cyclosporin in renal (abst) 396
new DNCB skin test (abst) 390
parathyroidectomy after renal (abst) 689
polycythemia and renal 691
post renal, incidence of lymphocele in CAPD (abst) ... 390
pre, effect of transfusion on IgG secretion (abst) 374
preoperative caeruloplasmin valuable in prediction (abst) 383
prolactinomas after renal 389
psycological aspects of CAPD (abst) 693
Ranitidine not influence blood ciclosporin levels (abst) 401
recipient selection, pancreas and kidney 371
rejection, early indicators of (abst) 386
renal artery stenosis, results of surgical repair (abst) .. 699
renal, control of loin pain, C3 glomerulonephritis (abst) 862
renal handling of water and sodium chloride after (abst) 385
renal, magnetic resonance imaging in (abst) 401
renal, ocular side effects of immunosuppression (abst) 709
renal, pregnancy: are graft/fetus risks predictable (abst) 382
risk factors associated with aseptic bone necrosis (abst) 389
segmental of pancreas (abst) 385
significance of vascular lesions in cyclosporyne (abst) 392
study of adrenal function (abst) 385
study of digital substraction angiography (abst) 375
survival results between centers, UK (abst) 372
tissue typing S-170
transfusion (abst) 372
triple drug immunosuppression, high risk renal (abst). 391
use of fine needle aspiration biopsy in follow up (abst) 373
value of needle biopsy in (abst) 708
viral infections in (abst) 376
vs hemodialysis in ESRF secondary to Fabry's disease (abst) 375
Transport rates
mechanism of dextrose-enchanced peritoneal mass 16
Transport, peritoneal
influence of furosemide on guanidines (abst) 270
Transtubular transport in cyst formation 447
Triaminic administration for influenza
resulted in temporary oligoanuric ARF (abst) 253
Trilene, 1,2Dichloropropane (abst) 228
Trimethoprim, for cystitis (abst) 863
TSH, TRH through intraperitoneal (abst) 313
Tuberculosis
in renal failure, in ethnic minority groups 336
in dialysis (abst) 335
Tubular
and microproteins, antiTBM interstitial nephritis (abst) 703
acidosis, hyperkalemic renal 801
action of diuretics 477
basement membrane changes in polycystic disease 744
cyst formation, NA-K ATPase 447
damage red blood cell casts and decreased renal function 69
fluid, autologous proximal activity of (abst) 861
function abnormalities systemic lupus erythematosus (abst) 865
glomerular alterations low dose cadmium nephropathy (abst) 228
lesions a study on renal biopsies by light microscopy (abst) 229
maturation in infants Beta 2-microglobulin used 153
necrosis, acute protective effect of Verapamil on (abst) 257
nephrotoxicity after i.v. urography in CRF (abst) .....
secretion of bicarbonate by alligator kidney 760
sodium resorption effects of enalapril and furosemide (abst) 707
Tubule
characterization by adenylate cyclase sensitivity (abst) 689

kidney cold flush preservation for microperfusion studies ... 982
renal effect of prolactine on Na-K-ATPase activity (abst) ... 253
Tubuloglomerular feedback signals
Cyclic AMP-calcium interaction in transmission of ... 728
Tubulo-interstitial changes
value in prognosis of membraneous glomerulonephrites (abst) ... 259
Tubulointerstitial disease, lead induced ... 212
Tunnel syndrome, carpal, dialysis (abst) ... 711

Ultrafiltration
CCPD, CAPD ... S-26
& dialysis on osmolality, osmotic pressure, vascular refill ... 808, S-23
coefficient of isolated glomeruli in rats ... 926
effect of on neutrophil metabolic activation (abst) ... 346
in peritoneal treatment with LPS (abst) ... 310
ionized sodium, kinetics during (abst) ... 368
isolated treatment life-threatening overhydration (abst) 351
monitor UFM10-2 (abst) ... 320
plasma refilling rate in cardiac and nephrotic edema (abst) ... 331
pump-assisted continuous arteriovenous (abst) ... 694
quantity, mode and cardiovascular stability in HD (abst) ... 327
Ultrasonography
renal biopsy (abst) ... 283
use of (abst) ... 240
Ultrasound, RDT (abst) ... 355
Ultrastructural immunocytochemistry
in subcellular localization of renal kallikrein ... 36
Ultrastructural localization
of immune complexes and tissue antigens (abst) ... 860
Uninephrectomy risk (abst) ... 863
Uranyl nitrate
functional basis for the glomerular alterations, ARF ... 733
Urapidil in hypertensives (abst) ... 707
Uremia
acute, specific defects in insulin-mediated metabolism 490
acute, biopsy ... S-152
and dialytic treatment on adrenoceptor response (abst) 332
biofiltration vs. hemofiltration (abst) ... 365
calcitriol receptors in ... 245
choosing therapy ... S-54, S-116, S-124
dialysis, early benefits ... S-57
diuretic therapy ... S-154
effect of amino acids ... S-98
effect of low-nitrogen diet on hemodialysis (abst) ... 281
evaluate carbohydrate intolerance in (abst) ... 328
evoked potentials in, basal and other data (abst) ... 329
gastrointestinal tract ... S-157
glicoproteids content of platelets in (abst) ... 291
glucose intolerance (abst) ... 284, S-88
glycosylated hemoglobin in (abst) ... 294
hemoperfusion ... S-47, S-127
hepatitis B vaccine in non-dialyzed (abst) ... 290
hyperlipidemia ... S-184
hyperparathyroidism inorganic phosphate, calcium ... 932
hyperprolactinemia in (abst) ... 346
impaired polymorphonuclear cells chemotaxis in (abst) 302
intoxication ... S-2
lab investigation ... S-108
left ventricular function in (abst) ... 867
nifedipine in (abst) ... 706
plasmapheresis ... S-131
platelet function (abst) ... 297
renovascular hypertension and renal ischemia ... 247
spinal-recorded somatosensory evoked potentials (abst) 318
treatment bias ... S-38
with rheumatoid arthritis, oral gold therapy (abst) ... 327
world-wide perspective ... S-133
Uremic
anion gap, acid-base status and dialysis (abst) ... 357
autonomic neuropathy, PTH (abst) ... 352
cardiomyopathy (abst) ... 362
cyclic enzymatic method determines Na, K, ATPase (abst) ... 297
dermatitis, treatment HF (abst) ... 366
dialysis-induced changes in (abst) ... 328
encephalopathy (abst) ... 349
gastroduodenal disease in during hemodialysis (abst) . 331
hemofiltration without heparinisation, bleeding risk (abst) ... 364
hyperlipidemia and renal function (abst) ... 296
lack of suppressive beta blockers (abst) ... 242
L-carnitine treatment (abst) ... 359
Lonazolac, new non-steriod antiinflammatory drug (abst) ... 277
lymphocytes normalization by interleukin-2 (abst) ... 273
myocardial beta adrenergic receptor response (abst) ... 250
need world-wide ... S-29
neurotoxicity in PTH ... S-5
on CAPD, reversal of hypertrophy (abst) ... 314
osteodystrophy bicarbonate vs. acetate dialysis (abst) 323
otoneurological analysis of brain-stem hearing (abst) . 345
patients biochemical determinant factors serum levels (abst) ... 244
polyneuropathy ECG QT-interval on dialysis (abst) ... 339
(abst) ... 299
reduced dialytic program for ischemic heart disease (abst) ... 345
spinal fluid aluminium levels in hemodialyzed (abst) ... 321
suppressor T-cell activity during HD in (abst) ... 358
syndrome, plasmapheresis for cyclosporin-induced (abst) ... 377
theophylline metabolites in serum, toxicity risks (abst) 872
thrombocytopathy role of secondary hyperparathyroidism ... 241
thyroid function ... S-166
toxin on lipoprotein lipase (abst) ... 370
toxicity, VST (abst) ... 286
Ureteral obstruction
hemodynamic effects of enalapril on neonatial partial . 891
Uric acid
renal handling during gestation (abst) ... 237
Uric acid and cyclosporin (abst) ... 397
Urinary
acidification, hyperkalemic renal tubular, furosemide . 801
albumin, chromatography ... 168
albumin, electrical charge ... 168
childhood 6-ketoprostaglandin F1a and thromboxane (abst) ... 857
clearance rate, morphine (abst) ... 280
enzymes, diagnostic value in kidney damage due to jaundice ... 223
interleukin 1, in reject (abst) ... 393
kallikrein excretion by specific immunoassay ... 75
kininogen in regulation of kinin generation ... 975
obstruction, RF (abst) ... 694
pathogens, virulence of ... 717

polar lipids in primary chronic glomerular disease (abst) 264
proteins, SDS-page (abst) 390
RBP, transplantation (abst) 374
sediment transmission electron microscopy in ARF 58
stones in child (abst) 288
Urine
bladder of inhibitors of calcium oxalate crystal growth 636
creatinine clearance (abst) 283
enzyme activity in ARF (abst) 284
Gentamicin induces increase of calcium, magnesium (abst) 689
human cytomegalovirus in, patients with CRF (abst) . 287
neutral proteinases in glomerular disease (abst) 261
Urography
renal function ionic and non-ionic contrast media 254
tubular lesions, a study on renal biopsies (abst) 229

Vaccination policy, renal failure (abst) 712
Vascular calcification
in hemodialysis patients (abst) 244
Vascular calcinosis risk factors (abst) 351
Vascular lesions
significance in cyclosporyne treated renal transp. (abst) 392
Vasculities, renal (abst) 259
Vasoconstriction, cyclosporine in rats 767
Vasopressin release
drinking inhibits release of in dehydrated sheep (abst) 861
Veno-occlusive disease, liver (abst) 380
Ventricular ectopy
diuretic-induced hypokalemia 988
Ventricular funtion, PTH in HD (abst) 325
Verapamil
bioavailability (abst) 279
blunts hemodialysis-induced leukopenia 321
drug interactions with (abst) 707
effect on ARF (abst) 279
effects of (abst) 256
ischemia (abst) 371
prevents warm ischemia-induced acute renal failure (abst) 858
protective effect of on the ischaemic ATN (abst) 257
Vibration sensory threshold (abst) 286
Vitamin C harmful, RDT (abst) 319
Vitamin D metabolites
hyperparathyroidism and iron stores and AL(OH)3 (abst) 239
Vitamin D metabolites treatment (abst) 239

Wegener's granulomatosis
cyclophosphamide dependent nephritis (abst) 261
(abst) 704

Yersinia enterocolitica bacteraemia
hemosiderosis predisposition on hemodialysis 321

Zinc and lymphocyte count in CRF (abst) 295

$1,25(OH)_2D_3$ and $24,25(OH)_2$
extrarenal production of in anephric patients (abst) 242